#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Bayesian computational markers of relapse in methamphetamine dependence
#Text=Methamphetamine use disorder is associated with a high likelihood of relapse.
1-1	0-8	Bayesian	_	
1-2	9-22	computational	_	
1-3	23-30	markers	_	
1-4	31-33	of	_	
1-5	34-41	relapse	_	
1-6	42-44	in	_	
1-7	45-60	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]	
1-8	61-71	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]	
1-9	72-87	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[2]	
1-10	88-91	use	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[2]	
1-11	92-100	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[2]	
1-12	101-103	is	_	
1-13	104-114	associated	_	
1-14	115-119	with	_	
1-15	120-121	a	_	
1-16	122-126	high	_	
1-17	127-137	likelihood	_	
1-18	138-140	of	_	
1-19	141-148	relapse	_	
1-20	148-149	.	_	

#Text=Identifying robust predictors of relapse that have explanatory power is critical to develop secondary prevention based on a mechanistic understanding of relapse.
2-1	150-161	Identifying	_	
2-2	162-168	robust	_	
2-3	169-179	predictors	_	
2-4	180-182	of	_	
2-5	183-190	relapse	_	
2-6	191-195	that	_	
2-7	196-200	have	_	
2-8	201-212	explanatory	_	
2-9	213-218	power	_	
2-10	219-221	is	_	
2-11	222-230	critical	_	
2-12	231-233	to	_	
2-13	234-241	develop	_	
2-14	242-251	secondary	_	
2-15	252-262	prevention	_	
2-16	263-268	based	_	
2-17	269-271	on	_	
2-18	272-273	a	_	
2-19	274-285	mechanistic	_	
2-20	286-299	understanding	_	
2-21	300-302	of	_	
2-22	303-310	relapse	_	
2-23	310-311	.	_	

#Text=Computational approaches have the potential to identify such predictive markers of psychiatric illness, with the advantage of providing a finer mechanistic explanation of the cognitive processes underlying psychiatric vulnerability.
3-1	312-325	Computational	_	
3-2	326-336	approaches	_	
3-3	337-341	have	_	
3-4	342-345	the	_	
3-5	346-355	potential	_	
3-6	356-358	to	_	
3-7	359-367	identify	_	
3-8	368-372	such	_	
3-9	373-383	predictive	_	
3-10	384-391	markers	_	
3-11	392-394	of	_	
3-12	395-406	psychiatric	_	
3-13	407-414	illness	_	
3-14	414-415	,	_	
3-15	416-420	with	_	
3-16	421-424	the	_	
3-17	425-434	advantage	_	
3-18	435-437	of	_	
3-19	438-447	providing	_	
3-20	448-449	a	_	
3-21	450-455	finer	_	
3-22	456-467	mechanistic	_	
3-23	468-479	explanation	_	
3-24	480-482	of	_	
3-25	483-486	the	_	
3-26	487-496	cognitive	_	
3-27	497-506	processes	_	
3-28	507-517	underlying	_	
3-29	518-529	psychiatric	_	
3-30	530-543	vulnerability	_	
3-31	543-544	.	_	

#Text=In this study, sixty-two recently sober methamphetamine-dependent individuals were recruited from a 28-day inpatient treatment program, and completed a Stop Signal Task (SST) while undergoing functional magnetic resonance imaging (fMRI).
4-1	545-547	In	_	
4-2	548-552	this	_	
4-3	553-558	study	_	
4-4	558-559	,	_	
4-5	560-569	sixty-two	_	
4-6	570-578	recently	_	
4-7	579-584	sober	_	
4-8	585-610	methamphetamine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]	
4-9	611-622	individuals	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]	
4-10	623-627	were	_	
4-11	628-637	recruited	_	
4-12	638-642	from	_	
4-13	643-644	a	_	
4-14	645-647	28	_	
4-15	647-648	-	_	
4-16	648-651	day	_	
4-17	652-661	inpatient	_	
4-18	662-671	treatment	_	
4-19	672-679	program	_	
4-20	679-680	,	_	
4-21	681-684	and	_	
4-22	685-694	completed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-23	695-696	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-24	697-701	Stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-25	702-708	Signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-26	709-713	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-27	714-715	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-28	715-718	SST	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-29	718-719	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-30	720-725	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-31	726-736	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-32	737-747	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-33	748-756	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-34	757-766	resonance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-35	767-774	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-36	775-776	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-37	776-780	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-38	780-781	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]	
4-39	781-782	.	_	

#Text=These individuals were prospectively followed for 1 year and assessed for relapse to methamphetamine use.
5-1	783-788	These	_	
5-2	789-800	individuals	_	
5-3	801-805	were	_	
5-4	806-819	prospectively	_	
5-5	820-828	followed	_	
5-6	829-832	for	_	
5-7	833-834	1	_	
5-8	834-835	 	_	
5-9	835-839	year	_	
5-10	840-843	and	_	
5-11	844-852	assessed	_	
5-12	853-856	for	_	
5-13	857-864	relapse	_	
5-14	865-867	to	_	
5-15	868-883	methamphetamine	_	
5-16	884-887	use	_	
5-17	887-888	.	_	

#Text=Thirty-three percent of followed participants reported relapse.
6-1	889-901	Thirty-three	_	
6-2	902-909	percent	_	
6-3	910-912	of	_	
6-4	913-921	followed	_	
6-5	922-934	participants	_	
6-6	935-943	reported	_	
6-7	944-951	relapse	_	
6-8	951-952	.	_	

#Text=We found that neural activity associated with two types of Bayesian prediction error, i.e. the difference between actual and expected need to stop on a given trial, significantly differentiated those individuals who remained abstinent and those who relapsed.
7-1	953-955	We	_	
7-2	956-961	found	_	
7-3	962-966	that	_	
7-4	967-973	neural	_	
7-5	974-982	activity	_	
7-6	983-993	associated	_	
7-7	994-998	with	_	
7-8	999-1002	two	_	
7-9	1003-1008	types	_	
7-10	1009-1011	of	_	
7-11	1012-1020	Bayesian	_	
7-12	1021-1031	prediction	_	
7-13	1032-1037	error	_	
7-14	1037-1038	,	_	
7-15	1039-1042	i.e	_	
7-16	1042-1043	.	_	
7-17	1044-1047	the	_	
7-18	1048-1058	difference	_	
7-19	1059-1066	between	_	
7-20	1067-1073	actual	_	
7-21	1074-1077	and	_	
7-22	1078-1086	expected	_	
7-23	1087-1091	need	_	
7-24	1092-1094	to	_	
7-25	1095-1099	stop	_	
7-26	1100-1102	on	_	
7-27	1103-1104	a	_	
7-28	1105-1110	given	_	
7-29	1111-1116	trial	_	
7-30	1116-1117	,	_	
7-31	1118-1131	significantly	_	
7-32	1132-1146	differentiated	_	
7-33	1147-1152	those	_	
7-34	1153-1164	individuals	_	
7-35	1165-1168	who	_	
7-36	1169-1177	remained	_	
7-37	1178-1187	abstinent	_	
7-38	1188-1191	and	_	
7-39	1192-1197	those	_	
7-40	1198-1201	who	_	
7-41	1202-1210	relapsed	_	
7-42	1210-1211	.	_	

#Text=Specifically, relapsed individuals exhibited smaller neural activations to such Bayesian prediction errors relative to those individuals who remained abstinent in the left temporoparietal junction (Cohen's d = 0.91), the left inferior frontal gyrus (Cohen's d = 0.57), and left anterior insula (Cohen's d = 0.63).
8-1	1212-1224	Specifically	_	
8-2	1224-1225	,	_	
8-3	1226-1234	relapsed	_	
8-4	1235-1246	individuals	_	
8-5	1247-1256	exhibited	_	
8-6	1257-1264	smaller	_	
8-7	1265-1271	neural	_	
8-8	1272-1283	activations	_	
8-9	1284-1286	to	_	
8-10	1287-1291	such	_	
8-11	1292-1300	Bayesian	_	
8-12	1301-1311	prediction	_	
8-13	1312-1318	errors	_	
8-14	1319-1327	relative	_	
8-15	1328-1330	to	_	
8-16	1331-1336	those	_	
8-17	1337-1348	individuals	_	
8-18	1349-1352	who	_	
8-19	1353-1361	remained	_	
8-20	1362-1371	abstinent	_	
8-21	1372-1374	in	_	
8-22	1375-1378	the	_	
8-23	1379-1383	left	_	
8-24	1384-1399	temporoparietal	_	
8-25	1400-1408	junction	_	
8-26	1409-1410	(	_	
8-27	1410-1417	Cohen's	_	
8-28	1418-1419	d	_	
8-29	1419-1420	 	_	
8-30	1420-1421	=	_	
8-31	1421-1422	 	_	
8-32	1422-1426	0.91	_	
8-33	1426-1427	)	_	
8-34	1427-1428	,	_	
8-35	1429-1432	the	_	
8-36	1433-1437	left	_	
8-37	1438-1446	inferior	_	
8-38	1447-1454	frontal	_	
8-39	1455-1460	gyrus	_	
8-40	1461-1462	(	_	
8-41	1462-1469	Cohen's	_	
8-42	1470-1471	d	_	
8-43	1471-1472	 	_	
8-44	1472-1473	=	_	
8-45	1473-1474	 	_	
8-46	1474-1478	0.57	_	
8-47	1478-1479	)	_	
8-48	1479-1480	,	_	
8-49	1481-1484	and	_	
8-50	1485-1489	left	_	
8-51	1490-1498	anterior	_	
8-52	1499-1505	insula	_	
8-53	1506-1507	(	_	
8-54	1507-1514	Cohen's	_	
8-55	1515-1516	d	_	
8-56	1516-1517	 	_	
8-57	1517-1518	=	_	
8-58	1518-1519	 	_	
8-59	1519-1523	0.63	_	
8-60	1523-1524	)	_	
8-61	1524-1525	.	_	

#Text=In contrast, abstinent and relapsed participants did not differ in neural activation to non-model based task contrasts or on various self-report clinical measures.
9-1	1526-1528	In	_	
9-2	1529-1537	contrast	_	
9-3	1537-1538	,	_	
9-4	1539-1548	abstinent	_	
9-5	1549-1552	and	_	
9-6	1553-1561	relapsed	_	
9-7	1562-1574	participants	_	
9-8	1575-1578	did	_	
9-9	1579-1582	not	_	
9-10	1583-1589	differ	_	
9-11	1590-1592	in	_	
9-12	1593-1599	neural	_	
9-13	1600-1610	activation	_	
9-14	1611-1613	to	_	
9-15	1614-1623	non-model	_	
9-16	1624-1629	based	_	
9-17	1630-1634	task	_	
9-18	1635-1644	contrasts	_	
9-19	1645-1647	or	_	
9-20	1648-1650	on	_	
9-21	1651-1658	various	_	
9-22	1659-1670	self-report	_	
9-23	1671-1679	clinical	_	
9-24	1680-1688	measures	_	
9-25	1688-1689	.	_	

#Text=In conclusion, Bayesian cognitive models may help identify predictive biomarkers of relapse, while providing a computational explanation of belief processing and updating deficits in individuals with methamphetamine use disorder.
10-1	1690-1692	In	_	
10-2	1693-1703	conclusion	_	
10-3	1703-1704	,	_	
10-4	1705-1713	Bayesian	_	
10-5	1714-1723	cognitive	_	
10-6	1724-1730	models	_	
10-7	1731-1734	may	_	
10-8	1735-1739	help	_	
10-9	1740-1748	identify	_	
10-10	1749-1759	predictive	_	
10-11	1760-1770	biomarkers	_	
10-12	1771-1773	of	_	
10-13	1774-1781	relapse	_	
10-14	1781-1782	,	_	
10-15	1783-1788	while	_	
10-16	1789-1798	providing	_	
10-17	1799-1800	a	_	
10-18	1801-1814	computational	_	
10-19	1815-1826	explanation	_	
10-20	1827-1829	of	_	
10-21	1830-1836	belief	_	
10-22	1837-1847	processing	_	
10-23	1848-1851	and	_	
10-24	1852-1860	updating	_	
10-25	1861-1869	deficits	_	
10-26	1870-1872	in	_	
10-27	1873-1884	individuals	_	
10-28	1885-1889	with	_	
10-29	1890-1905	methamphetamine	_	
10-30	1906-1909	use	_	
10-31	1910-1918	disorder	_	
10-32	1918-1919	.	_	

#Text=Highlights
#Text=Methamphetamine-dependent individuals (MDI) face a high rate of relapse after treatment.
11-1	1920-1930	Highlights	_	
11-2	1931-1956	Methamphetamine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]	
11-3	1957-1968	individuals	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]	
11-4	1969-1970	(	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]	
11-5	1970-1973	MDI	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]	
11-6	1973-1974	)	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]	
11-7	1975-1979	face	_	
11-8	1980-1981	a	_	
11-9	1982-1986	high	_	
11-10	1987-1991	rate	_	
11-11	1992-1994	of	_	
11-12	1995-2002	relapse	_	
11-13	2003-2008	after	_	
11-14	2009-2018	treatment	_	
11-15	2018-2019	.	_	

#Text=Can a Bayesian learning modeling and fMRI be used to identify markers of relapse?
12-1	2020-2023	Can	_	
12-2	2024-2025	a	_	
12-3	2026-2034	Bayesian	_	
12-4	2035-2043	learning	_	
12-5	2044-2052	modeling	_	
12-6	2053-2056	and	_	
12-7	2057-2061	fMRI	_	
12-8	2062-2064	be	_	
12-9	2065-2069	used	_	
12-10	2070-2072	to	_	
12-11	2073-2081	identify	_	
12-12	2082-2089	markers	_	
12-13	2090-2092	of	_	
12-14	2093-2100	relapse	_	
12-15	2100-2101	?	_	

#Text=MDI who relapsed within 1 year have smaller activation to Bayesian model-based prediction errors.
13-1	2102-2105	MDI	_	
13-2	2106-2109	who	_	
13-3	2110-2118	relapsed	_	
13-4	2119-2125	within	_	
13-5	2126-2127	1	_	
13-6	2127-2128	 	_	
13-7	2128-2132	year	_	
13-8	2133-2137	have	_	
13-9	2138-2145	smaller	_	
13-10	2146-2156	activation	_	
13-11	2157-2159	to	_	
13-12	2160-2168	Bayesian	_	
13-13	2169-2180	model-based	_	
13-14	2181-2191	prediction	_	
13-15	2192-2198	errors	_	
13-16	2198-2199	.	_	

#Text=Such neural pattern was observed in left temporo-parietal junction, IFG, and anterior insula.
14-1	2200-2204	Such	_	
14-2	2205-2211	neural	_	
14-3	2212-2219	pattern	_	
14-4	2220-2223	was	_	
14-5	2224-2232	observed	_	
14-6	2233-2235	in	_	
14-7	2236-2240	left	_	
14-8	2241-2257	temporo-parietal	_	
14-9	2258-2266	junction	_	
14-10	2266-2267	,	_	
14-11	2268-2271	IFG	_	
14-12	2271-2272	,	_	
14-13	2273-2276	and	_	
14-14	2277-2285	anterior	_	
14-15	2286-2292	insula	_	
14-16	2292-2293	.	_	

#Text=MDI more likely to relapse show weaker tracking of uncertainty and updating of their belief model.
15-1	2294-2297	MDI	_	
15-2	2298-2302	more	_	
15-3	2303-2309	likely	_	
15-4	2310-2312	to	_	
15-5	2313-2320	relapse	_	
15-6	2321-2325	show	_	
15-7	2326-2332	weaker	_	
15-8	2333-2341	tracking	_	
15-9	2342-2344	of	_	
15-10	2345-2356	uncertainty	_	
15-11	2357-2360	and	_	
15-12	2361-2369	updating	_	
15-13	2370-2372	of	_	
15-14	2373-2378	their	_	
15-15	2379-2385	belief	_	
15-16	2386-2391	model	_	
15-17	2391-2392	.	_	

#Text=Introduction
#Text=Methamphetamine use disorder is associated with a high likelihood of and short time-span to relapse.
16-1	2393-2405	Introduction	_	
16-2	2406-2421	Methamphetamine	_	
16-3	2422-2425	use	_	
16-4	2426-2434	disorder	_	
16-5	2435-2437	is	_	
16-6	2438-2448	associated	_	
16-7	2449-2453	with	_	
16-8	2454-2455	a	_	
16-9	2456-2460	high	_	
16-10	2461-2471	likelihood	_	
16-11	2472-2474	of	_	
16-12	2475-2478	and	_	
16-13	2479-2484	short	_	
16-14	2485-2494	time-span	_	
16-15	2495-2497	to	_	
16-16	2498-2505	relapse	_	
16-17	2505-2506	.	_	

#Text=Identifying precise and robust predictors of relapse is therefore essential for improving the prevention and treatment of this disorder.
17-1	2507-2518	Identifying	_	
17-2	2519-2526	precise	_	
17-3	2527-2530	and	_	
17-4	2531-2537	robust	_	
17-5	2538-2548	predictors	_	
17-6	2549-2551	of	_	
17-7	2552-2559	relapse	_	
17-8	2560-2562	is	_	
17-9	2563-2572	therefore	_	
17-10	2573-2582	essential	_	
17-11	2583-2586	for	_	
17-12	2587-2596	improving	_	
17-13	2597-2600	the	_	
17-14	2601-2611	prevention	_	
17-15	2612-2615	and	_	
17-16	2616-2625	treatment	_	
17-17	2626-2628	of	_	
17-18	2629-2633	this	_	
17-19	2634-2642	disorder	_	
17-20	2642-2643	.	_	

#Text=Generative computational models have the potential to precisely disambiguate and quantify complex cognitive processes, which may in turn be used to identify specific neuro-cognitive treatment targets for a personalized approach to treating addictive disorders.
18-1	2644-2654	Generative	_	
18-2	2655-2668	computational	_	
18-3	2669-2675	models	_	
18-4	2676-2680	have	_	
18-5	2681-2684	the	_	
18-6	2685-2694	potential	_	
18-7	2695-2697	to	_	
18-8	2698-2707	precisely	_	
18-9	2708-2720	disambiguate	_	
18-10	2721-2724	and	_	
18-11	2725-2733	quantify	_	
18-12	2734-2741	complex	_	
18-13	2742-2751	cognitive	_	
18-14	2752-2761	processes	_	
18-15	2761-2762	,	_	
18-16	2763-2768	which	_	
18-17	2769-2772	may	_	
18-18	2773-2775	in	_	
18-19	2776-2780	turn	_	
18-20	2781-2783	be	_	
18-21	2784-2788	used	_	
18-22	2789-2791	to	_	
18-23	2792-2800	identify	_	
18-24	2801-2809	specific	_	
18-25	2810-2825	neuro-cognitive	_	
18-26	2826-2835	treatment	_	
18-27	2836-2843	targets	_	
18-28	2844-2847	for	_	
18-29	2848-2849	a	_	
18-30	2850-2862	personalized	_	
18-31	2863-2871	approach	_	
18-32	2872-2874	to	_	
18-33	2875-2883	treating	_	
18-34	2884-2893	addictive	_	
18-35	2894-2903	disorders	_	
18-36	2903-2904	.	_	

#Text=Recently, we showed that both healthy individuals and stimulant users continuously alter their response strategy in a standard inhibitory paradigm (stop-signal task, SST), such that dynamic fluctuations in their reaction time and performance are consistent with a Bayesian sequential adjustment of their beliefs and decision strategy.
19-1	2905-2913	Recently	_	
19-2	2913-2914	,	_	
19-3	2915-2917	we	_	
19-4	2918-2924	showed	_	
19-5	2925-2929	that	_	
19-6	2930-2934	both	_	
19-7	2935-2942	healthy	_	
19-8	2943-2954	individuals	_	
19-9	2955-2958	and	_	
19-10	2959-2968	stimulant	_	
19-11	2969-2974	users	_	
19-12	2975-2987	continuously	_	
19-13	2988-2993	alter	_	
19-14	2994-2999	their	_	
19-15	3000-3008	response	_	
19-16	3009-3017	strategy	_	
19-17	3018-3020	in	_	
19-18	3021-3022	a	_	
19-19	3023-3031	standard	_	
19-20	3032-3042	inhibitory	_	
19-21	3043-3051	paradigm	_	
19-22	3052-3053	(	_	
19-23	3053-3064	stop-signal	_	
19-24	3065-3069	task	_	
19-25	3069-3070	,	_	
19-26	3071-3074	SST	_	
19-27	3074-3075	)	_	
19-28	3075-3076	,	_	
19-29	3077-3081	such	_	
19-30	3082-3086	that	_	
19-31	3087-3094	dynamic	_	
19-32	3095-3107	fluctuations	_	
19-33	3108-3110	in	_	
19-34	3111-3116	their	_	
19-35	3117-3125	reaction	_	
19-36	3126-3130	time	_	
19-37	3131-3134	and	_	
19-38	3135-3146	performance	_	
19-39	3147-3150	are	_	
19-40	3151-3161	consistent	_	
19-41	3162-3166	with	_	
19-42	3167-3168	a	_	
19-43	3169-3177	Bayesian	_	
19-44	3178-3188	sequential	_	
19-45	3189-3199	adjustment	_	
19-46	3200-3202	of	_	
19-47	3203-3208	their	_	
19-48	3209-3216	beliefs	_	
19-49	3217-3220	and	_	
19-50	3221-3229	decision	_	
19-51	3230-3238	strategy	_	
19-52	3238-3239	.	_	

#Text=Whereas standard behavioral measures to assess performance in the SST, such as mean stop-signal reaction time (SSRT) or stop signal asynchrony dependent error rate, are relatively easy to obtain, Bayes-optimal model parameters have the advantage that they provide quantitative explanatory measures of an underlying putative cognitive process.
20-1	3240-3247	Whereas	_	
20-2	3248-3256	standard	_	
20-3	3257-3267	behavioral	_	
20-4	3268-3276	measures	_	
20-5	3277-3279	to	_	
20-6	3280-3286	assess	_	
20-7	3287-3298	performance	_	
20-8	3299-3301	in	_	
20-9	3302-3305	the	_	
20-10	3306-3309	SST	_	
20-11	3309-3310	,	_	
20-12	3311-3315	such	_	
20-13	3316-3318	as	_	
20-14	3319-3323	mean	_	
20-15	3324-3335	stop-signal	_	
20-16	3336-3344	reaction	_	
20-17	3345-3349	time	_	
20-18	3350-3351	(	_	
20-19	3351-3355	SSRT	_	
20-20	3355-3356	)	_	
20-21	3357-3359	or	_	
20-22	3360-3364	stop	_	
20-23	3365-3371	signal	_	
20-24	3372-3382	asynchrony	_	
20-25	3383-3392	dependent	_	
20-26	3393-3398	error	_	
20-27	3399-3403	rate	_	
20-28	3403-3404	,	_	
20-29	3405-3408	are	_	
20-30	3409-3419	relatively	_	
20-31	3420-3424	easy	_	
20-32	3425-3427	to	_	
20-33	3428-3434	obtain	_	
20-34	3434-3435	,	_	
20-35	3436-3449	Bayes-optimal	_	
20-36	3450-3455	model	_	
20-37	3456-3466	parameters	_	
20-38	3467-3471	have	_	
20-39	3472-3475	the	_	
20-40	3476-3485	advantage	_	
20-41	3486-3490	that	_	
20-42	3491-3495	they	_	
20-43	3496-3503	provide	_	
20-44	3504-3516	quantitative	_	
20-45	3517-3528	explanatory	_	
20-46	3529-3537	measures	_	
20-47	3538-3540	of	_	
20-48	3541-3543	an	_	
20-49	3544-3554	underlying	_	
20-50	3555-3563	putative	_	
20-51	3564-3573	cognitive	_	
20-52	3574-3581	process	_	
20-53	3581-3582	.	_	

#Text=Moreover, the model can be used to simulate data to better elucidate how behavioral dysfunctions emerge as a consequence of altered underlying cognitive processes.
21-1	3583-3591	Moreover	_	
21-2	3591-3592	,	_	
21-3	3593-3596	the	_	
21-4	3597-3602	model	_	
21-5	3603-3606	can	_	
21-6	3607-3609	be	_	
21-7	3610-3614	used	_	
21-8	3615-3617	to	_	
21-9	3618-3626	simulate	_	
21-10	3627-3631	data	_	
21-11	3632-3634	to	_	
21-12	3635-3641	better	_	
21-13	3642-3651	elucidate	_	
21-14	3652-3655	how	_	
21-15	3656-3666	behavioral	_	
21-16	3667-3679	dysfunctions	_	
21-17	3680-3686	emerge	_	
21-18	3687-3689	as	_	
21-19	3690-3691	a	_	
21-20	3692-3703	consequence	_	
21-21	3704-3706	of	_	
21-22	3707-3714	altered	_	
21-23	3715-3725	underlying	_	
21-24	3726-3735	cognitive	_	
21-25	3736-3745	processes	_	
21-26	3745-3746	.	_	

#Text=Here, we use a similar Bayesian approach combined with fast event-related fMRI to model methamphetamine-dependent individuals' real-time beliefs about the need to stop in the SST, and isolate neural markers of relapse one year after treatment.
22-1	3747-3751	Here	_	
22-2	3751-3752	,	_	
22-3	3753-3755	we	_	
22-4	3756-3759	use	_	
22-5	3760-3761	a	_	
22-6	3762-3769	similar	_	
22-7	3770-3778	Bayesian	_	
22-8	3779-3787	approach	_	
22-9	3788-3796	combined	_	
22-10	3797-3801	with	_	
22-11	3802-3806	fast	_	
22-12	3807-3820	event-related	_	
22-13	3821-3825	fMRI	_	
22-14	3826-3828	to	_	
22-15	3829-3834	model	_	
22-16	3835-3860	methamphetamine-dependent	_	
22-17	3861-3872	individuals	_	
22-18	3872-3873	'	_	
22-19	3874-3883	real-time	_	
22-20	3884-3891	beliefs	_	
22-21	3892-3897	about	_	
22-22	3898-3901	the	_	
22-23	3902-3906	need	_	
22-24	3907-3909	to	_	
22-25	3910-3914	stop	_	
22-26	3915-3917	in	_	
22-27	3918-3921	the	_	
22-28	3922-3925	SST	_	
22-29	3925-3926	,	_	
22-30	3927-3930	and	_	
22-31	3931-3938	isolate	_	
22-32	3939-3945	neural	_	
22-33	3946-3953	markers	_	
22-34	3954-3956	of	_	
22-35	3957-3964	relapse	_	
22-36	3965-3968	one	_	
22-37	3969-3973	year	_	
22-38	3974-3979	after	_	
22-39	3980-3989	treatment	_	
22-40	3989-3990	.	_	

#Text=We aimed to determine whether those computational neural markers of inhibitory function can meaningfully distinguish methamphetamine-dependent individuals who remain abstinent from those who relapse within a year.
23-1	3991-3993	We	_	
23-2	3994-3999	aimed	_	
23-3	4000-4002	to	_	
23-4	4003-4012	determine	_	
23-5	4013-4020	whether	_	
23-6	4021-4026	those	_	
23-7	4027-4040	computational	_	
23-8	4041-4047	neural	_	
23-9	4048-4055	markers	_	
23-10	4056-4058	of	_	
23-11	4059-4069	inhibitory	_	
23-12	4070-4078	function	_	
23-13	4079-4082	can	_	
23-14	4083-4095	meaningfully	_	
23-15	4096-4107	distinguish	_	
23-16	4108-4133	methamphetamine-dependent	_	
23-17	4134-4145	individuals	_	
23-18	4146-4149	who	_	
23-19	4150-4156	remain	_	
23-20	4157-4166	abstinent	_	
23-21	4167-4171	from	_	
23-22	4172-4177	those	_	
23-23	4178-4181	who	_	
23-24	4182-4189	relapse	_	
23-25	4190-4196	within	_	
23-26	4197-4198	a	_	
23-27	4199-4203	year	_	
23-28	4203-4204	.	_	

#Text=Based on recent studies pointing to weaker and less efficient neural encoding of Bayesian expectations of a stop response in the SST, and associated abnormalities in neural tracking of Bayesian prediction errors (i.e. difference between probability and actual occurrence of a stop signal on a given trial) in occasional stimulant users and methamphetamine-dependent individuals, we hypothesized that weaker or less efficient neural responses associated with Bayesian prediction errors would be observed in relapsed relative to abstinent individuals.
24-1	4205-4210	Based	_	
24-2	4211-4213	on	_	
24-3	4214-4220	recent	_	
24-4	4221-4228	studies	_	
24-5	4229-4237	pointing	_	
24-6	4238-4240	to	_	
24-7	4241-4247	weaker	_	
24-8	4248-4251	and	_	
24-9	4252-4256	less	_	
24-10	4257-4266	efficient	_	
24-11	4267-4273	neural	_	
24-12	4274-4282	encoding	_	
24-13	4283-4285	of	_	
24-14	4286-4294	Bayesian	_	
24-15	4295-4307	expectations	_	
24-16	4308-4310	of	_	
24-17	4311-4312	a	_	
24-18	4313-4317	stop	_	
24-19	4318-4326	response	_	
24-20	4327-4329	in	_	
24-21	4330-4333	the	_	
24-22	4334-4337	SST	_	
24-23	4337-4338	,	_	
24-24	4339-4342	and	_	
24-25	4343-4353	associated	_	
24-26	4354-4367	abnormalities	_	
24-27	4368-4370	in	_	
24-28	4371-4377	neural	_	
24-29	4378-4386	tracking	_	
24-30	4387-4389	of	_	
24-31	4390-4398	Bayesian	_	
24-32	4399-4409	prediction	_	
24-33	4410-4416	errors	_	
24-34	4417-4418	(	_	
24-35	4418-4421	i.e	_	
24-36	4421-4422	.	_	
24-37	4423-4433	difference	_	
24-38	4434-4441	between	_	
24-39	4442-4453	probability	_	
24-40	4454-4457	and	_	
24-41	4458-4464	actual	_	
24-42	4465-4475	occurrence	_	
24-43	4476-4478	of	_	
24-44	4479-4480	a	_	
24-45	4481-4485	stop	_	
24-46	4486-4492	signal	_	
24-47	4493-4495	on	_	
24-48	4496-4497	a	_	
24-49	4498-4503	given	_	
24-50	4504-4509	trial	_	
24-51	4509-4510	)	_	
24-52	4511-4513	in	_	
24-53	4514-4524	occasional	_	
24-54	4525-4534	stimulant	_	
24-55	4535-4540	users	_	
24-56	4541-4544	and	_	
24-57	4545-4570	methamphetamine-dependent	_	
24-58	4571-4582	individuals	_	
24-59	4582-4583	,	_	
24-60	4584-4586	we	_	
24-61	4587-4599	hypothesized	_	
24-62	4600-4604	that	_	
24-63	4605-4611	weaker	_	
24-64	4612-4614	or	_	
24-65	4615-4619	less	_	
24-66	4620-4629	efficient	_	
24-67	4630-4636	neural	_	
24-68	4637-4646	responses	_	
24-69	4647-4657	associated	_	
24-70	4658-4662	with	_	
24-71	4663-4671	Bayesian	_	
24-72	4672-4682	prediction	_	
24-73	4683-4689	errors	_	
24-74	4690-4695	would	_	
24-75	4696-4698	be	_	
24-76	4699-4707	observed	_	
24-77	4708-4710	in	_	
24-78	4711-4719	relapsed	_	
24-79	4720-4728	relative	_	
24-80	4729-4731	to	_	
24-81	4732-4741	abstinent	_	
24-82	4742-4753	individuals	_	
24-83	4753-4754	.	_	

#Text=Clusters in the inferior frontal gyrus (IFG; e.g., Brodmann area 44, 47) and overlapping the interior insula bilaterally, as well in the pre-Supplementary Motor Area (SMA) have been robustly implicated in guiding inhibitory function.
25-1	4755-4763	Clusters	_	
25-2	4764-4766	in	_	
25-3	4767-4770	the	_	
25-4	4771-4779	inferior	_	
25-5	4780-4787	frontal	_	
25-6	4788-4793	gyrus	_	
25-7	4794-4795	(	_	
25-8	4795-4798	IFG	_	
25-9	4798-4799	;	_	
25-10	4800-4803	e.g	_	
25-11	4803-4804	.	_	
25-12	4804-4805	,	_	
25-13	4806-4814	Brodmann	_	
25-14	4815-4819	area	_	
25-15	4820-4822	44	_	
25-16	4822-4823	,	_	
25-17	4824-4826	47	_	
25-18	4826-4827	)	_	
25-19	4828-4831	and	_	
25-20	4832-4843	overlapping	_	
25-21	4844-4847	the	_	
25-22	4848-4856	interior	_	
25-23	4857-4863	insula	_	
25-24	4864-4875	bilaterally	_	
25-25	4875-4876	,	_	
25-26	4877-4879	as	_	
25-27	4880-4884	well	_	
25-28	4885-4887	in	_	
25-29	4888-4891	the	_	
25-30	4892-4909	pre-Supplementary	_	
25-31	4910-4915	Motor	_	
25-32	4916-4920	Area	_	
25-33	4921-4922	(	_	
25-34	4922-4925	SMA	_	
25-35	4925-4926	)	_	
25-36	4927-4931	have	_	
25-37	4932-4936	been	_	
25-38	4937-4945	robustly	_	
25-39	4946-4956	implicated	_	
25-40	4957-4959	in	_	
25-41	4960-4967	guiding	_	
25-42	4968-4978	inhibitory	_	
25-43	4979-4987	function	_	
25-44	4987-4988	.	_	

#Text=In those regions, both structural deficits (reduced integrity of white matter fibers) and functional alterations have been observed in stimulant addicted individuals.
26-1	4989-4991	In	_	
26-2	4992-4997	those	_	
26-3	4998-5005	regions	_	
26-4	5005-5006	,	_	
26-5	5007-5011	both	_	
26-6	5012-5022	structural	_	
26-7	5023-5031	deficits	_	
26-8	5032-5033	(	_	
26-9	5033-5040	reduced	_	
26-10	5041-5050	integrity	_	
26-11	5051-5053	of	_	
26-12	5054-5059	white	_	
26-13	5060-5066	matter	_	
26-14	5067-5073	fibers	_	
26-15	5073-5074	)	_	
26-16	5075-5078	and	_	
26-17	5079-5089	functional	_	
26-18	5090-5101	alterations	_	
26-19	5102-5106	have	_	
26-20	5107-5111	been	_	
26-21	5112-5120	observed	_	
26-22	5121-5123	in	_	
26-23	5124-5133	stimulant	_	
26-24	5134-5142	addicted	_	
26-25	5143-5154	individuals	_	
26-26	5154-5155	.	_	

#Text=Larger activation patterns to unsigned Bayesian prediction errors in the SST have also been observed among occasional stimulant users progressing to problem use in a region overlapping the right anterior insula and IFG.
27-1	5156-5162	Larger	_	
27-2	5163-5173	activation	_	
27-3	5174-5182	patterns	_	
27-4	5183-5185	to	_	
27-5	5186-5194	unsigned	_	
27-6	5195-5203	Bayesian	_	
27-7	5204-5214	prediction	_	
27-8	5215-5221	errors	_	
27-9	5222-5224	in	_	
27-10	5225-5228	the	_	
27-11	5229-5232	SST	_	
27-12	5233-5237	have	_	
27-13	5238-5242	also	_	
27-14	5243-5247	been	_	
27-15	5248-5256	observed	_	
27-16	5257-5262	among	_	
27-17	5263-5273	occasional	_	
27-18	5274-5283	stimulant	_	
27-19	5284-5289	users	_	
27-20	5290-5301	progressing	_	
27-21	5302-5304	to	_	
27-22	5305-5312	problem	_	
27-23	5313-5316	use	_	
27-24	5317-5319	in	_	
27-25	5320-5321	a	_	
27-26	5322-5328	region	_	
27-27	5329-5340	overlapping	_	
27-28	5341-5344	the	_	
27-29	5345-5350	right	_	
27-30	5351-5359	anterior	_	
27-31	5360-5366	insula	_	
27-32	5367-5370	and	_	
27-33	5371-5374	IFG	_	
27-34	5374-5375	.	_	

#Text=Based on these combined findings, we expected abnormal prediction error activations in the IFG/anterior insula regions to be associated with more severe addictive profiles and thus with relapse status one year after treatment.
28-1	5376-5381	Based	_	
28-2	5382-5384	on	_	
28-3	5385-5390	these	_	
28-4	5391-5399	combined	_	
28-5	5400-5408	findings	_	
28-6	5408-5409	,	_	
28-7	5410-5412	we	_	
28-8	5413-5421	expected	_	
28-9	5422-5430	abnormal	_	
28-10	5431-5441	prediction	_	
28-11	5442-5447	error	_	
28-12	5448-5459	activations	_	
28-13	5460-5462	in	_	
28-14	5463-5466	the	_	
28-15	5467-5470	IFG	_	
28-16	5470-5471	/	_	
28-17	5471-5479	anterior	_	
28-18	5480-5486	insula	_	
28-19	5487-5494	regions	_	
28-20	5495-5497	to	_	
28-21	5498-5500	be	_	
28-22	5501-5511	associated	_	
28-23	5512-5516	with	_	
28-24	5517-5521	more	_	
28-25	5522-5528	severe	_	
28-26	5529-5538	addictive	_	
28-27	5539-5547	profiles	_	
28-28	5548-5551	and	_	
28-29	5552-5556	thus	_	
28-30	5557-5561	with	_	
28-31	5562-5569	relapse	_	
28-32	5570-5576	status	_	
28-33	5577-5580	one	_	
28-34	5581-5585	year	_	
28-35	5586-5591	after	_	
28-36	5592-5601	treatment	_	
28-37	5601-5602	.	_	

#Text=The anterior cingulate cortex (ACC) and anterior insula have also been robustly linked to encoding of prediction errors and more generally expectancy violation in a wide range of cognitive task, but notably in the SST.
29-1	5603-5606	The	_	
29-2	5607-5615	anterior	_	
29-3	5616-5625	cingulate	_	
29-4	5626-5632	cortex	_	
29-5	5633-5634	(	_	
29-6	5634-5637	ACC	_	
29-7	5637-5638	)	_	
29-8	5639-5642	and	_	
29-9	5643-5651	anterior	_	
29-10	5652-5658	insula	_	
29-11	5659-5663	have	_	
29-12	5664-5668	also	_	
29-13	5669-5673	been	_	
29-14	5674-5682	robustly	_	
29-15	5683-5689	linked	_	
29-16	5690-5692	to	_	
29-17	5693-5701	encoding	_	
29-18	5702-5704	of	_	
29-19	5705-5715	prediction	_	
29-20	5716-5722	errors	_	
29-21	5723-5726	and	_	
29-22	5727-5731	more	_	
29-23	5732-5741	generally	_	
29-24	5742-5752	expectancy	_	
29-25	5753-5762	violation	_	
29-26	5763-5765	in	_	
29-27	5766-5767	a	_	
29-28	5768-5772	wide	_	
29-29	5773-5778	range	_	
29-30	5779-5781	of	_	
29-31	5782-5791	cognitive	_	
29-32	5792-5796	task	_	
29-33	5796-5797	,	_	
29-34	5798-5801	but	_	
29-35	5802-5809	notably	_	
29-36	5810-5812	in	_	
29-37	5813-5816	the	_	
29-38	5817-5820	SST	_	
29-39	5820-5821	.	_	

#Text=At the computational level, both regions have been shown to encode volatility and the tracking of unexpected changes in the environment.
30-1	5822-5824	At	_	
30-2	5825-5828	the	_	
30-3	5829-5842	computational	_	
30-4	5843-5848	level	_	
30-5	5848-5849	,	_	
30-6	5850-5854	both	_	
30-7	5855-5862	regions	_	
30-8	5863-5867	have	_	
30-9	5868-5872	been	_	
30-10	5873-5878	shown	_	
30-11	5879-5881	to	_	
30-12	5882-5888	encode	_	
30-13	5889-5899	volatility	_	
30-14	5900-5903	and	_	
30-15	5904-5907	the	_	
30-16	5908-5916	tracking	_	
30-17	5917-5919	of	_	
30-18	5920-5930	unexpected	_	
30-19	5931-5938	changes	_	
30-20	5939-5941	in	_	
30-21	5942-5945	the	_	
30-22	5946-5957	environment	_	
30-23	5957-5958	.	_	

#Text=Using a similar modeling approach as used here, found that a region in the dorsal ACC overlapping pre-SMA was robustly associated with neural activation to an unsigned Bayesian prediction error in the SST, while we showed that occasional stimulant use was assoviated with weaker activations to the same type of prediction error in similar, albeit more caudal region of the ACC and in the posterior insular cortex.
31-1	5959-5964	Using	_	
31-2	5965-5966	a	_	
31-3	5967-5974	similar	_	
31-4	5975-5983	modeling	_	
31-5	5984-5992	approach	_	
31-6	5993-5995	as	_	
31-7	5996-6000	used	_	
31-8	6001-6005	here	_	
31-9	6005-6006	,	_	
31-10	6007-6012	found	_	
31-11	6013-6017	that	_	
31-12	6018-6019	a	_	
31-13	6020-6026	region	_	
31-14	6027-6029	in	_	
31-15	6030-6033	the	_	
31-16	6034-6040	dorsal	_	
31-17	6041-6044	ACC	_	
31-18	6045-6056	overlapping	_	
31-19	6057-6064	pre-SMA	_	
31-20	6065-6068	was	_	
31-21	6069-6077	robustly	_	
31-22	6078-6088	associated	_	
31-23	6089-6093	with	_	
31-24	6094-6100	neural	_	
31-25	6101-6111	activation	_	
31-26	6112-6114	to	_	
31-27	6115-6117	an	_	
31-28	6118-6126	unsigned	_	
31-29	6127-6135	Bayesian	_	
31-30	6136-6146	prediction	_	
31-31	6147-6152	error	_	
31-32	6153-6155	in	_	
31-33	6156-6159	the	_	
31-34	6160-6163	SST	_	
31-35	6163-6164	,	_	
31-36	6165-6170	while	_	
31-37	6171-6173	we	_	
31-38	6174-6180	showed	_	
31-39	6181-6185	that	_	
31-40	6186-6196	occasional	_	
31-41	6197-6206	stimulant	_	
31-42	6207-6210	use	_	
31-43	6211-6214	was	_	
31-44	6215-6225	assoviated	_	
31-45	6226-6230	with	_	
31-46	6231-6237	weaker	_	
31-47	6238-6249	activations	_	
31-48	6250-6252	to	_	
31-49	6253-6256	the	_	
31-50	6257-6261	same	_	
31-51	6262-6266	type	_	
31-52	6267-6269	of	_	
31-53	6270-6280	prediction	_	
31-54	6281-6286	error	_	
31-55	6287-6289	in	_	
31-56	6290-6297	similar	_	
31-57	6297-6298	,	_	
31-58	6299-6305	albeit	_	
31-59	6306-6310	more	_	
31-60	6311-6317	caudal	_	
31-61	6318-6324	region	_	
31-62	6325-6327	of	_	
31-63	6328-6331	the	_	
31-64	6332-6335	ACC	_	
31-65	6336-6339	and	_	
31-66	6340-6342	in	_	
31-67	6343-6346	the	_	
31-68	6347-6356	posterior	_	
31-69	6357-6364	insular	_	
31-70	6365-6371	cortex	_	
31-71	6371-6372	.	_	

#Text=Based on this research, we hypothesized that weaker or abnormal neural signals in those regions would be associated with less efficient tracking of model-based uncertainty and thus more apparent in relapsed individuals.
32-1	6373-6378	Based	_	
32-2	6379-6381	on	_	
32-3	6382-6386	this	_	
32-4	6387-6395	research	_	
32-5	6395-6396	,	_	
32-6	6397-6399	we	_	
32-7	6400-6412	hypothesized	_	
32-8	6413-6417	that	_	
32-9	6418-6424	weaker	_	
32-10	6425-6427	or	_	
32-11	6428-6436	abnormal	_	
32-12	6437-6443	neural	_	
32-13	6444-6451	signals	_	
32-14	6452-6454	in	_	
32-15	6455-6460	those	_	
32-16	6461-6468	regions	_	
32-17	6469-6474	would	_	
32-18	6475-6477	be	_	
32-19	6478-6488	associated	_	
32-20	6489-6493	with	_	
32-21	6494-6498	less	_	
32-22	6499-6508	efficient	_	
32-23	6509-6517	tracking	_	
32-24	6518-6520	of	_	
32-25	6521-6532	model-based	_	
32-26	6533-6544	uncertainty	_	
32-27	6545-6548	and	_	
32-28	6549-6553	thus	_	
32-29	6554-6558	more	_	
32-30	6559-6567	apparent	_	
32-31	6568-6570	in	_	
32-32	6571-6579	relapsed	_	
32-33	6580-6591	individuals	_	
32-34	6591-6592	.	_	

#Text=Finally, the superior temporal gyrus, specifically the temporoparietal junction, has been associated with dynamic learning and anticipatory processes, including proactive inhibition, i.e. the anticipation of the need to stop in the SST.
33-1	6593-6600	Finally	_	
33-2	6600-6601	,	_	
33-3	6602-6605	the	_	
33-4	6606-6614	superior	_	
33-5	6615-6623	temporal	_	
33-6	6624-6629	gyrus	_	
33-7	6629-6630	,	_	
33-8	6631-6643	specifically	_	
33-9	6644-6647	the	_	
33-10	6648-6663	temporoparietal	_	
33-11	6664-6672	junction	_	
33-12	6672-6673	,	_	
33-13	6674-6677	has	_	
33-14	6678-6682	been	_	
33-15	6683-6693	associated	_	
33-16	6694-6698	with	_	
33-17	6699-6706	dynamic	_	
33-18	6707-6715	learning	_	
33-19	6716-6719	and	_	
33-20	6720-6732	anticipatory	_	
33-21	6733-6742	processes	_	
33-22	6742-6743	,	_	
33-23	6744-6753	including	_	
33-24	6754-6763	proactive	_	
33-25	6764-6774	inhibition	_	
33-26	6774-6775	,	_	
33-27	6776-6779	i.e	_	
33-28	6779-6780	.	_	
33-29	6781-6784	the	_	
33-30	6785-6797	anticipation	_	
33-31	6798-6800	of	_	
33-32	6801-6804	the	_	
33-33	6805-6809	need	_	
33-34	6810-6812	to	_	
33-35	6813-6817	stop	_	
33-36	6818-6820	in	_	
33-37	6821-6824	the	_	
33-38	6825-6828	SST	_	
33-39	6828-6829	.	_	

#Text=The left temporoparietal junction, in particular, is involved in mathematical computations and has recently been implicated in Bayesian learning.
34-1	6830-6833	The	_	
34-2	6834-6838	left	_	
34-3	6839-6854	temporoparietal	_	
34-4	6855-6863	junction	_	
34-5	6863-6864	,	_	
34-6	6865-6867	in	_	
34-7	6868-6878	particular	_	
34-8	6878-6879	,	_	
34-9	6880-6882	is	_	
34-10	6883-6891	involved	_	
34-11	6892-6894	in	_	
34-12	6895-6907	mathematical	_	
34-13	6908-6920	computations	_	
34-14	6921-6924	and	_	
34-15	6925-6928	has	_	
34-16	6929-6937	recently	_	
34-17	6938-6942	been	_	
34-18	6943-6953	implicated	_	
34-19	6954-6956	in	_	
34-20	6957-6965	Bayesian	_	
34-21	6966-6974	learning	_	
34-22	6974-6975	.	_	

#Text=Given consistent evidence of learning deficits, and findings of hypo-activations of the superior temporal gyrus and temporoparietal junction during learning-based decision-making in methamphetamine dependence, we therefore expected potential computational learning inefficiencies to be reflected in weaker recruitment of this brain region among individuals more susceptible to relapse.
35-1	6976-6981	Given	_	
35-2	6982-6992	consistent	_	
35-3	6993-7001	evidence	_	
35-4	7002-7004	of	_	
35-5	7005-7013	learning	_	
35-6	7014-7022	deficits	_	
35-7	7022-7023	,	_	
35-8	7024-7027	and	_	
35-9	7028-7036	findings	_	
35-10	7037-7039	of	_	
35-11	7040-7056	hypo-activations	_	
35-12	7057-7059	of	_	
35-13	7060-7063	the	_	
35-14	7064-7072	superior	_	
35-15	7073-7081	temporal	_	
35-16	7082-7087	gyrus	_	
35-17	7088-7091	and	_	
35-18	7092-7107	temporoparietal	_	
35-19	7108-7116	junction	_	
35-20	7117-7123	during	_	
35-21	7124-7138	learning-based	_	
35-22	7139-7154	decision-making	_	
35-23	7155-7157	in	_	
35-24	7158-7173	methamphetamine	_	
35-25	7174-7184	dependence	_	
35-26	7184-7185	,	_	
35-27	7186-7188	we	_	
35-28	7189-7198	therefore	_	
35-29	7199-7207	expected	_	
35-30	7208-7217	potential	_	
35-31	7218-7231	computational	_	
35-32	7232-7240	learning	_	
35-33	7241-7255	inefficiencies	_	
35-34	7256-7258	to	_	
35-35	7259-7261	be	_	
35-36	7262-7271	reflected	_	
35-37	7272-7274	in	_	
35-38	7275-7281	weaker	_	
35-39	7282-7293	recruitment	_	
35-40	7294-7296	of	_	
35-41	7297-7301	this	_	
35-42	7302-7307	brain	_	
35-43	7308-7314	region	_	
35-44	7315-7320	among	_	
35-45	7321-7332	individuals	_	
35-46	7333-7337	more	_	
35-47	7338-7349	susceptible	_	
35-48	7350-7352	to	_	
35-49	7353-7360	relapse	_	
35-50	7360-7361	.	_	

#Text=Taken together, recent computational evidence suggests altered Bayesian learning during inhibitory control tasks such as the SST in stimulant users of varying clinical severity.
36-1	7362-7367	Taken	_	
36-2	7368-7376	together	_	
36-3	7376-7377	,	_	
36-4	7378-7384	recent	_	
36-5	7385-7398	computational	_	
36-6	7399-7407	evidence	_	
36-7	7408-7416	suggests	_	
36-8	7417-7424	altered	_	
36-9	7425-7433	Bayesian	_	
36-10	7434-7442	learning	_	
36-11	7443-7449	during	_	
36-12	7450-7460	inhibitory	_	
36-13	7461-7468	control	_	
36-14	7469-7474	tasks	_	
36-15	7475-7479	such	_	
36-16	7480-7482	as	_	
36-17	7483-7486	the	_	
36-18	7487-7490	SST	_	
36-19	7491-7493	in	_	
36-20	7494-7503	stimulant	_	
36-21	7504-7509	users	_	
36-22	7510-7512	of	_	
36-23	7513-7520	varying	_	
36-24	7521-7529	clinical	_	
36-25	7530-7538	severity	_	
36-26	7538-7539	.	_	

#Text=Given that areas identified above are both critical to inhibitory control implementation and have been linked to recruitment abnormalities in stimulant users during inhibitory control, we hypothesized that among individuals diagnosed with methamphetamine dependence, those more likely to relapse would exhibit less efficient inhibitory learning as reflected by weaker neural responses associated with anticipation and belief updating.
37-1	7540-7545	Given	_	
37-2	7546-7550	that	_	
37-3	7551-7556	areas	_	
37-4	7557-7567	identified	_	
37-5	7568-7573	above	_	
37-6	7574-7577	are	_	
37-7	7578-7582	both	_	
37-8	7583-7591	critical	_	
37-9	7592-7594	to	_	
37-10	7595-7605	inhibitory	_	
37-11	7606-7613	control	_	
37-12	7614-7628	implementation	_	
37-13	7629-7632	and	_	
37-14	7633-7637	have	_	
37-15	7638-7642	been	_	
37-16	7643-7649	linked	_	
37-17	7650-7652	to	_	
37-18	7653-7664	recruitment	_	
37-19	7665-7678	abnormalities	_	
37-20	7679-7681	in	_	
37-21	7682-7691	stimulant	_	
37-22	7692-7697	users	_	
37-23	7698-7704	during	_	
37-24	7705-7715	inhibitory	_	
37-25	7716-7723	control	_	
37-26	7723-7724	,	_	
37-27	7725-7727	we	_	
37-28	7728-7740	hypothesized	_	
37-29	7741-7745	that	_	
37-30	7746-7751	among	_	
37-31	7752-7763	individuals	_	
37-32	7764-7773	diagnosed	_	
37-33	7774-7778	with	_	
37-34	7779-7794	methamphetamine	_	
37-35	7795-7805	dependence	_	
37-36	7805-7806	,	_	
37-37	7807-7812	those	_	
37-38	7813-7817	more	_	
37-39	7818-7824	likely	_	
37-40	7825-7827	to	_	
37-41	7828-7835	relapse	_	
37-42	7836-7841	would	_	
37-43	7842-7849	exhibit	_	
37-44	7850-7854	less	_	
37-45	7855-7864	efficient	_	
37-46	7865-7875	inhibitory	_	
37-47	7876-7884	learning	_	
37-48	7885-7887	as	_	
37-49	7888-7897	reflected	_	
37-50	7898-7900	by	_	
37-51	7901-7907	weaker	_	
37-52	7908-7914	neural	_	
37-53	7915-7924	responses	_	
37-54	7925-7935	associated	_	
37-55	7936-7940	with	_	
37-56	7941-7953	anticipation	_	
37-57	7954-7957	and	_	
37-58	7958-7964	belief	_	
37-59	7965-7973	updating	_	
37-60	7973-7974	.	_	

#Text=We predicted these weaker neural signals would be particularly observable in regions key to inhibitory control and inhibitory learning, including the IFG, anterior insula, ACC, and temporoparietal junction.
38-1	7975-7977	We	_	
38-2	7978-7987	predicted	_	
38-3	7988-7993	these	_	
38-4	7994-8000	weaker	_	
38-5	8001-8007	neural	_	
38-6	8008-8015	signals	_	
38-7	8016-8021	would	_	
38-8	8022-8024	be	_	
38-9	8025-8037	particularly	_	
38-10	8038-8048	observable	_	
38-11	8049-8051	in	_	
38-12	8052-8059	regions	_	
38-13	8060-8063	key	_	
38-14	8064-8066	to	_	
38-15	8067-8077	inhibitory	_	
38-16	8078-8085	control	_	
38-17	8086-8089	and	_	
38-18	8090-8100	inhibitory	_	
38-19	8101-8109	learning	_	
38-20	8109-8110	,	_	
38-21	8111-8120	including	_	
38-22	8121-8124	the	_	
38-23	8125-8128	IFG	_	
38-24	8128-8129	,	_	
38-25	8130-8138	anterior	_	
38-26	8139-8145	insula	_	
38-27	8145-8146	,	_	
38-28	8147-8150	ACC	_	
38-29	8150-8151	,	_	
38-30	8152-8155	and	_	
38-31	8156-8171	temporoparietal	_	
38-32	8172-8180	junction	_	
38-33	8180-8181	.	_	

#Text=Methods
#Text=Participants
#Text=The study protocol was approved by the UCSD Human Research Protections Program and all subjects gave written informed consent.
39-1	8182-8189	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
39-2	8190-8202	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-3	8203-8206	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-4	8207-8212	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-5	8213-8221	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-6	8222-8225	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-7	8226-8234	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-8	8235-8237	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-9	8238-8241	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-10	8242-8246	UCSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-11	8247-8252	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-12	8253-8261	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-13	8262-8273	Protections	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-14	8274-8281	Program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-15	8282-8285	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-16	8286-8289	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-17	8290-8298	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-18	8299-8303	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-19	8304-8311	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-20	8312-8320	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-21	8321-8328	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
39-22	8328-8329	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Sixty-two (21% female) recently sober methamphetamine-dependent individuals were recruited from a 28-day inpatient Alcohol and Drug Treatment Program at the Veterans Affairs San Diego Healthcare System and Scripps Green Hospital (La Jolla, CA; cross-sectional analysis of these data published elsewhere).
40-1	8330-8339	Sixty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-2	8340-8341	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-3	8341-8344	21%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-4	8345-8351	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-5	8351-8352	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-6	8353-8361	recently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-7	8362-8367	sober	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-8	8368-8393	methamphetamine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]	
40-9	8394-8405	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]	
40-10	8406-8410	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-11	8411-8420	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-12	8421-8425	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-13	8426-8427	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-14	8428-8430	28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-15	8430-8431	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-16	8431-8434	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-17	8435-8444	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-18	8445-8452	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-19	8453-8456	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-20	8457-8461	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-21	8462-8471	Treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-22	8472-8479	Program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-23	8480-8482	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-24	8483-8486	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-25	8487-8495	Veterans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-26	8496-8503	Affairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-27	8504-8507	San	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-28	8508-8513	Diego	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-29	8514-8524	Healthcare	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-30	8525-8531	System	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-31	8532-8535	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-32	8536-8543	Scripps	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-33	8544-8549	Green	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-34	8550-8558	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-35	8559-8560	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-36	8560-8562	La	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-37	8563-8568	Jolla	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-38	8568-8569	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-39	8570-8572	CA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-40	8572-8573	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-41	8574-8589	cross-sectional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-42	8590-8598	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-43	8599-8601	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-44	8602-8607	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-45	8608-8612	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-46	8613-8622	published	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-47	8623-8632	elsewhere	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-48	8632-8633	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-49	8633-8634	.	_	

#Text=All study procedures, including the neuroimaging session examining brain and behavior responses during the SST, occurred during the third or fourth week of treatment for all participants (i.e., all had been abstinent from methamphetamine or any other drugs, including alcohol, for 3–4 weeks).
41-1	8635-8638	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-2	8639-8644	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-3	8645-8655	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-4	8655-8656	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-5	8657-8666	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-6	8667-8670	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-7	8671-8683	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-8	8684-8691	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-9	8692-8701	examining	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-10	8702-8707	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-11	8708-8711	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-12	8712-8720	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-13	8721-8730	responses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-14	8731-8737	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-15	8738-8741	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-16	8742-8745	SST	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-17	8745-8746	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-18	8747-8755	occurred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-19	8756-8762	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-20	8763-8766	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-21	8767-8772	third	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-22	8773-8775	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-23	8776-8782	fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-24	8783-8787	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-25	8788-8790	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-26	8791-8800	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-27	8801-8804	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-28	8805-8808	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-29	8809-8821	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-30	8822-8823	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-31	8823-8826	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-32	8826-8827	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-33	8827-8828	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-34	8829-8832	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-35	8833-8836	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-36	8837-8841	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-37	8842-8851	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-38	8852-8856	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-39	8857-8872	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-40	8873-8875	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-41	8876-8879	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-42	8880-8885	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-43	8886-8891	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-44	8891-8892	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-45	8893-8902	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-46	8903-8910	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-47	8910-8911	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-48	8912-8915	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-49	8916-8917	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-50	8917-8918	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-51	8918-8919	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-52	8919-8920	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-53	8920-8925	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-54	8925-8926	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
41-55	8926-8927	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=To maintain sobriety during the program, participants were screened for the presence of drugs via random urine toxicology or whenever they left the facility, and were terminated from the program if tested positive.
42-1	8928-8930	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-2	8931-8939	maintain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-3	8940-8948	sobriety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-4	8949-8955	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-5	8956-8959	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-6	8960-8967	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-7	8967-8968	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-8	8969-8981	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-9	8982-8986	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-10	8987-8995	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-11	8996-8999	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-12	9000-9003	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-13	9004-9012	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-14	9013-9015	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-15	9016-9021	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-16	9022-9025	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-17	9026-9032	random	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-18	9033-9038	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-19	9039-9049	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-20	9050-9052	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-21	9053-9061	whenever	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-22	9062-9066	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-23	9067-9071	left	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-24	9072-9075	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-25	9076-9084	facility	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-26	9084-9085	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-27	9086-9089	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-28	9090-9094	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-29	9095-9105	terminated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-30	9106-9110	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-31	9111-9114	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-32	9115-9122	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-33	9123-9125	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-34	9126-9132	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-35	9133-9141	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
42-36	9141-9142	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Participants also performed the North American Adult Reading Test as a measure of verbal intelligence, and completed self-report measures of personality and affective measures previously associated with stimulant addiction vulnerability, including the Barratt Impulsiveness Scale (BIS-11), the Sensation Seeking Scale (SSS-V), and the Beck Depression Inventory (BDI).
43-1	9143-9155	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-2	9156-9160	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-3	9161-9170	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-4	9171-9174	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-5	9175-9180	North	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[13]	
43-6	9181-9189	American	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[13]	
43-7	9190-9195	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[13]	
43-8	9196-9203	Reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[13]	
43-9	9204-9208	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest[13]	
43-10	9209-9211	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-11	9212-9213	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-12	9214-9221	measure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-13	9222-9224	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-14	9225-9231	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-15	9232-9244	intelligence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-16	9244-9245	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-17	9246-9249	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-18	9250-9259	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-19	9260-9271	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-20	9272-9280	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-21	9281-9283	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-22	9284-9295	personality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-23	9296-9299	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-24	9300-9309	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-25	9310-9318	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale[14]	
43-26	9319-9329	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-27	9330-9340	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-28	9341-9345	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-29	9346-9355	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-30	9356-9365	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-31	9366-9379	vulnerability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-32	9379-9380	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-33	9381-9390	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-34	9391-9394	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-35	9395-9402	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-36	9403-9416	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-37	9417-9422	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-38	9423-9424	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-39	9424-9427	BIS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-40	9427-9428	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-41	9428-9430	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[15]	
43-42	9430-9431	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-43	9431-9432	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-44	9433-9436	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-45	9437-9446	Sensation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-46	9447-9454	Seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-47	9455-9460	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-48	9461-9462	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-49	9462-9467	SSS-V	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-50	9467-9468	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-51	9468-9469	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-52	9470-9473	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-53	9474-9477	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
43-54	9478-9482	Beck	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-55	9483-9493	Depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-56	9494-9503	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-57	9504-9505	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-58	9505-9508	BDI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-59	9508-9509	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
43-60	9509-9510	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Lifetime DSM-IV Axis I and II diagnoses at baseline were assessed with the Semi Structured Assessment for the Genetics of Alcoholism and based on consensus meetings with the supervising clinician and trained study personnel, including a Masters-level research assistant and postdoctoral-level psychologist (see Supplementary Text 1 for exclusion criteria).
44-1	9511-9519	Lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-2	9520-9526	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-3	9527-9531	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-4	9532-9533	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-5	9534-9537	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-6	9538-9540	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-7	9541-9550	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-8	9551-9553	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-9	9554-9562	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-10	9563-9567	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-11	9568-9576	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-12	9577-9581	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-13	9582-9585	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-14	9586-9590	Semi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-15	9591-9601	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-16	9602-9612	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-17	9613-9616	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-18	9617-9620	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-19	9621-9629	Genetics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-20	9630-9632	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-21	9633-9643	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[18]	
44-22	9644-9647	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-23	9648-9653	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-24	9654-9656	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-25	9657-9666	consensus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-26	9667-9675	meetings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-27	9676-9680	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-28	9681-9684	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-29	9685-9696	supervising	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-30	9697-9706	clinician	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-31	9707-9710	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-32	9711-9718	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-33	9719-9724	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-34	9725-9734	personnel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-35	9734-9735	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-36	9736-9745	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-37	9746-9747	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-38	9748-9761	Masters-level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-39	9762-9770	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-40	9771-9780	assistant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-41	9781-9784	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-42	9785-9803	postdoctoral-level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-43	9804-9816	psychologist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-44	9817-9818	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-45	9818-9821	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-46	9822-9835	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-47	9836-9840	Text	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-48	9841-9842	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-49	9843-9846	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-50	9847-9856	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-51	9857-9865	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-52	9865-9866	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-53	9866-9867	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Methamphetamine dependence, and not DSM-5 diagnosis of methamphetamine use disorder, was assessed because DSM-IV was in effect at the start of the study.
45-1	9868-9883	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-2	9884-9894	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-3	9894-9895	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-4	9896-9899	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-5	9900-9903	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-6	9904-9907	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-7	9907-9908	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-8	9908-9909	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-9	9910-9919	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-10	9920-9922	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-11	9923-9938	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-12	9939-9942	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-13	9943-9951	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]	
45-14	9951-9952	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-15	9953-9956	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-16	9957-9965	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-17	9966-9973	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-18	9974-9980	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-19	9981-9984	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-20	9985-9987	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-21	9988-9994	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-22	9995-9997	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-23	9998-10001	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-24	10002-10007	start	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-25	10008-10010	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-26	10011-10014	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-27	10015-10020	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
45-28	10020-10021	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Participants were contacted one year later for a brief structured phone interview to assess for any use of methamphetamine, level of use, and time of relapse.
46-1	10022-10034	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-2	10035-10039	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-3	10040-10049	contacted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-4	10050-10053	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-5	10054-10058	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-6	10059-10064	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-7	10065-10068	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-8	10069-10070	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-9	10071-10076	brief	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-10	10077-10087	structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-11	10088-10093	phone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-12	10094-10103	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-13	10104-10106	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-14	10107-10113	assess	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-15	10114-10117	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-16	10118-10121	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-17	10122-10125	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-18	10126-10128	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-19	10129-10144	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-20	10144-10145	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-21	10146-10151	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-22	10152-10154	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-23	10155-10158	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-24	10158-10159	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-25	10160-10163	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-26	10164-10168	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-27	10169-10171	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-28	10172-10179	relapse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
46-29	10179-10180	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=At baseline, we also assessed for use and abuse/dependence criteria for other drugs (i.e., sedatives, hallucinogens, marijuana, cocaine or opiates) in the past year, as part of a larger longitudinal study, which also followed individuals with other primary drugs of abuse.
47-1	10181-10183	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-2	10184-10192	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-3	10192-10193	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-4	10194-10196	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-5	10197-10201	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-6	10202-10210	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-7	10211-10214	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-8	10215-10218	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-9	10219-10222	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-10	10223-10228	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-11	10228-10229	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-12	10229-10239	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-13	10240-10248	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-14	10249-10252	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-15	10253-10258	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-16	10259-10264	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-17	10265-10266	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-18	10266-10269	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-19	10269-10270	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-20	10270-10271	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-21	10272-10281	sedatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-22	10281-10282	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-23	10283-10296	hallucinogens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-24	10296-10297	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-25	10298-10307	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-26	10307-10308	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-27	10309-10316	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-28	10317-10319	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-29	10320-10327	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-30	10327-10328	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-31	10329-10331	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-32	10332-10335	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-33	10336-10340	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-34	10341-10345	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-35	10345-10346	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-36	10347-10349	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-37	10350-10354	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-38	10355-10357	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-39	10358-10359	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-40	10360-10366	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-41	10367-10379	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-42	10380-10385	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-43	10385-10386	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-44	10387-10392	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-45	10393-10397	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-46	10398-10406	followed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-47	10407-10418	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-48	10419-10423	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-49	10424-10429	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-50	10430-10437	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-51	10438-10443	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-52	10444-10446	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-53	10447-10452	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
47-54	10452-10453	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=For all participants in this study, methamphetamine was confirmed as participants' drug of choice.
48-1	10454-10457	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-2	10458-10461	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-3	10462-10474	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-4	10475-10477	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-5	10478-10482	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-6	10483-10488	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-7	10488-10489	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-8	10490-10505	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-9	10506-10509	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-10	10510-10519	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-11	10520-10522	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-12	10523-10535	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-13	10535-10536	'	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-14	10537-10541	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-15	10542-10544	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-16	10545-10551	choice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
48-17	10551-10552	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Relapse was defined as use of methamphetamine at any point during the follow-up period, while some participants may have additionally relapsed to any of these other substances (not assessed at follow-up).
49-1	10553-10560	Relapse	_	
49-2	10561-10564	was	_	
49-3	10565-10572	defined	_	
49-4	10573-10575	as	_	
49-5	10576-10579	use	_	
49-6	10580-10582	of	_	
49-7	10583-10598	methamphetamine	_	
49-8	10599-10601	at	_	
49-9	10602-10605	any	_	
49-10	10606-10611	point	_	
49-11	10612-10618	during	_	
49-12	10619-10622	the	_	
49-13	10623-10632	follow-up	_	
49-14	10633-10639	period	_	
49-15	10639-10640	,	_	
49-16	10641-10646	while	_	
49-17	10647-10651	some	_	
49-18	10652-10664	participants	_	
49-19	10665-10668	may	_	
49-20	10669-10673	have	_	
49-21	10674-10686	additionally	_	
49-22	10687-10695	relapsed	_	
49-23	10696-10698	to	_	
49-24	10699-10702	any	_	
49-25	10703-10705	of	_	
49-26	10706-10711	these	_	
49-27	10712-10717	other	_	
49-28	10718-10728	substances	_	
49-29	10729-10730	(	_	
49-30	10730-10733	not	_	
49-31	10734-10742	assessed	_	
49-32	10743-10745	at	_	
49-33	10746-10755	follow-up	_	
49-34	10755-10756	)	_	
49-35	10756-10757	.	_	

#Text=Based on interview responses, thirty-nine methamphetamine-dependent individuals remained abstinent from methamphetamine from the time of treatment to one-year follow-up.
50-1	10758-10763	Based	_	
50-2	10764-10766	on	_	
50-3	10767-10776	interview	_	
50-4	10777-10786	responses	_	
50-5	10786-10787	,	_	
50-6	10788-10799	thirty-nine	_	
50-7	10800-10825	methamphetamine-dependent	_	
50-8	10826-10837	individuals	_	
50-9	10838-10846	remained	_	
50-10	10847-10856	abstinent	_	
50-11	10857-10861	from	_	
50-12	10862-10877	methamphetamine	_	
50-13	10878-10882	from	_	
50-14	10883-10886	the	_	
50-15	10887-10891	time	_	
50-16	10892-10894	of	_	
50-17	10895-10904	treatment	_	
50-18	10905-10907	to	_	
50-19	10908-10916	one-year	_	
50-20	10917-10926	follow-up	_	
50-21	10926-10927	.	_	

#Text=Nineteen individuals reported that they relapsed.
51-1	10928-10936	Nineteen	_	
51-2	10937-10948	individuals	_	
51-3	10949-10957	reported	_	
51-4	10958-10962	that	_	
51-5	10963-10967	they	_	
51-6	10968-10976	relapsed	_	
51-7	10976-10977	.	_	

#Text=Four participants could not be tracked.
52-1	10978-10982	Four	_	
52-2	10983-10995	participants	_	
52-3	10996-11001	could	_	
52-4	11002-11005	not	_	
52-5	11006-11008	be	_	
52-6	11009-11016	tracked	_	
52-7	11016-11017	.	_	

#Text=Stop signal task
#Text=Participants completed a stop-signal task (6 blocks of 48 trials) while undergoing fMRI.
53-1	11018-11022	Stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-2	11023-11029	signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-3	11030-11034	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-4	11035-11047	Participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-5	11048-11057	completed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-6	11058-11059	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-7	11060-11071	stop-signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-8	11072-11076	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-9	11077-11078	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-10	11078-11079	6	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-11	11080-11086	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-12	11087-11089	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-13	11090-11092	48	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-14	11093-11099	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-15	11099-11100	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-16	11101-11106	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-17	11107-11117	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
53-18	11118-11122	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[22]	
53-19	11122-11123	.	_	

#Text=On 216 go trials (75% of all trials), they had to press as fast as possible the left button when an ‘X' appeared or the right button when an ‘O' appeared.
54-1	11124-11126	On	_	
54-2	11127-11130	216	_	
54-3	11131-11133	go	_	
54-4	11134-11140	trials	_	
54-5	11141-11142	(	_	
54-6	11142-11145	75%	_	
54-7	11146-11148	of	_	
54-8	11149-11152	all	_	
54-9	11153-11159	trials	_	
54-10	11159-11160	)	_	
54-11	11160-11161	,	_	
54-12	11162-11166	they	_	
54-13	11167-11170	had	_	
54-14	11171-11173	to	_	
54-15	11174-11179	press	_	
54-16	11180-11182	as	_	
54-17	11183-11187	fast	_	
54-18	11188-11190	as	_	
54-19	11191-11199	possible	_	
54-20	11200-11203	the	_	
54-21	11204-11208	left	_	
54-22	11209-11215	button	_	
54-23	11216-11220	when	_	
54-24	11221-11223	an	_	
54-25	11224-11225	‘	_	
54-26	11225-11226	X	_	
54-27	11226-11227	'	_	
54-28	11228-11236	appeared	_	
54-29	11237-11239	or	_	
54-30	11240-11243	the	_	
54-31	11244-11249	right	_	
54-32	11250-11256	button	_	
54-33	11257-11261	when	_	
54-34	11262-11264	an	_	
54-35	11265-11266	‘	_	
54-36	11266-11267	O	_	
54-37	11267-11268	'	_	
54-38	11269-11277	appeared	_	
54-39	11277-11278	.	_	

#Text=On 72 stop trials (25% of all trials), they heard a tone shortly after onset of the go stimulus, which instructed them not to press either button.
55-1	11279-11281	On	_	
55-2	11282-11284	72	_	
55-3	11285-11289	stop	_	
55-4	11290-11296	trials	_	
55-5	11297-11298	(	_	
55-6	11298-11301	25%	_	
55-7	11302-11304	of	_	
55-8	11305-11308	all	_	
55-9	11309-11315	trials	_	
55-10	11315-11316	)	_	
55-11	11316-11317	,	_	
55-12	11318-11322	they	_	
55-13	11323-11328	heard	_	
55-14	11329-11330	a	_	
55-15	11331-11335	tone	_	
55-16	11336-11343	shortly	_	
55-17	11344-11349	after	_	
55-18	11350-11355	onset	_	
55-19	11356-11358	of	_	
55-20	11359-11362	the	_	
55-21	11363-11365	go	_	
55-22	11366-11374	stimulus	_	
55-23	11374-11375	,	_	
55-24	11376-11381	which	_	
55-25	11382-11392	instructed	_	
55-26	11393-11397	them	_	
55-27	11398-11401	not	_	
55-28	11402-11404	to	_	
55-29	11405-11410	press	_	
55-30	11411-11417	either	_	
55-31	11418-11424	button	_	
55-32	11424-11425	.	_	

#Text=Each trial lasted around 1300 ms, and trials were separated by a 200-ms inter-stimulus intervals (blank screen).
56-1	11426-11430	Each	_	
56-2	11431-11436	trial	_	
56-3	11437-11443	lasted	_	
56-4	11444-11450	around	_	
56-5	11451-11455	1300	_	
56-6	11455-11456	 	_	
56-7	11456-11458	ms	_	
56-8	11458-11459	,	_	
56-9	11460-11463	and	_	
56-10	11464-11470	trials	_	
56-11	11471-11475	were	_	
56-12	11476-11485	separated	_	
56-13	11486-11488	by	_	
56-14	11489-11490	a	_	
56-15	11491-11494	200	_	
56-16	11494-11495	-	_	
56-17	11495-11497	ms	_	
56-18	11498-11512	inter-stimulus	_	
56-19	11513-11522	intervals	_	
56-20	11523-11524	(	_	
56-21	11524-11529	blank	_	
56-22	11530-11536	screen	_	
56-23	11536-11537	)	_	
56-24	11537-11538	.	_	

#Text=Individuals' reaction time (time from stimulus onset to button press) provided a natural jitter.
57-1	11539-11550	Individuals	_	
57-2	11550-11551	'	_	
57-3	11552-11560	reaction	_	
57-4	11561-11565	time	_	
57-5	11566-11567	(	_	
57-6	11567-11571	time	_	
57-7	11572-11576	from	_	
57-8	11577-11585	stimulus	_	
57-9	11586-11591	onset	_	
57-10	11592-11594	to	_	
57-11	11595-11601	button	_	
57-12	11602-11607	press	_	
57-13	11607-11608	)	_	
57-14	11609-11617	provided	_	
57-15	11618-11619	a	_	
57-16	11620-11627	natural	_	
57-17	11628-11634	jitter	_	
57-18	11634-11635	.	_	

#Text=The sequence of trial types presented was pseudo-randomized.
58-1	11636-11639	The	_	
58-2	11640-11648	sequence	_	
58-3	11649-11651	of	_	
58-4	11652-11657	trial	_	
58-5	11658-11663	types	_	
58-6	11664-11673	presented	_	
58-7	11674-11677	was	_	
58-8	11678-11695	pseudo-randomized	_	
58-9	11695-11696	.	_	

#Text=Finally, prior to scanning, participants completed the SST outside the scanner to determine their mean ‘Go’ reaction time (MRT).
59-1	11697-11704	Finally	_	
59-2	11704-11705	,	_	
59-3	11706-11711	prior	_	
59-4	11712-11714	to	_	
59-5	11715-11723	scanning	_	
59-6	11723-11724	,	_	
59-7	11725-11737	participants	_	
59-8	11738-11747	completed	_	
59-9	11748-11751	the	_	
59-10	11752-11755	SST	_	
59-11	11756-11763	outside	_	
59-12	11764-11767	the	_	
59-13	11768-11775	scanner	_	
59-14	11776-11778	to	_	
59-15	11779-11788	determine	_	
59-16	11789-11794	their	_	
59-17	11795-11799	mean	_	
59-18	11800-11801	‘	_	
59-19	11801-11803	Go	_	
59-20	11803-11804	’	_	
59-21	11805-11813	reaction	_	
59-22	11814-11818	time	_	
59-23	11819-11820	(	_	
59-24	11820-11823	MRT	_	
59-25	11823-11824	)	_	
59-26	11824-11825	.	_	

#Text=This measure was then used to determine the stop signal delay (SSD) for six different types stop trial of increasing difficulty, providing a subject-dependent jittered reference function.
60-1	11826-11830	This	_	
60-2	11831-11838	measure	_	
60-3	11839-11842	was	_	
60-4	11843-11847	then	_	
60-5	11848-11852	used	_	
60-6	11853-11855	to	_	
60-7	11856-11865	determine	_	
60-8	11866-11869	the	_	
60-9	11870-11874	stop	_	
60-10	11875-11881	signal	_	
60-11	11882-11887	delay	_	
60-12	11888-11889	(	_	
60-13	11889-11892	SSD	_	
60-14	11892-11893	)	_	
60-15	11894-11897	for	_	
60-16	11898-11901	six	_	
60-17	11902-11911	different	_	
60-18	11912-11917	types	_	
60-19	11918-11922	stop	_	
60-20	11923-11928	trial	_	
60-21	11929-11931	of	_	
60-22	11932-11942	increasing	_	
60-23	11943-11953	difficulty	_	
60-24	11953-11954	,	_	
60-25	11955-11964	providing	_	
60-26	11965-11966	a	_	
60-27	11967-11984	subject-dependent	_	
60-28	11985-11993	jittered	_	
60-29	11994-12003	reference	_	
60-30	12004-12012	function	_	
60-31	12012-12013	.	_	

#Text=Specifically, stop signals were delivered in equal amounts at MRT-0 ms, MRT-100 ms, MRT-200 ms, MRT-300 ms, MRT-400 ms, and MRT-500 ms providing an individually customized range of difficulty; see Supplementary Text 2 for task instructions).
61-1	12014-12026	Specifically	_	
61-2	12026-12027	,	_	
61-3	12028-12032	stop	_	
61-4	12033-12040	signals	_	
61-5	12041-12045	were	_	
61-6	12046-12055	delivered	_	
61-7	12056-12058	in	_	
61-8	12059-12064	equal	_	
61-9	12065-12072	amounts	_	
61-10	12073-12075	at	_	
61-11	12076-12079	MRT	_	
61-12	12079-12080	-	_	
61-13	12080-12081	0	_	
61-14	12081-12082	 	_	
61-15	12082-12084	ms	_	
61-16	12084-12085	,	_	
61-17	12086-12089	MRT	_	
61-18	12089-12090	-	_	
61-19	12090-12093	100	_	
61-20	12093-12094	 	_	
61-21	12094-12096	ms	_	
61-22	12096-12097	,	_	
61-23	12098-12101	MRT	_	
61-24	12101-12102	-	_	
61-25	12102-12105	200	_	
61-26	12105-12106	 	_	
61-27	12106-12108	ms	_	
61-28	12108-12109	,	_	
61-29	12110-12113	MRT	_	
61-30	12113-12114	-	_	
61-31	12114-12117	300	_	
61-32	12117-12118	 	_	
61-33	12118-12120	ms	_	
61-34	12120-12121	,	_	
61-35	12122-12125	MRT	_	
61-36	12125-12126	-	_	
61-37	12126-12129	400	_	
61-38	12129-12130	 	_	
61-39	12130-12132	ms	_	
61-40	12132-12133	,	_	
61-41	12134-12137	and	_	
61-42	12138-12141	MRT	_	
61-43	12141-12142	-	_	
61-44	12142-12145	500	_	
61-45	12145-12146	 	_	
61-46	12146-12148	ms	_	
61-47	12149-12158	providing	_	
61-48	12159-12161	an	_	
61-49	12162-12174	individually	_	
61-50	12175-12185	customized	_	
61-51	12186-12191	range	_	
61-52	12192-12194	of	_	
61-53	12195-12205	difficulty	_	
61-54	12205-12206	;	_	
61-55	12207-12210	see	_	
61-56	12211-12224	Supplementary	_	
61-57	12225-12229	Text	_	
61-58	12230-12231	2	_	
61-59	12232-12235	for	_	
61-60	12236-12240	task	_	
61-61	12241-12253	instructions	_	
61-62	12253-12254	)	_	
61-63	12254-12255	.	_	

#Text=Bayesian model of the inhibitory response expectation
#Text=To model behavior, we used a Bayes-optimal Dynamic Belief Model, which has been robustly established to capture behavioral adjustments in the SST in both healthy individuals and substance users.
62-1	12256-12264	Bayesian	_	
62-2	12265-12270	model	_	
62-3	12271-12273	of	_	
62-4	12274-12277	the	_	
62-5	12278-12288	inhibitory	_	
62-6	12289-12297	response	_	
62-7	12298-12309	expectation	_	
62-8	12310-12312	To	_	
62-9	12313-12318	model	_	
62-10	12319-12327	behavior	_	
62-11	12327-12328	,	_	
62-12	12329-12331	we	_	
62-13	12332-12336	used	_	
62-14	12337-12338	a	_	
62-15	12339-12352	Bayes-optimal	_	
62-16	12353-12360	Dynamic	_	
62-17	12361-12367	Belief	_	
62-18	12368-12373	Model	_	
62-19	12373-12374	,	_	
62-20	12375-12380	which	_	
62-21	12381-12384	has	_	
62-22	12385-12389	been	_	
62-23	12390-12398	robustly	_	
62-24	12399-12410	established	_	
62-25	12411-12413	to	_	
62-26	12414-12421	capture	_	
62-27	12422-12432	behavioral	_	
62-28	12433-12444	adjustments	_	
62-29	12445-12447	in	_	
62-30	12448-12451	the	_	
62-31	12452-12455	SST	_	
62-32	12456-12458	in	_	
62-33	12459-12463	both	_	
62-34	12464-12471	healthy	_	
62-35	12472-12483	individuals	_	
62-36	12484-12487	and	_	
62-37	12488-12497	substance	_	
62-38	12498-12503	users	_	
62-39	12503-12504	.	_	

#Text=The model assumes that one 1) updates the prior probability of encountering stop trials, P(stop), on a trial-by-trial basis based on trial history, and 2) adjusts behavior as a function of P(stop) with higher predicted P(stop) prompting slower Go RT and higher likelihood of correctly stopping on a stop trial.
63-1	12505-12508	The	_	
63-2	12509-12514	model	_	
63-3	12515-12522	assumes	_	
63-4	12523-12527	that	_	
63-5	12528-12531	one	_	
63-6	12532-12533	1	_	
63-7	12533-12534	)	_	
63-8	12535-12542	updates	_	
63-9	12543-12546	the	_	
63-10	12547-12552	prior	_	
63-11	12553-12564	probability	_	
63-12	12565-12567	of	_	
63-13	12568-12580	encountering	_	
63-14	12581-12585	stop	_	
63-15	12586-12592	trials	_	
63-16	12592-12593	,	_	
63-17	12594-12595	P	_	
63-18	12595-12596	(	_	
63-19	12596-12600	stop	_	
63-20	12600-12601	)	_	
63-21	12601-12602	,	_	
63-22	12603-12605	on	_	
63-23	12606-12607	a	_	
63-24	12608-12622	trial-by-trial	_	
63-25	12623-12628	basis	_	
63-26	12629-12634	based	_	
63-27	12635-12637	on	_	
63-28	12638-12643	trial	_	
63-29	12644-12651	history	_	
63-30	12651-12652	,	_	
63-31	12653-12656	and	_	
63-32	12657-12658	2	_	
63-33	12658-12659	)	_	
63-34	12660-12667	adjusts	_	
63-35	12668-12676	behavior	_	
63-36	12677-12679	as	_	
63-37	12680-12681	a	_	
63-38	12682-12690	function	_	
63-39	12691-12693	of	_	
63-40	12694-12695	P	_	
63-41	12695-12696	(	_	
63-42	12696-12700	stop	_	
63-43	12700-12701	)	_	
63-44	12702-12706	with	_	
63-45	12707-12713	higher	_	
63-46	12714-12723	predicted	_	
63-47	12724-12725	P	_	
63-48	12725-12726	(	_	
63-49	12726-12730	stop	_	
63-50	12730-12731	)	_	
63-51	12732-12741	prompting	_	
63-52	12742-12748	slower	_	
63-53	12749-12751	Go	_	
63-54	12752-12754	RT	_	
63-55	12755-12758	and	_	
63-56	12759-12765	higher	_	
63-57	12766-12776	likelihood	_	
63-58	12777-12779	of	_	
63-59	12780-12789	correctly	_	
63-60	12790-12798	stopping	_	
63-61	12799-12801	on	_	
63-62	12802-12803	a	_	
63-63	12804-12808	stop	_	
63-64	12809-12814	trial	_	
63-65	12814-12815	.	_	

#Text=Mathematically, on each trial k, Pk(stop) is the mean of the predictive distribution p(rk|sk-1), which is a mixture of the previous posterior distribution and a fixed prior distribution, with α and 1 − α acting as the mixing coefficients, respectively, and where Sk = (s1, …,sk) is 1 on stop trials and 0 on go trials:
#Text=with the posterior distribution being updated according to Bayes' Rule:
#Text=A.
64-1	12816-12830	Mathematically	_	
64-2	12830-12831	,	_	
64-3	12832-12834	on	_	
64-4	12835-12839	each	_	
64-5	12840-12845	trial	_	
64-6	12846-12847	k	_	
64-7	12847-12848	,	_	
64-8	12849-12851	Pk	_	
64-9	12851-12852	(	_	
64-10	12852-12856	stop	_	
64-11	12856-12857	)	_	
64-12	12858-12860	is	_	
64-13	12861-12864	the	_	
64-14	12865-12869	mean	_	
64-15	12870-12872	of	_	
64-16	12873-12876	the	_	
64-17	12877-12887	predictive	_	
64-18	12888-12900	distribution	_	
64-19	12901-12902	p	_	
64-20	12902-12903	(	_	
64-21	12903-12905	rk	_	
64-22	12905-12906	|	_	
64-23	12906-12908	sk	_	
64-24	12908-12909	-	_	
64-25	12909-12910	1	_	
64-26	12910-12911	)	_	
64-27	12911-12912	,	_	
64-28	12913-12918	which	_	
64-29	12919-12921	is	_	
64-30	12922-12923	a	_	
64-31	12924-12931	mixture	_	
64-32	12932-12934	of	_	
64-33	12935-12938	the	_	
64-34	12939-12947	previous	_	
64-35	12948-12957	posterior	_	
64-36	12958-12970	distribution	_	
64-37	12971-12974	and	_	
64-38	12975-12976	a	_	
64-39	12977-12982	fixed	_	
64-40	12983-12988	prior	_	
64-41	12989-13001	distribution	_	
64-42	13001-13002	,	_	
64-43	13003-13007	with	_	
64-44	13008-13009	α	_	
64-45	13010-13013	and	_	
64-46	13014-13015	1	_	
64-47	13015-13016	 	_	
64-48	13016-13017	−	_	
64-49	13017-13018	 	_	
64-50	13018-13019	α	_	
64-51	13020-13026	acting	_	
64-52	13027-13029	as	_	
64-53	13030-13033	the	_	
64-54	13034-13040	mixing	_	
64-55	13041-13053	coefficients	_	
64-56	13053-13054	,	_	
64-57	13055-13067	respectively	_	
64-58	13067-13068	,	_	
64-59	13069-13072	and	_	
64-60	13073-13078	where	_	
64-61	13079-13081	Sk	_	
64-62	13081-13082	 	_	
64-63	13082-13083	=	_	
64-64	13083-13084	 	_	
64-65	13084-13085	(	_	
64-66	13085-13087	s1	_	
64-67	13087-13088	,	_	
64-68	13089-13090	…	_	
64-69	13090-13091	,	_	
64-70	13091-13093	sk	_	
64-71	13093-13094	)	_	
64-72	13095-13097	is	_	
64-73	13098-13099	1	_	
64-74	13100-13102	on	_	
64-75	13103-13107	stop	_	
64-76	13108-13114	trials	_	
64-77	13115-13118	and	_	
64-78	13119-13120	0	_	
64-79	13121-13123	on	_	
64-80	13124-13126	go	_	
64-81	13127-13133	trials	_	
64-82	13133-13134	:	_	
64-83	13135-13139	with	_	
64-84	13140-13143	the	_	
64-85	13144-13153	posterior	_	
64-86	13154-13166	distribution	_	
64-87	13167-13172	being	_	
64-88	13173-13180	updated	_	
64-89	13181-13190	according	_	
64-90	13191-13193	to	_	
64-91	13194-13199	Bayes	_	
64-92	13199-13200	'	_	
64-93	13201-13205	Rule	_	
64-94	13205-13206	:	_	
64-95	13207-13208	A	_	
64-96	13208-13209	.	_	

#Text=P(stop) as a function of trial sequence.
65-1	13210-13211	P	_	
65-2	13211-13212	(	_	
65-3	13212-13216	stop	_	
65-4	13216-13217	)	_	
65-5	13218-13220	as	_	
65-6	13221-13222	a	_	
65-7	13223-13231	function	_	
65-8	13232-13234	of	_	
65-9	13235-13240	trial	_	
65-10	13241-13249	sequence	_	
65-11	13249-13250	.	_	

#Text=Top: for the sequence of go (green dots, outcome = 0) and stop (blue dots, outcome = 1) trials, Bayesian prior belief about encountering a stop trial (P(stop), red line), as predicted by the Dynamic Belief Model.
66-1	13251-13254	Top	_	
66-2	13254-13255	:	_	
66-3	13256-13259	for	_	
66-4	13260-13263	the	_	
66-5	13264-13272	sequence	_	
66-6	13273-13275	of	_	
66-7	13276-13278	go	_	
66-8	13279-13280	(	_	
66-9	13280-13285	green	_	
66-10	13286-13290	dots	_	
66-11	13290-13291	,	_	
66-12	13292-13299	outcome	_	
66-13	13299-13300	 	_	
66-14	13300-13301	=	_	
66-15	13301-13302	 	_	
66-16	13302-13303	0	_	
66-17	13303-13304	)	_	
66-18	13305-13308	and	_	
66-19	13309-13313	stop	_	
66-20	13314-13315	(	_	
66-21	13315-13319	blue	_	
66-22	13320-13324	dots	_	
66-23	13324-13325	,	_	
66-24	13326-13333	outcome	_	
66-25	13333-13334	 	_	
66-26	13334-13335	=	_	
66-27	13335-13336	 	_	
66-28	13336-13337	1	_	
66-29	13337-13338	)	_	
66-30	13339-13345	trials	_	
66-31	13345-13346	,	_	
66-32	13347-13355	Bayesian	_	
66-33	13356-13361	prior	_	
66-34	13362-13368	belief	_	
66-35	13369-13374	about	_	
66-36	13375-13387	encountering	_	
66-37	13388-13389	a	_	
66-38	13390-13394	stop	_	
66-39	13395-13400	trial	_	
66-40	13401-13402	(	_	
66-41	13402-13403	P	_	
66-42	13403-13404	(	_	
66-43	13404-13408	stop	_	
66-44	13408-13409	)	_	
66-45	13409-13410	,	_	
66-46	13411-13414	red	_	
66-47	13415-13419	line	_	
66-48	13419-13420	)	_	
66-49	13420-13421	,	_	
66-50	13422-13424	as	_	
66-51	13425-13434	predicted	_	
66-52	13435-13437	by	_	
66-53	13438-13441	the	_	
66-54	13442-13449	Dynamic	_	
66-55	13450-13456	Belief	_	
66-56	13457-13462	Model	_	
66-57	13462-13463	.	_	

#Text=P(stop) increases after each stop trial, and decreases after each go trial.
67-1	13464-13465	P	_	
67-2	13465-13466	(	_	
67-3	13466-13470	stop	_	
67-4	13470-13471	)	_	
67-5	13472-13481	increases	_	
67-6	13482-13487	after	_	
67-7	13488-13492	each	_	
67-8	13493-13497	stop	_	
67-9	13498-13503	trial	_	
67-10	13503-13504	,	_	
67-11	13505-13508	and	_	
67-12	13509-13518	decreases	_	
67-13	13519-13524	after	_	
67-14	13525-13529	each	_	
67-15	13530-13532	go	_	
67-16	13533-13538	trial	_	
67-17	13538-13539	.	_	

#Text=Bottom: The corresponding signed prediction error (SPE, red line, solid), SPE = stimulus outcome − P(stop), and unsigned prediction error (UPE, blue, dashed), SPE = |stimulus outcome − P(stop)|.
68-1	13540-13546	Bottom	_	
68-2	13546-13547	:	_	
68-3	13548-13551	The	_	
68-4	13552-13565	corresponding	_	
68-5	13566-13572	signed	_	
68-6	13573-13583	prediction	_	
68-7	13584-13589	error	_	
68-8	13590-13591	(	_	
68-9	13591-13594	SPE	_	
68-10	13594-13595	,	_	
68-11	13596-13599	red	_	
68-12	13600-13604	line	_	
68-13	13604-13605	,	_	
68-14	13606-13611	solid	_	
68-15	13611-13612	)	_	
68-16	13612-13613	,	_	
68-17	13614-13617	SPE	_	
68-18	13617-13618	 	_	
68-19	13618-13619	=	_	
68-20	13619-13620	 	_	
68-21	13620-13628	stimulus	_	
68-22	13629-13636	outcome	_	
68-23	13637-13638	−	_	
68-24	13639-13640	P	_	
68-25	13640-13641	(	_	
68-26	13641-13645	stop	_	
68-27	13645-13646	)	_	
68-28	13646-13647	,	_	
68-29	13648-13651	and	_	
68-30	13652-13660	unsigned	_	
68-31	13661-13671	prediction	_	
68-32	13672-13677	error	_	
68-33	13678-13679	(	_	
68-34	13679-13682	UPE	_	
68-35	13682-13683	,	_	
68-36	13684-13688	blue	_	
68-37	13688-13689	,	_	
68-38	13690-13696	dashed	_	
68-39	13696-13697	)	_	
68-40	13697-13698	,	_	
68-41	13699-13702	SPE	_	
68-42	13702-13703	 	_	
68-43	13703-13704	=	_	
68-44	13704-13705	 	_	
68-45	13705-13706	|	_	
68-46	13706-13714	stimulus	_	
68-47	13715-13722	outcome	_	
68-48	13723-13724	−	_	
68-49	13725-13726	P	_	
68-50	13726-13727	(	_	
68-51	13727-13731	stop	_	
68-52	13731-13732	)	_	
68-53	13732-13733	|	_	
68-54	13733-13734	.	_	

#Text=B.
69-1	13735-13736	B	_	
69-2	13736-13737	.	_	

#Text=Model fit for both methamphetamine dependent individuals who maintained abstinence over a 1 year (black; n = 39) and those who relapsed within 1 year of treatment (red; n = 19); data collapsed across all subjects for relapsed and abstinent groups separately, where Go trials were binned by P(stop) and average RT calculated for each bin separately; as predicted by our Bayes optimal decision-making model, a significant positive relationship was observed between individuals' Go reaction times (RT) and trial-wise P(stop) model estimates in each group; black and red lines represent best linear regression fit to mean go reaction time for each group.
70-1	13738-13743	Model	_	
70-2	13744-13747	fit	_	
70-3	13748-13751	for	_	
70-4	13752-13756	both	_	
70-5	13757-13772	methamphetamine	_	
70-6	13773-13782	dependent	_	
70-7	13783-13794	individuals	_	
70-8	13795-13798	who	_	
70-9	13799-13809	maintained	_	
70-10	13810-13820	abstinence	_	
70-11	13821-13825	over	_	
70-12	13826-13827	a	_	
70-13	13828-13829	1	_	
70-14	13829-13830	 	_	
70-15	13830-13834	year	_	
70-16	13835-13836	(	_	
70-17	13836-13841	black	_	
70-18	13841-13842	;	_	
70-19	13843-13844	n	_	
70-20	13844-13845	 	_	
70-21	13845-13846	=	_	
70-22	13846-13847	 	_	
70-23	13847-13849	39	_	
70-24	13849-13850	)	_	
70-25	13851-13854	and	_	
70-26	13855-13860	those	_	
70-27	13861-13864	who	_	
70-28	13865-13873	relapsed	_	
70-29	13874-13880	within	_	
70-30	13881-13882	1	_	
70-31	13882-13883	 	_	
70-32	13883-13887	year	_	
70-33	13888-13890	of	_	
70-34	13891-13900	treatment	_	
70-35	13901-13902	(	_	
70-36	13902-13905	red	_	
70-37	13905-13906	;	_	
70-38	13907-13908	n	_	
70-39	13908-13909	 	_	
70-40	13909-13910	=	_	
70-41	13910-13911	 	_	
70-42	13911-13913	19	_	
70-43	13913-13914	)	_	
70-44	13914-13915	;	_	
70-45	13916-13920	data	_	
70-46	13921-13930	collapsed	_	
70-47	13931-13937	across	_	
70-48	13938-13941	all	_	
70-49	13942-13950	subjects	_	
70-50	13951-13954	for	_	
70-51	13955-13963	relapsed	_	
70-52	13964-13967	and	_	
70-53	13968-13977	abstinent	_	
70-54	13978-13984	groups	_	
70-55	13985-13995	separately	_	
70-56	13995-13996	,	_	
70-57	13997-14002	where	_	
70-58	14003-14005	Go	_	
70-59	14006-14012	trials	_	
70-60	14013-14017	were	_	
70-61	14018-14024	binned	_	
70-62	14025-14027	by	_	
70-63	14028-14029	P	_	
70-64	14029-14030	(	_	
70-65	14030-14034	stop	_	
70-66	14034-14035	)	_	
70-67	14036-14039	and	_	
70-68	14040-14047	average	_	
70-69	14048-14050	RT	_	
70-70	14051-14061	calculated	_	
70-71	14062-14065	for	_	
70-72	14066-14070	each	_	
70-73	14071-14074	bin	_	
70-74	14075-14085	separately	_	
70-75	14085-14086	;	_	
70-76	14087-14089	as	_	
70-77	14090-14099	predicted	_	
70-78	14100-14102	by	_	
70-79	14103-14106	our	_	
70-80	14107-14112	Bayes	_	
70-81	14113-14120	optimal	_	
70-82	14121-14136	decision-making	_	
70-83	14137-14142	model	_	
70-84	14142-14143	,	_	
70-85	14144-14145	a	_	
70-86	14146-14157	significant	_	
70-87	14158-14166	positive	_	
70-88	14167-14179	relationship	_	
70-89	14180-14183	was	_	
70-90	14184-14192	observed	_	
70-91	14193-14200	between	_	
70-92	14201-14212	individuals	_	
70-93	14212-14213	'	_	
70-94	14214-14216	Go	_	
70-95	14217-14225	reaction	_	
70-96	14226-14231	times	_	
70-97	14232-14233	(	_	
70-98	14233-14235	RT	_	
70-99	14235-14236	)	_	
70-100	14237-14240	and	_	
70-101	14241-14251	trial-wise	_	
70-102	14252-14253	P	_	
70-103	14253-14254	(	_	
70-104	14254-14258	stop	_	
70-105	14258-14259	)	_	
70-106	14260-14265	model	_	
70-107	14266-14275	estimates	_	
70-108	14276-14278	in	_	
70-109	14279-14283	each	_	
70-110	14284-14289	group	_	
70-111	14289-14290	;	_	
70-112	14291-14296	black	_	
70-113	14297-14300	and	_	
70-114	14301-14304	red	_	
70-115	14305-14310	lines	_	
70-116	14311-14320	represent	_	
70-117	14321-14325	best	_	
70-118	14326-14332	linear	_	
70-119	14333-14343	regression	_	
70-120	14344-14347	fit	_	
70-121	14348-14350	to	_	
70-122	14351-14355	mean	_	
70-123	14356-14358	go	_	
70-124	14359-14367	reaction	_	
70-125	14368-14372	time	_	
70-126	14373-14376	for	_	
70-127	14377-14381	each	_	
70-128	14382-14387	group	_	
70-129	14387-14388	.	_	

#Text=Error bars = SEM.
71-1	14389-14394	Error	_	
71-2	14395-14399	bars	_	
71-3	14399-14400	 	_	
71-4	14400-14401	=	_	
71-5	14401-14402	 	_	
71-6	14402-14405	SEM	_	
71-7	14405-14406	.	_	

#Text=Fig. 1
#Text=In this study, model parameters for the beta distribution p0(r) and α were kept constant across all participants, based on prior simulations that sought to optimize behavioral fit at the group level, i.e., maximizing the goodness-of-fit of the linear regression of P(Stop) on RT across all participants (see Supplementary Text 3).
72-1	14407-14410	Fig	_	
72-2	14410-14411	.	_	
72-3	14412-14413	1	_	
72-4	14414-14416	In	_	
72-5	14417-14421	this	_	
72-6	14422-14427	study	_	
72-7	14427-14428	,	_	
72-8	14429-14434	model	_	
72-9	14435-14445	parameters	_	
72-10	14446-14449	for	_	
72-11	14450-14453	the	_	
72-12	14454-14458	beta	_	
72-13	14459-14471	distribution	_	
72-14	14472-14474	p0	_	
72-15	14474-14475	(	_	
72-16	14475-14476	r	_	
72-17	14476-14477	)	_	
72-18	14478-14481	and	_	
72-19	14482-14483	α	_	
72-20	14484-14488	were	_	
72-21	14489-14493	kept	_	
72-22	14494-14502	constant	_	
72-23	14503-14509	across	_	
72-24	14510-14513	all	_	
72-25	14514-14526	participants	_	
72-26	14526-14527	,	_	
72-27	14528-14533	based	_	
72-28	14534-14536	on	_	
72-29	14537-14542	prior	_	
72-30	14543-14554	simulations	_	
72-31	14555-14559	that	_	
72-32	14560-14566	sought	_	
72-33	14567-14569	to	_	
72-34	14570-14578	optimize	_	
72-35	14579-14589	behavioral	_	
72-36	14590-14593	fit	_	
72-37	14594-14596	at	_	
72-38	14597-14600	the	_	
72-39	14601-14606	group	_	
72-40	14607-14612	level	_	
72-41	14612-14613	,	_	
72-42	14614-14617	i.e	_	
72-43	14617-14618	.	_	
72-44	14618-14619	,	_	
72-45	14620-14630	maximizing	_	
72-46	14631-14634	the	_	
72-47	14635-14650	goodness-of-fit	_	
72-48	14651-14653	of	_	
72-49	14654-14657	the	_	
72-50	14658-14664	linear	_	
72-51	14665-14675	regression	_	
72-52	14676-14678	of	_	
72-53	14679-14680	P	_	
72-54	14680-14681	(	_	
72-55	14681-14685	Stop	_	
72-56	14685-14686	)	_	
72-57	14687-14689	on	_	
72-58	14690-14692	RT	_	
72-59	14693-14699	across	_	
72-60	14700-14703	all	_	
72-61	14704-14716	participants	_	
72-62	14717-14718	(	_	
72-63	14718-14721	see	_	
72-64	14722-14735	Supplementary	_	
72-65	14736-14740	Text	_	
72-66	14741-14742	3	_	
72-67	14742-14743	)	_	
72-68	14743-14744	.	_	

#Text=A fixed setting of p0 = Beta(a = 2.5,b = 7.5; s = a + b = 10; mean = 0.25) was used, and alpha was fit to participants' data (range tested: 0.25–1.0; α = 0.5 maximized overall fit across all participants; see Fig. 1A for P(stop) sequence).
73-1	14745-14746	A	_	
73-2	14747-14752	fixed	_	
73-3	14753-14760	setting	_	
73-4	14761-14763	of	_	
73-5	14764-14766	p0	_	
73-6	14766-14767	 	_	
73-7	14767-14768	=	_	
73-8	14768-14769	 	_	
73-9	14769-14773	Beta	_	
73-10	14773-14774	(	_	
73-11	14774-14775	a	_	
73-12	14775-14776	 	_	
73-13	14776-14777	=	_	
73-14	14777-14778	 	_	
73-15	14778-14781	2.5	_	
73-16	14781-14782	,	_	
73-17	14782-14783	b	_	
73-18	14783-14784	 	_	
73-19	14784-14785	=	_	
73-20	14785-14786	 	_	
73-21	14786-14789	7.5	_	
73-22	14789-14790	;	_	
73-23	14791-14792	s	_	
73-24	14792-14793	 	_	
73-25	14793-14794	=	_	
73-26	14794-14795	 	_	
73-27	14795-14796	a	_	
73-28	14796-14797	 	_	
73-29	14797-14798	+	_	
73-30	14798-14799	 	_	
73-31	14799-14800	b	_	
73-32	14800-14801	 	_	
73-33	14801-14802	=	_	
73-34	14802-14803	 	_	
73-35	14803-14805	10	_	
73-36	14805-14806	;	_	
73-37	14807-14811	mean	_	
73-38	14811-14812	 	_	
73-39	14812-14813	=	_	
73-40	14813-14814	 	_	
73-41	14814-14818	0.25	_	
73-42	14818-14819	)	_	
73-43	14820-14823	was	_	
73-44	14824-14828	used	_	
73-45	14828-14829	,	_	
73-46	14830-14833	and	_	
73-47	14834-14839	alpha	_	
73-48	14840-14843	was	_	
73-49	14844-14847	fit	_	
73-50	14848-14850	to	_	
73-51	14851-14863	participants	_	
73-52	14863-14864	'	_	
73-53	14865-14869	data	_	
73-54	14870-14871	(	_	
73-55	14871-14876	range	_	
73-56	14877-14883	tested	_	
73-57	14883-14884	:	_	
73-58	14885-14889	0.25	_	
73-59	14889-14890	–	_	
73-60	14890-14893	1.0	_	
73-61	14893-14894	;	_	
73-62	14895-14896	α	_	
73-63	14896-14897	 	_	
73-64	14897-14898	=	_	
73-65	14898-14899	 	_	
73-66	14899-14902	0.5	_	
73-67	14903-14912	maximized	_	
73-68	14913-14920	overall	_	
73-69	14921-14924	fit	_	
73-70	14925-14931	across	_	
73-71	14932-14935	all	_	
73-72	14936-14948	participants	_	
73-73	14948-14949	;	_	
73-74	14950-14953	see	_	
73-75	14954-14957	Fig	_	
73-76	14957-14958	.	_	
73-77	14959-14961	1A	_	
73-78	14962-14965	for	_	
73-79	14966-14967	P	_	
73-80	14967-14968	(	_	
73-81	14968-14972	stop	_	
73-82	14972-14973	)	_	
73-83	14974-14982	sequence	_	
73-84	14982-14983	)	_	
73-85	14983-14984	.	_	

#Text=Image acquisition and preprocessing
#Text=Using a fast event-related fMRI design, six T2*-weighted EPI functional runs were collected for each participant, along with one T1-weighted anatomical image.
74-1	14985-14990	Image	_	
74-2	14991-15002	acquisition	_	
74-3	15003-15006	and	_	
74-4	15007-15020	preprocessing	_	
74-5	15021-15026	Using	_	
74-6	15027-15028	a	_	
74-7	15029-15033	fast	_	
74-8	15034-15047	event-related	_	
74-9	15048-15052	fMRI	_	
74-10	15053-15059	design	_	
74-11	15059-15060	,	_	
74-12	15061-15064	six	_	
74-13	15065-15067	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-14	15067-15068	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-15	15068-15069	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-16	15069-15077	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-17	15078-15081	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-18	15082-15092	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-19	15093-15097	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
74-20	15098-15102	were	_	
74-21	15103-15112	collected	_	
74-22	15113-15116	for	_	
74-23	15117-15121	each	_	
74-24	15122-15133	participant	_	
74-25	15133-15134	,	_	
74-26	15135-15140	along	_	
74-27	15141-15145	with	_	
74-28	15146-15149	one	_	
74-29	15150-15152	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
74-30	15152-15153	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
74-31	15153-15161	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
74-32	15162-15172	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
74-33	15173-15178	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	
74-34	15178-15179	.	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[24]	

#Text=Each scanning session was conducted on a 3 T General Electric scanner with the following parameters: T2*-weighted EPI, repetition time = 2000 ms, echo time = 40 ms, 64 × 64 matrix, 30 4-mm axial slices, FOV = 220 × 220 mm, in-plane voxel size = 3.437, and flip angle = 90o.
75-1	15180-15184	Each	_	
75-2	15185-15193	scanning	_	
75-3	15194-15201	session	_	
75-4	15202-15205	was	_	
75-5	15206-15215	conducted	_	
75-6	15216-15218	on	_	
75-7	15219-15220	a	_	
75-8	15221-15222	3	_	
75-9	15222-15223	 	_	
75-10	15223-15224	T	_	
75-11	15225-15232	General	_	
75-12	15233-15241	Electric	_	
75-13	15242-15249	scanner	_	
75-14	15250-15254	with	_	
75-15	15255-15258	the	_	
75-16	15259-15268	following	_	
75-17	15269-15279	parameters	_	
75-18	15279-15280	:	_	
75-19	15281-15283	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
75-20	15283-15284	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
75-21	15284-15285	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
75-22	15285-15293	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
75-23	15294-15297	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
75-24	15297-15298	,	_	
75-25	15299-15309	repetition	_	
75-26	15310-15314	time	_	
75-27	15314-15315	 	_	
75-28	15315-15316	=	_	
75-29	15316-15317	 	_	
75-30	15317-15321	2000	_	
75-31	15321-15322	 	_	
75-32	15322-15324	ms	_	
75-33	15324-15325	,	_	
75-34	15326-15330	echo	_	
75-35	15331-15335	time	_	
75-36	15335-15336	 	_	
75-37	15336-15337	=	_	
75-38	15337-15338	 	_	
75-39	15338-15340	40	_	
75-40	15340-15341	 	_	
75-41	15341-15343	ms	_	
75-42	15343-15344	,	_	
75-43	15345-15347	64	_	
75-44	15347-15348	 	_	
75-45	15348-15349	×	_	
75-46	15349-15350	 	_	
75-47	15350-15352	64	_	
75-48	15353-15359	matrix	_	
75-49	15359-15360	,	_	
75-50	15361-15363	30	_	
75-51	15364-15365	4	_	
75-52	15365-15366	-	_	
75-53	15366-15368	mm	_	
75-54	15369-15374	axial	_	
75-55	15375-15381	slices	_	
75-56	15381-15382	,	_	
75-57	15383-15386	FOV	_	
75-58	15386-15387	 	_	
75-59	15387-15388	=	_	
75-60	15388-15389	 	_	
75-61	15389-15392	220	_	
75-62	15392-15393	 	_	
75-63	15393-15394	×	_	
75-64	15394-15395	 	_	
75-65	15395-15398	220	_	
75-66	15398-15399	 	_	
75-67	15399-15401	mm	_	
75-68	15401-15402	,	_	
75-69	15403-15411	in-plane	_	
75-70	15412-15417	voxel	_	
75-71	15418-15422	size	_	
75-72	15422-15423	 	_	
75-73	15423-15424	=	_	
75-74	15424-15425	 	_	
75-75	15425-15430	3.437	_	
75-76	15430-15431	,	_	
75-77	15432-15435	and	_	
75-78	15436-15440	flip	_	
75-79	15441-15446	angle	_	
75-80	15446-15447	 	_	
75-81	15447-15448	=	_	
75-82	15448-15449	 	_	
75-83	15449-15452	90o	_	
75-84	15452-15453	.	_	

#Text=Each run included 256 repetitions for a length of 8 min and 32 s.
76-1	15454-15458	Each	_	
76-2	15459-15462	run	_	
76-3	15463-15471	included	_	
76-4	15472-15475	256	_	
76-5	15476-15487	repetitions	_	
76-6	15488-15491	for	_	
76-7	15492-15493	a	_	
76-8	15494-15500	length	_	
76-9	15501-15503	of	_	
76-10	15504-15505	8	_	
76-11	15505-15506	 	_	
76-12	15506-15509	min	_	
76-13	15510-15513	and	_	
76-14	15514-15516	32	_	
76-15	15516-15517	 	_	
76-16	15517-15518	s	_	
76-17	15518-15519	.	_	

#Text=Functional volume acquisitions were time-locked to task onset.
77-1	15520-15530	Functional	_	
77-2	15531-15537	volume	_	
77-3	15538-15550	acquisitions	_	
77-4	15551-15555	were	_	
77-5	15556-15567	time-locked	_	
77-6	15568-15570	to	_	
77-7	15571-15575	task	_	
77-8	15576-15581	onset	_	
77-9	15581-15582	.	_	

#Text=During the same experimental session, we collected a T1-weighted image (MPRAGE, TR = 11.4 ms, TE = 4.4 ms, flip angle = 10 degree, FOV = 256 × 256, 1 mm3 voxels) to be used for anatomical reference.
78-1	15583-15589	During	_	
78-2	15590-15593	the	_	
78-3	15594-15598	same	_	
78-4	15599-15611	experimental	_	
78-5	15612-15619	session	_	
78-6	15619-15620	,	_	
78-7	15621-15623	we	_	
78-8	15624-15633	collected	_	
78-9	15634-15635	a	_	
78-10	15636-15638	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-11	15638-15639	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-12	15639-15647	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-13	15648-15653	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-14	15654-15655	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-15	15655-15661	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
78-16	15661-15662	,	_	
78-17	15663-15665	TR	_	
78-18	15665-15666	 	_	
78-19	15666-15667	=	_	
78-20	15667-15668	 	_	
78-21	15668-15672	11.4	_	
78-22	15672-15673	 	_	
78-23	15673-15675	ms	_	
78-24	15675-15676	,	_	
78-25	15677-15679	TE	_	
78-26	15679-15680	 	_	
78-27	15680-15681	=	_	
78-28	15681-15682	 	_	
78-29	15682-15685	4.4	_	
78-30	15685-15686	 	_	
78-31	15686-15688	ms	_	
78-32	15688-15689	,	_	
78-33	15690-15694	flip	_	
78-34	15695-15700	angle	_	
78-35	15700-15701	 	_	
78-36	15701-15702	=	_	
78-37	15702-15703	 	_	
78-38	15703-15705	10	_	
78-39	15706-15712	degree	_	
78-40	15712-15713	,	_	
78-41	15714-15717	FOV	_	
78-42	15717-15718	 	_	
78-43	15718-15719	=	_	
78-44	15719-15720	 	_	
78-45	15720-15723	256	_	
78-46	15723-15724	 	_	
78-47	15724-15725	×	_	
78-48	15725-15726	 	_	
78-49	15726-15729	256	_	
78-50	15729-15730	,	_	
78-51	15731-15732	1	_	
78-52	15732-15733	 	_	
78-53	15733-15736	mm3	_	
78-54	15737-15743	voxels	_	
78-55	15743-15744	)	_	
78-56	15745-15747	to	_	
78-57	15748-15750	be	_	
78-58	15751-15755	used	_	
78-59	15756-15759	for	_	
78-60	15760-15770	anatomical	_	
78-61	15771-15780	reference	_	
78-62	15780-15781	.	_	

#Text=All structural and functional image processing and analysis was performed with the Analysis of Functional Neuroimages (AFNI) software package, and MRI x-y slices were reconstructed into AFNI BRIK format.
79-1	15782-15785	All	_	
79-2	15786-15796	structural	_	
79-3	15797-15800	and	_	
79-4	15801-15811	functional	_	
79-5	15812-15817	image	_	
79-6	15818-15828	processing	_	
79-7	15829-15832	and	_	
79-8	15833-15841	analysis	_	
79-9	15842-15845	was	_	
79-10	15846-15855	performed	_	
79-11	15856-15860	with	_	
79-12	15861-15864	the	_	
79-13	15865-15873	Analysis	_	
79-14	15874-15876	of	_	
79-15	15877-15887	Functional	_	
79-16	15888-15899	Neuroimages	_	
79-17	15900-15901	(	_	
79-18	15901-15905	AFNI	_	
79-19	15905-15906	)	_	
79-20	15907-15915	software	_	
79-21	15916-15923	package	_	
79-22	15923-15924	,	_	
79-23	15925-15928	and	_	
79-24	15929-15932	MRI	_	
79-25	15933-15936	x-y	_	
79-26	15937-15943	slices	_	
79-27	15944-15948	were	_	
79-28	15949-15962	reconstructed	_	
79-29	15963-15967	into	_	
79-30	15968-15972	AFNI	_	
79-31	15973-15977	BRIK	_	
79-32	15978-15984	format	_	
79-33	15984-15985	.	_	

#Text=Echoplanar images underwent automatic coregistration to the anatomical image and each participant dataset was visually inspected to confirm successful alignment.
80-1	15986-15996	Echoplanar	_	
80-2	15997-16003	images	_	
80-3	16004-16013	underwent	_	
80-4	16014-16023	automatic	_	
80-5	16024-16038	coregistration	_	
80-6	16039-16041	to	_	
80-7	16042-16045	the	_	
80-8	16046-16056	anatomical	_	
80-9	16057-16062	image	_	
80-10	16063-16066	and	_	
80-11	16067-16071	each	_	
80-12	16072-16083	participant	_	
80-13	16084-16091	dataset	_	
80-14	16092-16095	was	_	
80-15	16096-16104	visually	_	
80-16	16105-16114	inspected	_	
80-17	16115-16117	to	_	
80-18	16118-16125	confirm	_	
80-19	16126-16136	successful	_	
80-20	16137-16146	alignment	_	
80-21	16146-16147	.	_	

#Text=Outlier voxels were identified in the aligned images based on whether a given time point greatly exceeded the mean number of voxel outliers for the time-series.
81-1	16148-16155	Outlier	_	
81-2	16156-16162	voxels	_	
81-3	16163-16167	were	_	
81-4	16168-16178	identified	_	
81-5	16179-16181	in	_	
81-6	16182-16185	the	_	
81-7	16186-16193	aligned	_	
81-8	16194-16200	images	_	
81-9	16201-16206	based	_	
81-10	16207-16209	on	_	
81-11	16210-16217	whether	_	
81-12	16218-16219	a	_	
81-13	16220-16225	given	_	
81-14	16226-16230	time	_	
81-15	16231-16236	point	_	
81-16	16237-16244	greatly	_	
81-17	16245-16253	exceeded	_	
81-18	16254-16257	the	_	
81-19	16258-16262	mean	_	
81-20	16263-16269	number	_	
81-21	16270-16272	of	_	
81-22	16273-16278	voxel	_	
81-23	16279-16287	outliers	_	
81-24	16288-16291	for	_	
81-25	16292-16295	the	_	
81-26	16296-16307	time-series	_	
81-27	16307-16308	.	_	

#Text=Time points with high numbers of outlier voxels were excluded from subsequent analyses.
82-1	16309-16313	Time	_	
82-2	16314-16320	points	_	
82-3	16321-16325	with	_	
82-4	16326-16330	high	_	
82-5	16331-16338	numbers	_	
82-6	16339-16341	of	_	
82-7	16342-16349	outlier	_	
82-8	16350-16356	voxels	_	
82-9	16357-16361	were	_	
82-10	16362-16370	excluded	_	
82-11	16371-16375	from	_	
82-12	16376-16386	subsequent	_	
82-13	16387-16395	analyses	_	
82-14	16395-16396	.	_	

#Text=First-level fMRI analyses
#Text=In a first general linear model (GLM), Go, Stop Success/SS, and Stop Error/SE trials were distinguished and convolved with a canonical hemodynamic response function (Go Error trials were scarce and not included in these analyses).
83-1	16397-16408	First-level	_	
83-2	16409-16413	fMRI	_	
83-3	16414-16422	analyses	_	
83-4	16423-16425	In	_	
83-5	16426-16427	a	_	
83-6	16428-16433	first	_	
83-7	16434-16441	general	_	
83-8	16442-16448	linear	_	
83-9	16449-16454	model	_	
83-10	16455-16456	(	_	
83-11	16456-16459	GLM	_	
83-12	16459-16460	)	_	
83-13	16460-16461	,	_	
83-14	16462-16464	Go	_	
83-15	16464-16465	,	_	
83-16	16466-16470	Stop	_	
83-17	16471-16478	Success	_	
83-18	16478-16479	/	_	
83-19	16479-16481	SS	_	
83-20	16481-16482	,	_	
83-21	16483-16486	and	_	
83-22	16487-16491	Stop	_	
83-23	16492-16497	Error	_	
83-24	16497-16498	/	_	
83-25	16498-16500	SE	_	
83-26	16501-16507	trials	_	
83-27	16508-16512	were	_	
83-28	16513-16526	distinguished	_	
83-29	16527-16530	and	_	
83-30	16531-16540	convolved	_	
83-31	16541-16545	with	_	
83-32	16546-16547	a	_	
83-33	16548-16557	canonical	_	
83-34	16558-16569	hemodynamic	_	
83-35	16570-16578	response	_	
83-36	16579-16587	function	_	
83-37	16588-16589	(	_	
83-38	16589-16591	Go	_	
83-39	16592-16597	Error	_	
83-40	16598-16604	trials	_	
83-41	16605-16609	were	_	
83-42	16610-16616	scarce	_	
83-43	16617-16620	and	_	
83-44	16621-16624	not	_	
83-45	16625-16633	included	_	
83-46	16634-16636	in	_	
83-47	16637-16642	these	_	
83-48	16643-16651	analyses	_	
83-49	16651-16652	)	_	
83-50	16652-16653	.	_	

#Text=Each was entered as both categorical and P(stop)-modulated regressor (i.e., Go, SS, SE, GoxPk(stop), SSxPk(stop), and SExPk(stop)).
84-1	16654-16658	Each	_	
84-2	16659-16662	was	_	
84-3	16663-16670	entered	_	
84-4	16671-16673	as	_	
84-5	16674-16678	both	_	
84-6	16679-16690	categorical	_	
84-7	16691-16694	and	_	
84-8	16695-16696	P	_	
84-9	16696-16697	(	_	
84-10	16697-16701	stop	_	
84-11	16701-16702	)	_	
84-12	16702-16703	-	_	
84-13	16703-16712	modulated	_	
84-14	16713-16722	regressor	_	
84-15	16723-16724	(	_	
84-16	16724-16727	i.e	_	
84-17	16727-16728	.	_	
84-18	16728-16729	,	_	
84-19	16730-16732	Go	_	
84-20	16732-16733	,	_	
84-21	16734-16736	SS	_	
84-22	16736-16737	,	_	
84-23	16738-16740	SE	_	
84-24	16740-16741	,	_	
84-25	16742-16747	GoxPk	_	
84-26	16747-16748	(	_	
84-27	16748-16752	stop	_	
84-28	16752-16753	)	_	
84-29	16753-16754	,	_	
84-30	16755-16760	SSxPk	_	
84-31	16760-16761	(	_	
84-32	16761-16765	stop	_	
84-33	16765-16766	)	_	
84-34	16766-16767	,	_	
84-35	16768-16771	and	_	
84-36	16772-16777	SExPk	_	
84-37	16777-16778	(	_	
84-38	16778-16782	stop	_	
84-39	16782-16783	)	_	
84-40	16783-16784	)	_	
84-41	16784-16785	.	_	

#Text=To more specifically isolate neural activity related to belief updating processes vs uncertainty tracking, a second GLM was created with two types of trial-wise Bayesian prediction errors as parametric regressors, representing the discrepancy between expected likelihood of having to stop on the upcoming trial (i.e., P(stop)) and actual trial type observed (i.e., Go = 0, Stop = 1).
85-1	16786-16788	To	_	
85-2	16789-16793	more	_	
85-3	16794-16806	specifically	_	
85-4	16807-16814	isolate	_	
85-5	16815-16821	neural	_	
85-6	16822-16830	activity	_	
85-7	16831-16838	related	_	
85-8	16839-16841	to	_	
85-9	16842-16848	belief	_	
85-10	16849-16857	updating	_	
85-11	16858-16867	processes	_	
85-12	16868-16870	vs	_	
85-13	16871-16882	uncertainty	_	
85-14	16883-16891	tracking	_	
85-15	16891-16892	,	_	
85-16	16893-16894	a	_	
85-17	16895-16901	second	_	
85-18	16902-16905	GLM	_	
85-19	16906-16909	was	_	
85-20	16910-16917	created	_	
85-21	16918-16922	with	_	
85-22	16923-16926	two	_	
85-23	16927-16932	types	_	
85-24	16933-16935	of	_	
85-25	16936-16946	trial-wise	_	
85-26	16947-16955	Bayesian	_	
85-27	16956-16966	prediction	_	
85-28	16967-16973	errors	_	
85-29	16974-16976	as	_	
85-30	16977-16987	parametric	_	
85-31	16988-16998	regressors	_	
85-32	16998-16999	,	_	
85-33	17000-17012	representing	_	
85-34	17013-17016	the	_	
85-35	17017-17028	discrepancy	_	
85-36	17029-17036	between	_	
85-37	17037-17045	expected	_	
85-38	17046-17056	likelihood	_	
85-39	17057-17059	of	_	
85-40	17060-17066	having	_	
85-41	17067-17069	to	_	
85-42	17070-17074	stop	_	
85-43	17075-17077	on	_	
85-44	17078-17081	the	_	
85-45	17082-17090	upcoming	_	
85-46	17091-17096	trial	_	
85-47	17097-17098	(	_	
85-48	17098-17101	i.e	_	
85-49	17101-17102	.	_	
85-50	17102-17103	,	_	
85-51	17104-17105	P	_	
85-52	17105-17106	(	_	
85-53	17106-17110	stop	_	
85-54	17110-17111	)	_	
85-55	17111-17112	)	_	
85-56	17113-17116	and	_	
85-57	17117-17123	actual	_	
85-58	17124-17129	trial	_	
85-59	17130-17134	type	_	
85-60	17135-17143	observed	_	
85-61	17144-17145	(	_	
85-62	17145-17148	i.e	_	
85-63	17148-17149	.	_	
85-64	17149-17150	,	_	
85-65	17151-17153	Go	_	
85-66	17153-17154	 	_	
85-67	17154-17155	=	_	
85-68	17155-17156	 	_	
85-69	17156-17157	0	_	
85-70	17157-17158	,	_	
85-71	17159-17163	Stop	_	
85-72	17163-17164	 	_	
85-73	17164-17165	=	_	
85-74	17165-17166	 	_	
85-75	17166-17167	1	_	
85-76	17167-17168	)	_	
85-77	17168-17169	.	_	

#Text=These regressors included in this order the signed prediction error (SPE = outcome-P(stop) = sk-Pk(stop)) and the unsigned prediction error (UPE = |outcome-Pk(stop)| = |sk-Pk(stop)|; see Fig. 1A, bottom), as well as trial error (0 = correct or 1 = error) to control for performance error related activity.
86-1	17170-17175	These	_	
86-2	17176-17186	regressors	_	
86-3	17187-17195	included	_	
86-4	17196-17198	in	_	
86-5	17199-17203	this	_	
86-6	17204-17209	order	_	
86-7	17210-17213	the	_	
86-8	17214-17220	signed	_	
86-9	17221-17231	prediction	_	
86-10	17232-17237	error	_	
86-11	17238-17239	(	_	
86-12	17239-17242	SPE	_	
86-13	17242-17243	 	_	
86-14	17243-17244	=	_	
86-15	17244-17245	 	_	
86-16	17245-17254	outcome-P	_	
86-17	17254-17255	(	_	
86-18	17255-17259	stop	_	
86-19	17259-17260	)	_	
86-20	17260-17261	 	_	
86-21	17261-17262	=	_	
86-22	17262-17263	 	_	
86-23	17263-17268	sk-Pk	_	
86-24	17268-17269	(	_	
86-25	17269-17273	stop	_	
86-26	17273-17274	)	_	
86-27	17274-17275	)	_	
86-28	17276-17279	and	_	
86-29	17280-17283	the	_	
86-30	17284-17292	unsigned	_	
86-31	17293-17303	prediction	_	
86-32	17304-17309	error	_	
86-33	17310-17311	(	_	
86-34	17311-17314	UPE	_	
86-35	17314-17315	 	_	
86-36	17315-17316	=	_	
86-37	17316-17317	 	_	
86-38	17317-17318	|	_	
86-39	17318-17328	outcome-Pk	_	
86-40	17328-17329	(	_	
86-41	17329-17333	stop	_	
86-42	17333-17334	)	_	
86-43	17334-17335	|	_	
86-44	17335-17336	 	_	
86-45	17336-17337	=	_	
86-46	17337-17338	 	_	
86-47	17338-17339	|	_	
86-48	17339-17344	sk-Pk	_	
86-49	17344-17345	(	_	
86-50	17345-17349	stop	_	
86-51	17349-17350	)	_	
86-52	17350-17351	|	_	
86-53	17351-17352	;	_	
86-54	17353-17356	see	_	
86-55	17357-17360	Fig	_	
86-56	17360-17361	.	_	
86-57	17362-17364	1A	_	
86-58	17364-17365	,	_	
86-59	17366-17372	bottom	_	
86-60	17372-17373	)	_	
86-61	17373-17374	,	_	
86-62	17375-17377	as	_	
86-63	17378-17382	well	_	
86-64	17383-17385	as	_	
86-65	17386-17391	trial	_	
86-66	17392-17397	error	_	
86-67	17398-17399	(	_	
86-68	17399-17400	0	_	
86-69	17400-17401	 	_	
86-70	17401-17402	=	_	
86-71	17402-17403	 	_	
86-72	17403-17410	correct	_	
86-73	17411-17413	or	_	
86-74	17414-17415	1	_	
86-75	17415-17416	 	_	
86-76	17416-17417	=	_	
86-77	17417-17418	 	_	
86-78	17418-17423	error	_	
86-79	17423-17424	)	_	
86-80	17425-17427	to	_	
86-81	17428-17435	control	_	
86-82	17436-17439	for	_	
86-83	17440-17451	performance	_	
86-84	17452-17457	error	_	
86-85	17458-17465	related	_	
86-86	17466-17474	activity	_	
86-87	17474-17475	.	_	

#Text=Each of these regressors were orthogonalized with respect to the preceding one given the non-trivial collinearity between them.
87-1	17476-17480	Each	_	
87-2	17481-17483	of	_	
87-3	17484-17489	these	_	
87-4	17490-17500	regressors	_	
87-5	17501-17505	were	_	
87-6	17506-17520	orthogonalized	_	
87-7	17521-17525	with	_	
87-8	17526-17533	respect	_	
87-9	17534-17536	to	_	
87-10	17537-17540	the	_	
87-11	17541-17550	preceding	_	
87-12	17551-17554	one	_	
87-13	17555-17560	given	_	
87-14	17561-17564	the	_	
87-15	17565-17576	non-trivial	_	
87-16	17577-17589	collinearity	_	
87-17	17590-17597	between	_	
87-18	17598-17602	them	_	
87-19	17602-17603	.	_	

#Text=Both GLMs included the following regressors of no-interest: a baseline regressor (inter-trial intervals), three linear drift regressors (x,y,z), and three motion regressors (pitch, yaw, roll), and Go RTs (residualized with respect to P(stop)) to control for motor response confounds.
88-1	17604-17608	Both	_	
88-2	17609-17613	GLMs	_	
88-3	17614-17622	included	_	
88-4	17623-17626	the	_	
88-5	17627-17636	following	_	
88-6	17637-17647	regressors	_	
88-7	17648-17650	of	_	
88-8	17651-17662	no-interest	_	
88-9	17662-17663	:	_	
88-10	17664-17665	a	_	
88-11	17666-17674	baseline	_	
88-12	17675-17684	regressor	_	
88-13	17685-17686	(	_	
88-14	17686-17697	inter-trial	_	
88-15	17698-17707	intervals	_	
88-16	17707-17708	)	_	
88-17	17708-17709	,	_	
88-18	17710-17715	three	_	
88-19	17716-17722	linear	_	
88-20	17723-17728	drift	_	
88-21	17729-17739	regressors	_	
88-22	17740-17741	(	_	
88-23	17741-17742	x	_	
88-24	17742-17743	,	_	
88-25	17743-17744	y	_	
88-26	17744-17745	,	_	
88-27	17745-17746	z	_	
88-28	17746-17747	)	_	
88-29	17747-17748	,	_	
88-30	17749-17752	and	_	
88-31	17753-17758	three	_	
88-32	17759-17765	motion	_	
88-33	17766-17776	regressors	_	
88-34	17777-17778	(	_	
88-35	17778-17783	pitch	_	
88-36	17783-17784	,	_	
88-37	17785-17788	yaw	_	
88-38	17788-17789	,	_	
88-39	17790-17794	roll	_	
88-40	17794-17795	)	_	
88-41	17795-17796	,	_	
88-42	17797-17800	and	_	
88-43	17801-17803	Go	_	
88-44	17804-17807	RTs	_	
88-45	17808-17809	(	_	
88-46	17809-17821	residualized	_	
88-47	17822-17826	with	_	
88-48	17827-17834	respect	_	
88-49	17835-17837	to	_	
88-50	17838-17839	P	_	
88-51	17839-17840	(	_	
88-52	17840-17844	stop	_	
88-53	17844-17845	)	_	
88-54	17845-17846	)	_	
88-55	17847-17849	to	_	
88-56	17850-17857	control	_	
88-57	17858-17861	for	_	
88-58	17862-17867	motor	_	
88-59	17868-17876	response	_	
88-60	17877-17886	confounds	_	
88-61	17886-17887	.	_	

#Text=Images were spatially filtered (Gaussian full width half maximum 4 mm) to account for individual anatomical differences.
89-1	17888-17894	Images	_	
89-2	17895-17899	were	_	
89-3	17900-17909	spatially	_	
89-4	17910-17918	filtered	_	
89-5	17919-17920	(	_	
89-6	17920-17928	Gaussian	_	
89-7	17929-17933	full	_	
89-8	17934-17939	width	_	
89-9	17940-17944	half	_	
89-10	17945-17952	maximum	_	
89-11	17953-17954	4	_	
89-12	17954-17955	 	_	
89-13	17955-17957	mm	_	
89-14	17957-17958	)	_	
89-15	17959-17961	to	_	
89-16	17962-17969	account	_	
89-17	17970-17973	for	_	
89-18	17974-17984	individual	_	
89-19	17985-17995	anatomical	_	
89-20	17996-18007	differences	_	
89-21	18007-18008	.	_	

#Text=Automated Talairach transformations were applied to anatomical images and functional images were subsequently transformed into Talairach space.
90-1	18009-18018	Automated	_	
90-2	18019-18028	Talairach	_	
90-3	18029-18044	transformations	_	
90-4	18045-18049	were	_	
90-5	18050-18057	applied	_	
90-6	18058-18060	to	_	
90-7	18061-18071	anatomical	_	
90-8	18072-18078	images	_	
90-9	18079-18082	and	_	
90-10	18083-18093	functional	_	
90-11	18094-18100	images	_	
90-12	18101-18105	were	_	
90-13	18106-18118	subsequently	_	
90-14	18119-18130	transformed	_	
90-15	18131-18135	into	_	
90-16	18136-18145	Talairach	_	
90-17	18146-18151	space	_	
90-18	18151-18152	.	_	

#Text=Percent signal change (%SC) was determined by dividing the signal for each regressor of interest by the baseline regressor.
91-1	18153-18160	Percent	_	
91-2	18161-18167	signal	_	
91-3	18168-18174	change	_	
91-4	18175-18176	(	_	
91-5	18176-18177	%	_	
91-6	18177-18179	SC	_	
91-7	18179-18180	)	_	
91-8	18181-18184	was	_	
91-9	18185-18195	determined	_	
91-10	18196-18198	by	_	
91-11	18199-18207	dividing	_	
91-12	18208-18211	the	_	
91-13	18212-18218	signal	_	
91-14	18219-18222	for	_	
91-15	18223-18227	each	_	
91-16	18228-18237	regressor	_	
91-17	18238-18240	of	_	
91-18	18241-18249	interest	_	
91-19	18250-18252	by	_	
91-20	18253-18256	the	_	
91-21	18257-18265	baseline	_	
91-22	18266-18275	regressor	_	
91-23	18275-18276	.	_	

#Text=Second-level analyses
#Text=At the between-subject level, two types of voxelwise mixed-effects linear models (LME) were fit to the coefficients of our first-level GLM.
92-1	18277-18289	Second-level	_	
92-2	18290-18298	analyses	_	
92-3	18299-18301	At	_	
92-4	18302-18305	the	_	
92-5	18306-18321	between-subject	_	
92-6	18322-18327	level	_	
92-7	18327-18328	,	_	
92-8	18329-18332	two	_	
92-9	18333-18338	types	_	
92-10	18339-18341	of	_	
92-11	18342-18351	voxelwise	_	
92-12	18352-18365	mixed-effects	_	
92-13	18366-18372	linear	_	
92-14	18373-18379	models	_	
92-15	18380-18381	(	_	
92-16	18381-18384	LME	_	
92-17	18384-18385	)	_	
92-18	18386-18390	were	_	
92-19	18391-18394	fit	_	
92-20	18395-18397	to	_	
92-21	18398-18401	the	_	
92-22	18402-18414	coefficients	_	
92-23	18415-18417	of	_	
92-24	18418-18421	our	_	
92-25	18422-18433	first-level	_	
92-26	18434-18437	GLM	_	
92-27	18437-18438	.	_	

#Text=In the first LME, we first tested for the interaction of clinical status (abstinent vs relapsed) and modulation of P(Stop) under each Go vs Stop trials (i.e, GoxP(stop) vs StopxPk(stop), SS and SE were averaged), with subject treated as random intercept effect.
93-1	18439-18441	In	_	
93-2	18442-18445	the	_	
93-3	18446-18451	first	_	
93-4	18452-18455	LME	_	
93-5	18455-18456	,	_	
93-6	18457-18459	we	_	
93-7	18460-18465	first	_	
93-8	18466-18472	tested	_	
93-9	18473-18476	for	_	
93-10	18477-18480	the	_	
93-11	18481-18492	interaction	_	
93-12	18493-18495	of	_	
93-13	18496-18504	clinical	_	
93-14	18505-18511	status	_	
93-15	18512-18513	(	_	
93-16	18513-18522	abstinent	_	
93-17	18523-18525	vs	_	
93-18	18526-18534	relapsed	_	
93-19	18534-18535	)	_	
93-20	18536-18539	and	_	
93-21	18540-18550	modulation	_	
93-22	18551-18553	of	_	
93-23	18554-18555	P	_	
93-24	18555-18556	(	_	
93-25	18556-18560	Stop	_	
93-26	18560-18561	)	_	
93-27	18562-18567	under	_	
93-28	18568-18572	each	_	
93-29	18573-18575	Go	_	
93-30	18576-18578	vs	_	
93-31	18579-18583	Stop	_	
93-32	18584-18590	trials	_	
93-33	18591-18592	(	_	
93-34	18592-18595	i.e	_	
93-35	18595-18596	,	_	
93-36	18597-18601	GoxP	_	
93-37	18601-18602	(	_	
93-38	18602-18606	stop	_	
93-39	18606-18607	)	_	
93-40	18608-18610	vs	_	
93-41	18611-18618	StopxPk	_	
93-42	18618-18619	(	_	
93-43	18619-18623	stop	_	
93-44	18623-18624	)	_	
93-45	18624-18625	,	_	
93-46	18626-18628	SS	_	
93-47	18629-18632	and	_	
93-48	18633-18635	SE	_	
93-49	18636-18640	were	_	
93-50	18641-18649	averaged	_	
93-51	18649-18650	)	_	
93-52	18650-18651	,	_	
93-53	18652-18656	with	_	
93-54	18657-18664	subject	_	
93-55	18665-18672	treated	_	
93-56	18673-18675	as	_	
93-57	18676-18682	random	_	
93-58	18683-18692	intercept	_	
93-59	18693-18699	effect	_	
93-60	18699-18700	.	_	

#Text=Whole brain statistical maps were obtained for the group main effect (reflecting areas tracking a clinical status group difference in prior P(stop) value irrespective of trial type) and the clinical status X P(stop) modulated trial type interaction.
94-1	18701-18706	Whole	_	
94-2	18707-18712	brain	_	
94-3	18713-18724	statistical	_	
94-4	18725-18729	maps	_	
94-5	18730-18734	were	_	
94-6	18735-18743	obtained	_	
94-7	18744-18747	for	_	
94-8	18748-18751	the	_	
94-9	18752-18757	group	_	
94-10	18758-18762	main	_	
94-11	18763-18769	effect	_	
94-12	18770-18771	(	_	
94-13	18771-18781	reflecting	_	
94-14	18782-18787	areas	_	
94-15	18788-18796	tracking	_	
94-16	18797-18798	a	_	
94-17	18799-18807	clinical	_	
94-18	18808-18814	status	_	
94-19	18815-18820	group	_	
94-20	18821-18831	difference	_	
94-21	18832-18834	in	_	
94-22	18835-18840	prior	_	
94-23	18841-18842	P	_	
94-24	18842-18843	(	_	
94-25	18843-18847	stop	_	
94-26	18847-18848	)	_	
94-27	18849-18854	value	_	
94-28	18855-18867	irrespective	_	
94-29	18868-18870	of	_	
94-30	18871-18876	trial	_	
94-31	18877-18881	type	_	
94-32	18881-18882	)	_	
94-33	18883-18886	and	_	
94-34	18887-18890	the	_	
94-35	18891-18899	clinical	_	
94-36	18900-18906	status	_	
94-37	18907-18908	X	_	
94-38	18909-18910	P	_	
94-39	18910-18911	(	_	
94-40	18911-18915	stop	_	
94-41	18915-18916	)	_	
94-42	18917-18926	modulated	_	
94-43	18927-18932	trial	_	
94-44	18933-18937	type	_	
94-45	18938-18949	interaction	_	
94-46	18949-18950	.	_	

#Text=In order to assess for potential group difference in the modulation of trial accuracy (i.e., successful vs failed inhibition) by P(stop), a similar LME approach was used.
95-1	18951-18953	In	_	
95-2	18954-18959	order	_	
95-3	18960-18962	to	_	
95-4	18963-18969	assess	_	
95-5	18970-18973	for	_	
95-6	18974-18983	potential	_	
95-7	18984-18989	group	_	
95-8	18990-19000	difference	_	
95-9	19001-19003	in	_	
95-10	19004-19007	the	_	
95-11	19008-19018	modulation	_	
95-12	19019-19021	of	_	
95-13	19022-19027	trial	_	
95-14	19028-19036	accuracy	_	
95-15	19037-19038	(	_	
95-16	19038-19041	i.e	_	
95-17	19041-19042	.	_	
95-18	19042-19043	,	_	
95-19	19044-19054	successful	_	
95-20	19055-19057	vs	_	
95-21	19058-19064	failed	_	
95-22	19065-19075	inhibition	_	
95-23	19075-19076	)	_	
95-24	19077-19079	by	_	
95-25	19080-19081	P	_	
95-26	19081-19082	(	_	
95-27	19082-19086	stop	_	
95-28	19086-19087	)	_	
95-29	19087-19088	,	_	
95-30	19089-19090	a	_	
95-31	19091-19098	similar	_	
95-32	19099-19102	LME	_	
95-33	19103-19111	approach	_	
95-34	19112-19115	was	_	
95-35	19116-19120	used	_	
95-36	19120-19121	.	_	

#Text=Specifically, we obtained statistical maps for the main effect of clinical status (reflecting potential group difference in P(stop) activation on Stop trials irrespective of accuracy) and for the clinical status X P(stop) modulated trial type (SE vs SS) interaction.
96-1	19122-19134	Specifically	_	
96-2	19134-19135	,	_	
96-3	19136-19138	we	_	
96-4	19139-19147	obtained	_	
96-5	19148-19159	statistical	_	
96-6	19160-19164	maps	_	
96-7	19165-19168	for	_	
96-8	19169-19172	the	_	
96-9	19173-19177	main	_	
96-10	19178-19184	effect	_	
96-11	19185-19187	of	_	
96-12	19188-19196	clinical	_	
96-13	19197-19203	status	_	
96-14	19204-19205	(	_	
96-15	19205-19215	reflecting	_	
96-16	19216-19225	potential	_	
96-17	19226-19231	group	_	
96-18	19232-19242	difference	_	
96-19	19243-19245	in	_	
96-20	19246-19247	P	_	
96-21	19247-19248	(	_	
96-22	19248-19252	stop	_	
96-23	19252-19253	)	_	
96-24	19254-19264	activation	_	
96-25	19265-19267	on	_	
96-26	19268-19272	Stop	_	
96-27	19273-19279	trials	_	
96-28	19280-19292	irrespective	_	
96-29	19293-19295	of	_	
96-30	19296-19304	accuracy	_	
96-31	19304-19305	)	_	
96-32	19306-19309	and	_	
96-33	19310-19313	for	_	
96-34	19314-19317	the	_	
96-35	19318-19326	clinical	_	
96-36	19327-19333	status	_	
96-37	19334-19335	X	_	
96-38	19336-19337	P	_	
96-39	19337-19338	(	_	
96-40	19338-19342	stop	_	
96-41	19342-19343	)	_	
96-42	19344-19353	modulated	_	
96-43	19354-19359	trial	_	
96-44	19360-19364	type	_	
96-45	19365-19366	(	_	
96-46	19366-19368	SE	_	
96-47	19369-19371	vs	_	
96-48	19372-19374	SS	_	
96-49	19374-19375	)	_	
96-50	19376-19387	interaction	_	
96-51	19387-19388	.	_	

#Text=To correct for multiple comparisons, we used a cluster threshold adjustment based on Monte Carlo simulations (generated with AFNI's 3dClustSim program).
97-1	19389-19391	To	_	
97-2	19392-19399	correct	_	
97-3	19400-19403	for	_	
97-4	19404-19412	multiple	_	
97-5	19413-19424	comparisons	_	
97-6	19424-19425	,	_	
97-7	19426-19428	we	_	
97-8	19429-19433	used	_	
97-9	19434-19435	a	_	
97-10	19436-19443	cluster	_	
97-11	19444-19453	threshold	_	
97-12	19454-19464	adjustment	_	
97-13	19465-19470	based	_	
97-14	19471-19473	on	_	
97-15	19474-19479	Monte	_	
97-16	19480-19485	Carlo	_	
97-17	19486-19497	simulations	_	
97-18	19498-19499	(	_	
97-19	19499-19508	generated	_	
97-20	19509-19513	with	_	
97-21	19514-19520	AFNI's	_	
97-22	19521-19531	3dClustSim	_	
97-23	19532-19539	program	_	
97-24	19539-19540	)	_	
97-25	19540-19541	.	_	

#Text=We first calculated spatial autocorrelation function (acf) parameters from the 1st glm model residuals, using the 3dFHWMx function (which does not assume a purely Gaussian acf function, but rather a mixture of Gaussian and mono-exponential).
98-1	19542-19544	We	_	
98-2	19545-19550	first	_	
98-3	19551-19561	calculated	_	
98-4	19562-19569	spatial	_	
98-5	19570-19585	autocorrelation	_	
98-6	19586-19594	function	_	
98-7	19595-19596	(	_	
98-8	19596-19599	acf	_	
98-9	19599-19600	)	_	
98-10	19601-19611	parameters	_	
98-11	19612-19616	from	_	
98-12	19617-19620	the	_	
98-13	19621-19624	1st	_	
98-14	19625-19628	glm	_	
98-15	19629-19634	model	_	
98-16	19635-19644	residuals	_	
98-17	19644-19645	,	_	
98-18	19646-19651	using	_	
98-19	19652-19655	the	_	
98-20	19656-19663	3dFHWMx	_	
98-21	19664-19672	function	_	
98-22	19673-19674	(	_	
98-23	19674-19679	which	_	
98-24	19680-19684	does	_	
98-25	19685-19688	not	_	
98-26	19689-19695	assume	_	
98-27	19696-19697	a	_	
98-28	19698-19704	purely	_	
98-29	19705-19713	Gaussian	_	
98-30	19714-19717	acf	_	
98-31	19718-19726	function	_	
98-32	19726-19727	,	_	
98-33	19728-19731	but	_	
98-34	19732-19738	rather	_	
98-35	19739-19740	a	_	
98-36	19741-19748	mixture	_	
98-37	19749-19751	of	_	
98-38	19752-19760	Gaussian	_	
98-39	19761-19764	and	_	
98-40	19765-19781	mono-exponential	_	
98-41	19781-19782	)	_	
98-42	19782-19783	.	_	

#Text=The obtained parameters, averaged across participants, were fed to the 3dClustSim function to determine FWER corrected cluster size.
99-1	19784-19787	The	_	
99-2	19788-19796	obtained	_	
99-3	19797-19807	parameters	_	
99-4	19807-19808	,	_	
99-5	19809-19817	averaged	_	
99-6	19818-19824	across	_	
99-7	19825-19837	participants	_	
99-8	19837-19838	,	_	
99-9	19839-19843	were	_	
99-10	19844-19847	fed	_	
99-11	19848-19850	to	_	
99-12	19851-19854	the	_	
99-13	19855-19865	3dClustSim	_	
99-14	19866-19874	function	_	
99-15	19875-19877	to	_	
99-16	19878-19887	determine	_	
99-17	19888-19892	FWER	_	
99-18	19893-19902	corrected	_	
99-19	19903-19910	cluster	_	
99-20	19911-19915	size	_	
99-21	19915-19916	.	_	

#Text=Based on the simulations, a minimum cluster volume of 896 μL was found to be sufficient to correct for multiple comparisons at FWER = p < .05 with a minimum voxelwise significant threshold of p < .005.
100-1	19917-19922	Based	_	
100-2	19923-19925	on	_	
100-3	19926-19929	the	_	
100-4	19930-19941	simulations	_	
100-5	19941-19942	,	_	
100-6	19943-19944	a	_	
100-7	19945-19952	minimum	_	
100-8	19953-19960	cluster	_	
100-9	19961-19967	volume	_	
100-10	19968-19970	of	_	
100-11	19971-19974	896	_	
100-12	19974-19975	 	_	
100-13	19975-19977	μL	_	
100-14	19978-19981	was	_	
100-15	19982-19987	found	_	
100-16	19988-19990	to	_	
100-17	19991-19993	be	_	
100-18	19994-20004	sufficient	_	
100-19	20005-20007	to	_	
100-20	20008-20015	correct	_	
100-21	20016-20019	for	_	
100-22	20020-20028	multiple	_	
100-23	20029-20040	comparisons	_	
100-24	20041-20043	at	_	
100-25	20044-20048	FWER	_	
100-26	20048-20049	 	_	
100-27	20049-20050	=	_	
100-28	20050-20051	 	_	
100-29	20051-20052	p	_	
100-30	20052-20053	 	_	
100-31	20053-20054	<	_	
100-32	20054-20055	 	_	
100-33	20055-20058	.05	_	
100-34	20059-20063	with	_	
100-35	20064-20065	a	_	
100-36	20066-20073	minimum	_	
100-37	20074-20083	voxelwise	_	
100-38	20084-20095	significant	_	
100-39	20096-20105	threshold	_	
100-40	20106-20108	of	_	
100-41	20109-20110	p	_	
100-42	20110-20111	 	_	
100-43	20111-20112	<	_	
100-44	20112-20113	 	_	
100-45	20113-20117	.005	_	
100-46	20117-20118	.	_	

#Text=While less conservative than using a p < .001 or p < .002 voxelwise threshold, this setting provides a balance of adequate correction for multiple comparisons while ensuring a substantial minimum cluster size.
101-1	20119-20124	While	_	
101-2	20125-20129	less	_	
101-3	20130-20142	conservative	_	
101-4	20143-20147	than	_	
101-5	20148-20153	using	_	
101-6	20154-20155	a	_	
101-7	20156-20157	p	_	
101-8	20157-20158	 	_	
101-9	20158-20159	<	_	
101-10	20159-20160	 	_	
101-11	20160-20164	.001	_	
101-12	20165-20167	or	_	
101-13	20168-20169	p	_	
101-14	20169-20170	 	_	
101-15	20170-20171	<	_	
101-16	20171-20172	 	_	
101-17	20172-20176	.002	_	
101-18	20177-20186	voxelwise	_	
101-19	20187-20196	threshold	_	
101-20	20196-20197	,	_	
101-21	20198-20202	this	_	
101-22	20203-20210	setting	_	
101-23	20211-20219	provides	_	
101-24	20220-20221	a	_	
101-25	20222-20229	balance	_	
101-26	20230-20232	of	_	
101-27	20233-20241	adequate	_	
101-28	20242-20252	correction	_	
101-29	20253-20256	for	_	
101-30	20257-20265	multiple	_	
101-31	20266-20277	comparisons	_	
101-32	20278-20283	while	_	
101-33	20284-20292	ensuring	_	
101-34	20293-20294	a	_	
101-35	20295-20306	substantial	_	
101-36	20307-20314	minimum	_	
101-37	20315-20322	cluster	_	
101-38	20323-20327	size	_	
101-39	20327-20328	.	_	

#Text=We also note that this threshold is still relatively conservative in light of previous work having applied this Bayesian computational model in similar populations and experimental settings, which would provide grounds for a more focused search within the brain based on regions of interest.
102-1	20329-20331	We	_	
102-2	20332-20336	also	_	
102-3	20337-20341	note	_	
102-4	20342-20346	that	_	
102-5	20347-20351	this	_	
102-6	20352-20361	threshold	_	
102-7	20362-20364	is	_	
102-8	20365-20370	still	_	
102-9	20371-20381	relatively	_	
102-10	20382-20394	conservative	_	
102-11	20395-20397	in	_	
102-12	20398-20403	light	_	
102-13	20404-20406	of	_	
102-14	20407-20415	previous	_	
102-15	20416-20420	work	_	
102-16	20421-20427	having	_	
102-17	20428-20435	applied	_	
102-18	20436-20440	this	_	
102-19	20441-20449	Bayesian	_	
102-20	20450-20463	computational	_	
102-21	20464-20469	model	_	
102-22	20470-20472	in	_	
102-23	20473-20480	similar	_	
102-24	20481-20492	populations	_	
102-25	20493-20496	and	_	
102-26	20497-20509	experimental	_	
102-27	20510-20518	settings	_	
102-28	20518-20519	,	_	
102-29	20520-20525	which	_	
102-30	20526-20531	would	_	
102-31	20532-20539	provide	_	
102-32	20540-20547	grounds	_	
102-33	20548-20551	for	_	
102-34	20552-20553	a	_	
102-35	20554-20558	more	_	
102-36	20559-20566	focused	_	
102-37	20567-20573	search	_	
102-38	20574-20580	within	_	
102-39	20581-20584	the	_	
102-40	20585-20590	brain	_	
102-41	20591-20596	based	_	
102-42	20597-20599	on	_	
102-43	20600-20607	regions	_	
102-44	20608-20610	of	_	
102-45	20611-20619	interest	_	
102-46	20619-20620	.	_	

#Text=Finally, within the regions identified with those LMEs, we identified those that were consistent with a potential group difference in either type of Bayesian prediction errors (UPE or SPE), using our second GLM for regions of interest (ROI) analyses.
103-1	20621-20628	Finally	_	
103-2	20628-20629	,	_	
103-3	20630-20636	within	_	
103-4	20637-20640	the	_	
103-5	20641-20648	regions	_	
103-6	20649-20659	identified	_	
103-7	20660-20664	with	_	
103-8	20665-20670	those	_	
103-9	20671-20675	LMEs	_	
103-10	20675-20676	,	_	
103-11	20677-20679	we	_	
103-12	20680-20690	identified	_	
103-13	20691-20696	those	_	
103-14	20697-20701	that	_	
103-15	20702-20706	were	_	
103-16	20707-20717	consistent	_	
103-17	20718-20722	with	_	
103-18	20723-20724	a	_	
103-19	20725-20734	potential	_	
103-20	20735-20740	group	_	
103-21	20741-20751	difference	_	
103-22	20752-20754	in	_	
103-23	20755-20761	either	_	
103-24	20762-20766	type	_	
103-25	20767-20769	of	_	
103-26	20770-20778	Bayesian	_	
103-27	20779-20789	prediction	_	
103-28	20790-20796	errors	_	
103-29	20797-20798	(	_	
103-30	20798-20801	UPE	_	
103-31	20802-20804	or	_	
103-32	20805-20808	SPE	_	
103-33	20808-20809	)	_	
103-34	20809-20810	,	_	
103-35	20811-20816	using	_	
103-36	20817-20820	our	_	
103-37	20821-20827	second	_	
103-38	20828-20831	GLM	_	
103-39	20832-20835	for	_	
103-40	20836-20843	regions	_	
103-41	20844-20846	of	_	
103-42	20847-20855	interest	_	
103-43	20856-20857	(	_	
103-44	20857-20860	ROI	_	
103-45	20860-20861	)	_	
103-46	20862-20870	analyses	_	
103-47	20870-20871	.	_	

#Text=Moreover, for regions consistent with a group main effect or group X trial type interaction, we specifically checked for convergence between results from the second GLM and the pattern of activation to P(Stop) as function of trial type (first GLM).
104-1	20872-20880	Moreover	_	
104-2	20880-20881	,	_	
104-3	20882-20885	for	_	
104-4	20886-20893	regions	_	
104-5	20894-20904	consistent	_	
104-6	20905-20909	with	_	
104-7	20910-20911	a	_	
104-8	20912-20917	group	_	
104-9	20918-20922	main	_	
104-10	20923-20929	effect	_	
104-11	20930-20932	or	_	
104-12	20933-20938	group	_	
104-13	20939-20940	X	_	
104-14	20941-20946	trial	_	
104-15	20947-20951	type	_	
104-16	20952-20963	interaction	_	
104-17	20963-20964	,	_	
104-18	20965-20967	we	_	
104-19	20968-20980	specifically	_	
104-20	20981-20988	checked	_	
104-21	20989-20992	for	_	
104-22	20993-21004	convergence	_	
104-23	21005-21012	between	_	
104-24	21013-21020	results	_	
104-25	21021-21025	from	_	
104-26	21026-21029	the	_	
104-27	21030-21036	second	_	
104-28	21037-21040	GLM	_	
104-29	21041-21044	and	_	
104-30	21045-21048	the	_	
104-31	21049-21056	pattern	_	
104-32	21057-21059	of	_	
104-33	21060-21070	activation	_	
104-34	21071-21073	to	_	
104-35	21074-21075	P	_	
104-36	21075-21076	(	_	
104-37	21076-21080	Stop	_	
104-38	21080-21081	)	_	
104-39	21082-21084	as	_	
104-40	21085-21093	function	_	
104-41	21094-21096	of	_	
104-42	21097-21102	trial	_	
104-43	21103-21107	type	_	
104-44	21108-21109	(	_	
104-45	21109-21114	first	_	
104-46	21115-21118	GLM	_	
104-47	21118-21119	)	_	
104-48	21119-21120	.	_	

#Text=Specifically, regions with non-zero P(stop) activations of opposite signs or with the same signs across Go and Stop trials, should be consistent with a significant group difference in UPE and SPE activations, respectively.
105-1	21121-21133	Specifically	_	
105-2	21133-21134	,	_	
105-3	21135-21142	regions	_	
105-4	21143-21147	with	_	
105-5	21148-21156	non-zero	_	
105-6	21157-21158	P	_	
105-7	21158-21159	(	_	
105-8	21159-21163	stop	_	
105-9	21163-21164	)	_	
105-10	21165-21176	activations	_	
105-11	21177-21179	of	_	
105-12	21180-21188	opposite	_	
105-13	21189-21194	signs	_	
105-14	21195-21197	or	_	
105-15	21198-21202	with	_	
105-16	21203-21206	the	_	
105-17	21207-21211	same	_	
105-18	21212-21217	signs	_	
105-19	21218-21224	across	_	
105-20	21225-21227	Go	_	
105-21	21228-21231	and	_	
105-22	21232-21236	Stop	_	
105-23	21237-21243	trials	_	
105-24	21243-21244	,	_	
105-25	21245-21251	should	_	
105-26	21252-21254	be	_	
105-27	21255-21265	consistent	_	
105-28	21266-21270	with	_	
105-29	21271-21272	a	_	
105-30	21273-21284	significant	_	
105-31	21285-21290	group	_	
105-32	21291-21301	difference	_	
105-33	21302-21304	in	_	
105-34	21305-21308	UPE	_	
105-35	21309-21312	and	_	
105-36	21313-21316	SPE	_	
105-37	21317-21328	activations	_	
105-38	21328-21329	,	_	
105-39	21330-21342	respectively	_	
105-40	21342-21343	.	_	

#Text=This is because an SPE is equal to 0 - P(stop) = − P(stop) on Go trials, and SPE = 1 – P(stop) on Stop trials, and thus negatively correlated with P(stop) on both type of trials.
106-1	21344-21348	This	_	
106-2	21349-21351	is	_	
106-3	21352-21359	because	_	
106-4	21360-21362	an	_	
106-5	21363-21366	SPE	_	
106-6	21367-21369	is	_	
106-7	21370-21375	equal	_	
106-8	21376-21378	to	_	
106-9	21379-21380	0	_	
106-10	21381-21382	-	_	
106-11	21383-21384	P	_	
106-12	21384-21385	(	_	
106-13	21385-21389	stop	_	
106-14	21389-21390	)	_	
106-15	21390-21391	 	_	
106-16	21391-21392	=	_	
106-17	21392-21393	 	_	
106-18	21393-21394	−	_	
106-19	21395-21396	P	_	
106-20	21396-21397	(	_	
106-21	21397-21401	stop	_	
106-22	21401-21402	)	_	
106-23	21403-21405	on	_	
106-24	21406-21408	Go	_	
106-25	21409-21415	trials	_	
106-26	21415-21416	,	_	
106-27	21417-21420	and	_	
106-28	21421-21424	SPE	_	
106-29	21424-21425	 	_	
106-30	21425-21426	=	_	
106-31	21426-21427	 	_	
106-32	21427-21428	1	_	
106-33	21429-21430	–	_	
106-34	21431-21432	P	_	
106-35	21432-21433	(	_	
106-36	21433-21437	stop	_	
106-37	21437-21438	)	_	
106-38	21439-21441	on	_	
106-39	21442-21446	Stop	_	
106-40	21447-21453	trials	_	
106-41	21453-21454	,	_	
106-42	21455-21458	and	_	
106-43	21459-21463	thus	_	
106-44	21464-21474	negatively	_	
106-45	21475-21485	correlated	_	
106-46	21486-21490	with	_	
106-47	21491-21492	P	_	
106-48	21492-21493	(	_	
106-49	21493-21497	stop	_	
106-50	21497-21498	)	_	
106-51	21499-21501	on	_	
106-52	21502-21506	both	_	
106-53	21507-21511	type	_	
106-54	21512-21514	of	_	
106-55	21515-21521	trials	_	
106-56	21521-21522	.	_	

#Text=In contrast, UPE is equal to |0 - P(stop)| = P(stop) on Go trials and to |1 - P(stop)| = 1 – P(stop) on Stop trials, and thus should be positively correlated on Go trials but negatively correlated with P(stop) on Stop trials (see.
107-1	21523-21525	In	_	
107-2	21526-21534	contrast	_	
107-3	21534-21535	,	_	
107-4	21536-21539	UPE	_	
107-5	21540-21542	is	_	
107-6	21543-21548	equal	_	
107-7	21549-21551	to	_	
107-8	21552-21553	|	_	
107-9	21553-21554	0	_	
107-10	21555-21556	-	_	
107-11	21557-21558	P	_	
107-12	21558-21559	(	_	
107-13	21559-21563	stop	_	
107-14	21563-21564	)	_	
107-15	21564-21565	|	_	
107-16	21565-21566	 	_	
107-17	21566-21567	=	_	
107-18	21567-21568	 	_	
107-19	21568-21569	P	_	
107-20	21569-21570	(	_	
107-21	21570-21574	stop	_	
107-22	21574-21575	)	_	
107-23	21576-21578	on	_	
107-24	21579-21581	Go	_	
107-25	21582-21588	trials	_	
107-26	21589-21592	and	_	
107-27	21593-21595	to	_	
107-28	21596-21597	|	_	
107-29	21597-21598	1	_	
107-30	21599-21600	-	_	
107-31	21601-21602	P	_	
107-32	21602-21603	(	_	
107-33	21603-21607	stop	_	
107-34	21607-21608	)	_	
107-35	21608-21609	|	_	
107-36	21609-21610	 	_	
107-37	21610-21611	=	_	
107-38	21611-21612	 	_	
107-39	21612-21613	1	_	
107-40	21614-21615	–	_	
107-41	21616-21617	P	_	
107-42	21617-21618	(	_	
107-43	21618-21622	stop	_	
107-44	21622-21623	)	_	
107-45	21624-21626	on	_	
107-46	21627-21631	Stop	_	
107-47	21632-21638	trials	_	
107-48	21638-21639	,	_	
107-49	21640-21643	and	_	
107-50	21644-21648	thus	_	
107-51	21649-21655	should	_	
107-52	21656-21658	be	_	
107-53	21659-21669	positively	_	
107-54	21670-21680	correlated	_	
107-55	21681-21683	on	_	
107-56	21684-21686	Go	_	
107-57	21687-21693	trials	_	
107-58	21694-21697	but	_	
107-59	21698-21708	negatively	_	
107-60	21709-21719	correlated	_	
107-61	21720-21724	with	_	
107-62	21725-21726	P	_	
107-63	21726-21727	(	_	
107-64	21727-21731	stop	_	
107-65	21731-21732	)	_	
107-66	21733-21735	on	_	
107-67	21736-21740	Stop	_	
107-68	21741-21747	trials	_	
107-69	21748-21749	(	_	
107-70	21749-21752	see	_	
107-71	21752-21753	.	_	

#Text=Results
#Text=Participants characteristics and drug use
#Text=Participants' baseline characteristics as a function of group status (N = 58).
108-1	21754-21761	Results	_	
108-2	21762-21774	Participants	_	
108-3	21775-21790	characteristics	_	
108-4	21791-21794	and	_	
108-5	21795-21799	drug	_	
108-6	21800-21803	use	_	
108-7	21804-21816	Participants	_	
108-8	21816-21817	'	_	
108-9	21818-21826	baseline	_	
108-10	21827-21842	characteristics	_	
108-11	21843-21845	as	_	
108-12	21846-21847	a	_	
108-13	21848-21856	function	_	
108-14	21857-21859	of	_	
108-15	21860-21865	group	_	
108-16	21866-21872	status	_	
108-17	21873-21874	(	_	
108-18	21874-21875	N	_	
108-19	21875-21876	 	_	
108-20	21876-21877	=	_	
108-21	21877-21878	 	_	
108-22	21878-21880	58	_	
108-23	21880-21881	)	_	
108-24	21881-21882	.	_	

#Text=Table 1\t \t
#Text=\tRelapsed individuals (n = 19)\t\tAbstinent individuals (n = 39)\t\t\t \tMean\tSD\tMean\tSD\tP value\t \tDemographics\t\t\t\t\t\t \t Gendera (% Female)\t22%\t–\t23%\t–\tp = .90\t \t Ethnicityb (% White, Non-Hispanic)\t63%\t–\t55%\t–\tp = .25\t \t Age\t36.9\t9.3\t38.2\t11.2\tp = .65\t \t Verbal IQ\t110\t7.8\t108\t9.5\tp = .39\t \tDrug Use (Self-Report)\t\t\t\t\t\t \t Methamphetamine lifetime uses\t9777\t12,432\t16,525\t36,246\tp = .41c\t \t Cocaine lifetime uses (usersd)\t2833 (17)\t6438\t2898 (35)\t6496\tp = .41c\t \t Cannabis lifetime uses (usersd)\t5007 (19)\t9031\t12,110 (36)\t32,540\tp = .62c\t \t Alcohol: typical drinks/week (userse)\t3.0 (15)\t3.0\t3.1(8)\t2.8\tp = .75\t \t Nicotine: typical cigarettes/day (userse)\t8.7 (10)\t8.9\t13.3(31)\t9.5\tp = .08\t \t Opiates lifetime uses\t77 (4)\t135\t414 (10)\t925\tp = .47c\t \t Hallucinogens lifetime uses\t74 (8)\t161\t208 (12)\t377\tp = .31c\t \tDrug Use (Dependence Diagnoses.)f\t\t\t\t\t\t \t Cocaine\t2\t\t6\t\t\t \t Cannabis\t4\t\t3\t\t\t \t Opiates\t1\t\t1\t\t\t \t Hallucinogens\t0\t\t0\t\t\t \tPersonality/Mood\t\t\t\t\t\t \t Baratt Impulsivity Scale (BIS)\t78.4\t9.6\t76.6\t11.8\tp = .60\t \t Sensation Seeking Scale (SSS)\t23.2\t6.0\t23.9\t5.4\tp = .65\t \t Beck Depression Inventory (BDI)\t7.8\t6.7\t6.7\t6.1\tp = .61\t \tAttention/Hyperactivity\t\t\t\t\t\t \t ADHD Attention Symptoms\t1.8\t3.4\t1.9\t2.8\tp = .92\t \t ADHD Hyperactivity Symptoms\t1.9\t3.5\t2.3\t3.2\tp = .76\t \t Conduct Symptoms\t1.4\t1.6\t1.5\t1.3\tp = .78\t \t
#Text=IQ = intelligence quotient (based on North American Adult Reading Test).
109-1	21883-21888	Table	_	
109-2	21889-21890	1	_	
109-3	21895-21903	Relapsed	_	
109-4	21904-21915	individuals	_	
109-5	21916-21917	(	_	
109-6	21917-21918	n	_	
109-7	21918-21919	 	_	
109-8	21919-21920	=	_	
109-9	21920-21921	 	_	
109-10	21921-21923	19	_	
109-11	21923-21924	)	_	
109-12	21926-21935	Abstinent	_	
109-13	21936-21947	individuals	_	
109-14	21948-21949	(	_	
109-15	21949-21950	n	_	
109-16	21950-21951	 	_	
109-17	21951-21952	=	_	
109-18	21952-21953	 	_	
109-19	21953-21955	39	_	
109-20	21955-21956	)	_	
109-21	21961-21965	Mean	_	
109-22	21966-21968	SD	_	
109-23	21969-21973	Mean	_	
109-24	21974-21976	SD	_	
109-25	21977-21978	P	_	
109-26	21979-21984	value	_	
109-27	21987-21999	Demographics	_	
109-28	22007-22008	 	_	
109-29	22008-22015	Gendera	_	
109-30	22016-22017	(	_	
109-31	22017-22018	%	_	
109-32	22019-22025	Female	_	
109-33	22025-22026	)	_	
109-34	22027-22030	22%	_	
109-35	22031-22032	–	_	
109-36	22033-22036	23%	_	
109-37	22037-22038	–	_	
109-38	22039-22040	p	_	
109-39	22040-22041	 	_	
109-40	22041-22042	=	_	
109-41	22042-22043	 	_	
109-42	22043-22046	.90	_	
109-43	22049-22050	 	_	
109-44	22050-22060	Ethnicityb	_	
109-45	22061-22062	(	_	
109-46	22062-22063	%	_	
109-47	22064-22069	White	_	
109-48	22069-22070	,	_	
109-49	22071-22083	Non-Hispanic	_	
109-50	22083-22084	)	_	
109-51	22085-22088	63%	_	
109-52	22089-22090	–	_	
109-53	22091-22094	55%	_	
109-54	22095-22096	–	_	
109-55	22097-22098	p	_	
109-56	22098-22099	 	_	
109-57	22099-22100	=	_	
109-58	22100-22101	 	_	
109-59	22101-22104	.25	_	
109-60	22107-22108	 	_	
109-61	22108-22111	Age	_	
109-62	22112-22116	36.9	_	
109-63	22117-22120	9.3	_	
109-64	22121-22125	38.2	_	
109-65	22126-22130	11.2	_	
109-66	22131-22132	p	_	
109-67	22132-22133	 	_	
109-68	22133-22134	=	_	
109-69	22134-22135	 	_	
109-70	22135-22138	.65	_	
109-71	22141-22142	 	_	
109-72	22142-22148	Verbal	_	
109-73	22149-22151	IQ	_	
109-74	22152-22155	110	_	
109-75	22156-22159	7.8	_	
109-76	22160-22163	108	_	
109-77	22164-22167	9.5	_	
109-78	22168-22169	p	_	
109-79	22169-22170	 	_	
109-80	22170-22171	=	_	
109-81	22171-22172	 	_	
109-82	22172-22175	.39	_	
109-83	22178-22182	Drug	_	
109-84	22183-22186	Use	_	
109-85	22187-22188	(	_	
109-86	22188-22199	Self-Report	_	
109-87	22199-22200	)	_	
109-88	22208-22209	 	_	
109-89	22209-22224	Methamphetamine	_	
109-90	22225-22233	lifetime	_	
109-91	22234-22238	uses	_	
109-92	22239-22243	9777	_	
109-93	22244-22250	12,432	_	
109-94	22251-22257	16,525	_	
109-95	22258-22264	36,246	_	
109-96	22265-22266	p	_	
109-97	22266-22267	 	_	
109-98	22267-22268	=	_	
109-99	22268-22269	 	_	
109-100	22269-22273	.41c	_	
109-101	22276-22277	 	_	
109-102	22277-22284	Cocaine	_	
109-103	22285-22293	lifetime	_	
109-104	22294-22298	uses	_	
109-105	22299-22300	(	_	
109-106	22300-22306	usersd	_	
109-107	22306-22307	)	_	
109-108	22308-22312	2833	_	
109-109	22313-22314	(	_	
109-110	22314-22316	17	_	
109-111	22316-22317	)	_	
109-112	22318-22322	6438	_	
109-113	22323-22327	2898	_	
109-114	22328-22329	(	_	
109-115	22329-22331	35	_	
109-116	22331-22332	)	_	
109-117	22333-22337	6496	_	
109-118	22338-22339	p	_	
109-119	22339-22340	 	_	
109-120	22340-22341	=	_	
109-121	22341-22342	 	_	
109-122	22342-22346	.41c	_	
109-123	22349-22350	 	_	
109-124	22350-22358	Cannabis	_	
109-125	22359-22367	lifetime	_	
109-126	22368-22372	uses	_	
109-127	22373-22374	(	_	
109-128	22374-22380	usersd	_	
109-129	22380-22381	)	_	
109-130	22382-22386	5007	_	
109-131	22387-22388	(	_	
109-132	22388-22390	19	_	
109-133	22390-22391	)	_	
109-134	22392-22396	9031	_	
109-135	22397-22403	12,110	_	
109-136	22404-22405	(	_	
109-137	22405-22407	36	_	
109-138	22407-22408	)	_	
109-139	22409-22415	32,540	_	
109-140	22416-22417	p	_	
109-141	22417-22418	 	_	
109-142	22418-22419	=	_	
109-143	22419-22420	 	_	
109-144	22420-22424	.62c	_	
109-145	22427-22428	 	_	
109-146	22428-22435	Alcohol	_	
109-147	22435-22436	:	_	
109-148	22437-22444	typical	_	
109-149	22445-22451	drinks	_	
109-150	22451-22452	/	_	
109-151	22452-22456	week	_	
109-152	22457-22458	(	_	
109-153	22458-22464	userse	_	
109-154	22464-22465	)	_	
109-155	22466-22469	3.0	_	
109-156	22470-22471	(	_	
109-157	22471-22473	15	_	
109-158	22473-22474	)	_	
109-159	22475-22478	3.0	_	
109-160	22479-22482	3.1	_	
109-161	22482-22483	(	_	
109-162	22483-22484	8	_	
109-163	22484-22485	)	_	
109-164	22486-22489	2.8	_	
109-165	22490-22491	p	_	
109-166	22491-22492	 	_	
109-167	22492-22493	=	_	
109-168	22493-22494	 	_	
109-169	22494-22497	.75	_	
109-170	22500-22501	 	_	
109-171	22501-22509	Nicotine	_	
109-172	22509-22510	:	_	
109-173	22511-22518	typical	_	
109-174	22519-22529	cigarettes	_	
109-175	22529-22530	/	_	
109-176	22530-22533	day	_	
109-177	22534-22535	(	_	
109-178	22535-22541	userse	_	
109-179	22541-22542	)	_	
109-180	22543-22546	8.7	_	
109-181	22547-22548	(	_	
109-182	22548-22550	10	_	
109-183	22550-22551	)	_	
109-184	22552-22555	8.9	_	
109-185	22556-22560	13.3	_	
109-186	22560-22561	(	_	
109-187	22561-22563	31	_	
109-188	22563-22564	)	_	
109-189	22565-22568	9.5	_	
109-190	22569-22570	p	_	
109-191	22570-22571	 	_	
109-192	22571-22572	=	_	
109-193	22572-22573	 	_	
109-194	22573-22576	.08	_	
109-195	22579-22580	 	_	
109-196	22580-22587	Opiates	_	
109-197	22588-22596	lifetime	_	
109-198	22597-22601	uses	_	
109-199	22602-22604	77	_	
109-200	22605-22606	(	_	
109-201	22606-22607	4	_	
109-202	22607-22608	)	_	
109-203	22609-22612	135	_	
109-204	22613-22616	414	_	
109-205	22617-22618	(	_	
109-206	22618-22620	10	_	
109-207	22620-22621	)	_	
109-208	22622-22625	925	_	
109-209	22626-22627	p	_	
109-210	22627-22628	 	_	
109-211	22628-22629	=	_	
109-212	22629-22630	 	_	
109-213	22630-22634	.47c	_	
109-214	22637-22638	 	_	
109-215	22638-22651	Hallucinogens	_	
109-216	22652-22660	lifetime	_	
109-217	22661-22665	uses	_	
109-218	22666-22668	74	_	
109-219	22669-22670	(	_	
109-220	22670-22671	8	_	
109-221	22671-22672	)	_	
109-222	22673-22676	161	_	
109-223	22677-22680	208	_	
109-224	22681-22682	(	_	
109-225	22682-22684	12	_	
109-226	22684-22685	)	_	
109-227	22686-22689	377	_	
109-228	22690-22691	p	_	
109-229	22691-22692	 	_	
109-230	22692-22693	=	_	
109-231	22693-22694	 	_	
109-232	22694-22698	.31c	_	
109-233	22701-22705	Drug	_	
109-234	22706-22709	Use	_	
109-235	22710-22711	(	_	
109-236	22711-22721	Dependence	_	
109-237	22722-22731	Diagnoses	_	
109-238	22731-22732	.	_	
109-239	22732-22733	)	_	
109-240	22733-22734	f	_	
109-241	22742-22743	 	_	
109-242	22743-22750	Cocaine	_	
109-243	22751-22752	2	_	
109-244	22754-22755	6	_	
109-245	22760-22761	 	_	
109-246	22761-22769	Cannabis	_	
109-247	22770-22771	4	_	
109-248	22773-22774	3	_	
109-249	22779-22780	 	_	
109-250	22780-22787	Opiates	_	
109-251	22788-22789	1	_	
109-252	22791-22792	1	_	
109-253	22797-22798	 	_	
109-254	22798-22811	Hallucinogens	_	
109-255	22812-22813	0	_	
109-256	22815-22816	0	_	
109-257	22821-22832	Personality	_	
109-258	22832-22833	/	_	
109-259	22833-22837	Mood	_	
109-260	22845-22846	 	_	
109-261	22846-22852	Baratt	_	
109-262	22853-22864	Impulsivity	_	
109-263	22865-22870	Scale	_	
109-264	22871-22872	(	_	
109-265	22872-22875	BIS	_	
109-266	22875-22876	)	_	
109-267	22877-22881	78.4	_	
109-268	22882-22885	9.6	_	
109-269	22886-22890	76.6	_	
109-270	22891-22895	11.8	_	
109-271	22896-22897	p	_	
109-272	22897-22898	 	_	
109-273	22898-22899	=	_	
109-274	22899-22900	 	_	
109-275	22900-22903	.60	_	
109-276	22906-22907	 	_	
109-277	22907-22916	Sensation	_	
109-278	22917-22924	Seeking	_	
109-279	22925-22930	Scale	_	
109-280	22931-22932	(	_	
109-281	22932-22935	SSS	_	
109-282	22935-22936	)	_	
109-283	22937-22941	23.2	_	
109-284	22942-22945	6.0	_	
109-285	22946-22950	23.9	_	
109-286	22951-22954	5.4	_	
109-287	22955-22956	p	_	
109-288	22956-22957	 	_	
109-289	22957-22958	=	_	
109-290	22958-22959	 	_	
109-291	22959-22962	.65	_	
109-292	22965-22966	 	_	
109-293	22966-22970	Beck	_	
109-294	22971-22981	Depression	_	
109-295	22982-22991	Inventory	_	
109-296	22992-22993	(	_	
109-297	22993-22996	BDI	_	
109-298	22996-22997	)	_	
109-299	22998-23001	7.8	_	
109-300	23002-23005	6.7	_	
109-301	23006-23009	6.7	_	
109-302	23010-23013	6.1	_	
109-303	23014-23015	p	_	
109-304	23015-23016	 	_	
109-305	23016-23017	=	_	
109-306	23017-23018	 	_	
109-307	23018-23021	.61	_	
109-308	23024-23033	Attention	_	
109-309	23033-23034	/	_	
109-310	23034-23047	Hyperactivity	_	
109-311	23055-23056	 	_	
109-312	23056-23060	ADHD	_	
109-313	23061-23070	Attention	_	
109-314	23071-23079	Symptoms	_	
109-315	23080-23083	1.8	_	
109-316	23084-23087	3.4	_	
109-317	23088-23091	1.9	_	
109-318	23092-23095	2.8	_	
109-319	23096-23097	p	_	
109-320	23097-23098	 	_	
109-321	23098-23099	=	_	
109-322	23099-23100	 	_	
109-323	23100-23103	.92	_	
109-324	23106-23107	 	_	
109-325	23107-23111	ADHD	_	
109-326	23112-23125	Hyperactivity	_	
109-327	23126-23134	Symptoms	_	
109-328	23135-23138	1.9	_	
109-329	23139-23142	3.5	_	
109-330	23143-23146	2.3	_	
109-331	23147-23150	3.2	_	
109-332	23151-23152	p	_	
109-333	23152-23153	 	_	
109-334	23153-23154	=	_	
109-335	23154-23155	 	_	
109-336	23155-23158	.76	_	
109-337	23161-23162	 	_	
109-338	23162-23169	Conduct	_	
109-339	23170-23178	Symptoms	_	
109-340	23179-23182	1.4	_	
109-341	23183-23186	1.6	_	
109-342	23187-23190	1.5	_	
109-343	23191-23194	1.3	_	
109-344	23195-23196	p	_	
109-345	23196-23197	 	_	
109-346	23197-23198	=	_	
109-347	23198-23199	 	_	
109-348	23199-23202	.78	_	
109-349	23206-23208	IQ	_	
109-350	23208-23209	 	_	
109-351	23209-23210	=	_	
109-352	23210-23211	 	_	
109-353	23211-23223	intelligence	_	
109-354	23224-23232	quotient	_	
109-355	23233-23234	(	_	
109-356	23234-23239	based	_	
109-357	23240-23242	on	_	
109-358	23243-23248	North	_	
109-359	23249-23257	American	_	
109-360	23258-23263	Adult	_	
109-361	23264-23271	Reading	_	
109-362	23272-23276	Test	_	
109-363	23276-23277	)	_	
109-364	23277-23278	.	_	

#Text=Chi-square test: χ2(1) = 0.5, p = .82.
110-1	23279-23289	Chi-square	_	
110-2	23290-23294	test	_	
110-3	23294-23295	:	_	
110-4	23296-23298	χ2	_	
110-5	23298-23299	(	_	
110-6	23299-23300	1	_	
110-7	23300-23301	)	_	
110-8	23301-23302	 	_	
110-9	23302-23303	=	_	
110-10	23303-23304	 	_	
110-11	23304-23307	0.5	_	
110-12	23307-23308	,	_	
110-13	23309-23310	p	_	
110-14	23310-23311	 	_	
110-15	23311-23312	=	_	
110-16	23312-23313	 	_	
110-17	23313-23316	.82	_	
110-18	23316-23317	.	_	

#Text=Chi-square test: χ2(5) = 6.6, p = .25.
#Text=t-test computed using natural log transformed +0.5 values (due to non-normal distributions) replicated results or raw data.
111-1	23318-23328	Chi-square	_	
111-2	23329-23333	test	_	
111-3	23333-23334	:	_	
111-4	23335-23337	χ2	_	
111-5	23337-23338	(	_	
111-6	23338-23339	5	_	
111-7	23339-23340	)	_	
111-8	23340-23341	 	_	
111-9	23341-23342	=	_	
111-10	23342-23343	 	_	
111-11	23343-23346	6.6	_	
111-12	23346-23347	,	_	
111-13	23348-23349	p	_	
111-14	23349-23350	 	_	
111-15	23350-23351	=	_	
111-16	23351-23352	 	_	
111-17	23352-23355	.25	_	
111-18	23355-23356	.	_	
111-19	23357-23363	t-test	_	
111-20	23364-23372	computed	_	
111-21	23373-23378	using	_	
111-22	23379-23386	natural	_	
111-23	23387-23390	log	_	
111-24	23391-23402	transformed	_	
111-25	23403-23404	+	_	
111-26	23404-23407	0.5	_	
111-27	23408-23414	values	_	
111-28	23415-23416	(	_	
111-29	23416-23419	due	_	
111-30	23420-23422	to	_	
111-31	23423-23433	non-normal	_	
111-32	23434-23447	distributions	_	
111-33	23447-23448	)	_	
111-34	23449-23459	replicated	_	
111-35	23460-23467	results	_	
111-36	23468-23470	or	_	
111-37	23471-23474	raw	_	
111-38	23475-23479	data	_	
111-39	23479-23480	.	_	

#Text=Number of past and/or current users mean was calculated with (other participants denied any past/present uses).
112-1	23481-23487	Number	_	
112-2	23488-23490	of	_	
112-3	23491-23495	past	_	
112-4	23496-23499	and	_	
112-5	23499-23500	/	_	
112-6	23500-23502	or	_	
112-7	23503-23510	current	_	
112-8	23511-23516	users	_	
112-9	23517-23521	mean	_	
112-10	23522-23525	was	_	
112-11	23526-23536	calculated	_	
112-12	23537-23541	with	_	
112-13	23542-23543	(	_	
112-14	23543-23548	other	_	
112-15	23549-23561	participants	_	
112-16	23562-23568	denied	_	
112-17	23569-23572	any	_	
112-18	23573-23577	past	_	
112-19	23577-23578	/	_	
112-20	23578-23585	present	_	
112-21	23586-23590	uses	_	
112-22	23590-23591	)	_	
112-23	23591-23592	.	_	

#Text=Number of current users mean was calculated with (other participants denied any current use).
113-1	23593-23599	Number	_	
113-2	23600-23602	of	_	
113-3	23603-23610	current	_	
113-4	23611-23616	users	_	
113-5	23617-23621	mean	_	
113-6	23622-23625	was	_	
113-7	23626-23636	calculated	_	
113-8	23637-23641	with	_	
113-9	23642-23643	(	_	
113-10	23643-23648	other	_	
113-11	23649-23661	participants	_	
113-12	23662-23668	denied	_	
113-13	23669-23672	any	_	
113-14	23673-23680	current	_	
113-15	23681-23684	use	_	
113-16	23684-23685	)	_	
113-17	23685-23686	.	_	

#Text=Number of participants who met criteria for dependence diagnosis for corresponding drug (in addition to methamphetamine) at baseline; note: methamphetamine was confirmed as primary drug of abuse for all participants based on clinical assessment (based on number of dependence criteria and overall lifetime uses).
114-1	23687-23693	Number	_	
114-2	23694-23696	of	_	
114-3	23697-23709	participants	_	
114-4	23710-23713	who	_	
114-5	23714-23717	met	_	
114-6	23718-23726	criteria	_	
114-7	23727-23730	for	_	
114-8	23731-23741	dependence	_	
114-9	23742-23751	diagnosis	_	
114-10	23752-23755	for	_	
114-11	23756-23769	corresponding	_	
114-12	23770-23774	drug	_	
114-13	23775-23776	(	_	
114-14	23776-23778	in	_	
114-15	23779-23787	addition	_	
114-16	23788-23790	to	_	
114-17	23791-23806	methamphetamine	_	
114-18	23806-23807	)	_	
114-19	23808-23810	at	_	
114-20	23811-23819	baseline	_	
114-21	23819-23820	;	_	
114-22	23821-23825	note	_	
114-23	23825-23826	:	_	
114-24	23827-23842	methamphetamine	_	
114-25	23843-23846	was	_	
114-26	23847-23856	confirmed	_	
114-27	23857-23859	as	_	
114-28	23860-23867	primary	_	
114-29	23868-23872	drug	_	
114-30	23873-23875	of	_	
114-31	23876-23881	abuse	_	
114-32	23882-23885	for	_	
114-33	23886-23889	all	_	
114-34	23890-23902	participants	_	
114-35	23903-23908	based	_	
114-36	23909-23911	on	_	
114-37	23912-23920	clinical	_	
114-38	23921-23931	assessment	_	
114-39	23932-23933	(	_	
114-40	23933-23938	based	_	
114-41	23939-23941	on	_	
114-42	23942-23948	number	_	
114-43	23949-23951	of	_	
114-44	23952-23962	dependence	_	
114-45	23963-23971	criteria	_	
114-46	23972-23975	and	_	
114-47	23976-23983	overall	_	
114-48	23984-23992	lifetime	_	
114-49	23993-23997	uses	_	
114-50	23997-23998	)	_	
114-51	23998-23999	.	_	

#Text=Relapsed participants did not differ from those who remained sober in terms of ethnicity, gender, age, and verbal IQ (p > .05).
115-1	24000-24008	Relapsed	_	
115-2	24009-24021	participants	_	
115-3	24022-24025	did	_	
115-4	24026-24029	not	_	
115-5	24030-24036	differ	_	
115-6	24037-24041	from	_	
115-7	24042-24047	those	_	
115-8	24048-24051	who	_	
115-9	24052-24060	remained	_	
115-10	24061-24066	sober	_	
115-11	24067-24069	in	_	
115-12	24070-24075	terms	_	
115-13	24076-24078	of	_	
115-14	24079-24088	ethnicity	_	
115-15	24088-24089	,	_	
115-16	24090-24096	gender	_	
115-17	24096-24097	,	_	
115-18	24098-24101	age	_	
115-19	24101-24102	,	_	
115-20	24103-24106	and	_	
115-21	24107-24113	verbal	_	
115-22	24114-24116	IQ	_	
115-23	24117-24118	(	_	
115-24	24118-24119	p	_	
115-25	24119-24120	 	_	
115-26	24120-24121	>	_	
115-27	24121-24122	 	_	
115-28	24122-24125	.05	_	
115-29	24125-24126	)	_	
115-30	24126-24127	.	_	

#Text=At baseline, groups differed neither in reported lifetime methamphetamine, cocaine, marijuana uses, nor in average number of cigarettes/week and alcoholic drinks/week over the past year (p > .05; see Table 1).
116-1	24128-24130	At	_	
116-2	24131-24139	baseline	_	
116-3	24139-24140	,	_	
116-4	24141-24147	groups	_	
116-5	24148-24156	differed	_	
116-6	24157-24164	neither	_	
116-7	24165-24167	in	_	
116-8	24168-24176	reported	_	
116-9	24177-24185	lifetime	_	
116-10	24186-24201	methamphetamine	_	
116-11	24201-24202	,	_	
116-12	24203-24210	cocaine	_	
116-13	24210-24211	,	_	
116-14	24212-24221	marijuana	_	
116-15	24222-24226	uses	_	
116-16	24226-24227	,	_	
116-17	24228-24231	nor	_	
116-18	24232-24234	in	_	
116-19	24235-24242	average	_	
116-20	24243-24249	number	_	
116-21	24250-24252	of	_	
116-22	24253-24263	cigarettes	_	
116-23	24263-24264	/	_	
116-24	24264-24268	week	_	
116-25	24269-24272	and	_	
116-26	24273-24282	alcoholic	_	
116-27	24283-24289	drinks	_	
116-28	24289-24290	/	_	
116-29	24290-24294	week	_	
116-30	24295-24299	over	_	
116-31	24300-24303	the	_	
116-32	24304-24308	past	_	
116-33	24309-24313	year	_	
116-34	24314-24315	(	_	
116-35	24315-24316	p	_	
116-36	24316-24317	 	_	
116-37	24317-24318	>	_	
116-38	24318-24319	 	_	
116-39	24319-24322	.05	_	
116-40	24322-24323	;	_	
116-41	24324-24327	see	_	
116-42	24328-24333	Table	_	
116-43	24334-24335	1	_	
116-44	24335-24336	)	_	
116-45	24336-24337	.	_	

#Text=Model-based behavioral adjustment
#Text=Supporting our model's assumptions, a positive linear relationship between Go RT and P(stop) was observed in all participants (B = 276 ms, t(56) = 2.8,p = .008, model omnibus test: χ2(1) = 127,p < .001; mean Pearson correlation coefficient: r = 0.17).
117-1	24338-24349	Model-based	_	
117-2	24350-24360	behavioral	_	
117-3	24361-24371	adjustment	_	
117-4	24372-24382	Supporting	_	
117-5	24383-24386	our	_	
117-6	24387-24394	model's	_	
117-7	24395-24406	assumptions	_	
117-8	24406-24407	,	_	
117-9	24408-24409	a	_	
117-10	24410-24418	positive	_	
117-11	24419-24425	linear	_	
117-12	24426-24438	relationship	_	
117-13	24439-24446	between	_	
117-14	24447-24449	Go	_	
117-15	24450-24452	RT	_	
117-16	24453-24456	and	_	
117-17	24457-24458	P	_	
117-18	24458-24459	(	_	
117-19	24459-24463	stop	_	
117-20	24463-24464	)	_	
117-21	24465-24468	was	_	
117-22	24469-24477	observed	_	
117-23	24478-24480	in	_	
117-24	24481-24484	all	_	
117-25	24485-24497	participants	_	
117-26	24498-24499	(	_	
117-27	24499-24500	B	_	
117-28	24500-24501	 	_	
117-29	24501-24502	=	_	
117-30	24502-24503	 	_	
117-31	24503-24506	276	_	
117-32	24506-24507	 	_	
117-33	24507-24509	ms	_	
117-34	24509-24510	,	_	
117-35	24511-24512	t	_	
117-36	24512-24513	(	_	
117-37	24513-24515	56	_	
117-38	24515-24516	)	_	
117-39	24516-24517	 	_	
117-40	24517-24518	=	_	
117-41	24518-24519	 	_	
117-42	24519-24522	2.8	_	
117-43	24522-24523	,	_	
117-44	24523-24524	p	_	
117-45	24524-24525	 	_	
117-46	24525-24526	=	_	
117-47	24526-24527	 	_	
117-48	24527-24531	.008	_	
117-49	24531-24532	,	_	
117-50	24533-24538	model	_	
117-51	24539-24546	omnibus	_	
117-52	24547-24551	test	_	
117-53	24551-24552	:	_	
117-54	24553-24555	χ2	_	
117-55	24555-24556	(	_	
117-56	24556-24557	1	_	
117-57	24557-24558	)	_	
117-58	24558-24559	 	_	
117-59	24559-24560	=	_	
117-60	24560-24561	 	_	
117-61	24561-24564	127	_	
117-62	24564-24565	,	_	
117-63	24565-24566	p	_	
117-64	24566-24567	 	_	
117-65	24567-24568	<	_	
117-66	24568-24569	 	_	
117-67	24569-24573	.001	_	
117-68	24573-24574	;	_	
117-69	24575-24579	mean	_	
117-70	24580-24587	Pearson	_	
117-71	24588-24599	correlation	_	
117-72	24600-24611	coefficient	_	
117-73	24611-24612	:	_	
117-74	24613-24614	r	_	
117-75	24614-24615	 	_	
117-76	24615-24616	=	_	
117-77	24616-24617	 	_	
117-78	24617-24621	0.17	_	
117-79	24621-24622	)	_	
117-80	24622-24623	.	_	

#Text=Neither the group main effect on Go RT (χ2(1) = 0.02,p = .90); Mean RT: Relapsed = 579 ms; Abstinent = 572 ms), nor the group by P(stop) interaction (χ2(1) = 1.8,p = .18), were statistically significant (see Fig. 1B).
118-1	24624-24631	Neither	_	
118-2	24632-24635	the	_	
118-3	24636-24641	group	_	
118-4	24642-24646	main	_	
118-5	24647-24653	effect	_	
118-6	24654-24656	on	_	
118-7	24657-24659	Go	_	
118-8	24660-24662	RT	_	
118-9	24663-24664	(	_	
118-10	24664-24666	χ2	_	
118-11	24666-24667	(	_	
118-12	24667-24668	1	_	
118-13	24668-24669	)	_	
118-14	24669-24670	 	_	
118-15	24670-24671	=	_	
118-16	24671-24672	 	_	
118-17	24672-24676	0.02	_	
118-18	24676-24677	,	_	
118-19	24677-24678	p	_	
118-20	24678-24679	 	_	
118-21	24679-24680	=	_	
118-22	24680-24681	 	_	
118-23	24681-24684	.90	_	
118-24	24684-24685	)	_	
118-25	24685-24686	;	_	
118-26	24687-24691	Mean	_	
118-27	24692-24694	RT	_	
118-28	24694-24695	:	_	
118-29	24696-24704	Relapsed	_	
118-30	24704-24705	 	_	
118-31	24705-24706	=	_	
118-32	24706-24707	 	_	
118-33	24707-24710	579	_	
118-34	24710-24711	 	_	
118-35	24711-24713	ms	_	
118-36	24713-24714	;	_	
118-37	24715-24724	Abstinent	_	
118-38	24724-24725	 	_	
118-39	24725-24726	=	_	
118-40	24726-24727	 	_	
118-41	24727-24730	572	_	
118-42	24730-24731	 	_	
118-43	24731-24733	ms	_	
118-44	24733-24734	)	_	
118-45	24734-24735	,	_	
118-46	24736-24739	nor	_	
118-47	24740-24743	the	_	
118-48	24744-24749	group	_	
118-49	24750-24752	by	_	
118-50	24753-24754	P	_	
118-51	24754-24755	(	_	
118-52	24755-24759	stop	_	
118-53	24759-24760	)	_	
118-54	24761-24772	interaction	_	
118-55	24773-24774	(	_	
118-56	24774-24776	χ2	_	
118-57	24776-24777	(	_	
118-58	24777-24778	1	_	
118-59	24778-24779	)	_	
118-60	24779-24780	 	_	
118-61	24780-24781	=	_	
118-62	24781-24782	 	_	
118-63	24782-24785	1.8	_	
118-64	24785-24786	,	_	
118-65	24786-24787	p	_	
118-66	24787-24788	 	_	
118-67	24788-24789	=	_	
118-68	24789-24790	 	_	
118-69	24790-24793	.18	_	
118-70	24793-24794	)	_	
118-71	24794-24795	,	_	
118-72	24796-24800	were	_	
118-73	24801-24814	statistically	_	
118-74	24815-24826	significant	_	
118-75	24827-24828	(	_	
118-76	24828-24831	see	_	
118-77	24832-24835	Fig	_	
118-78	24835-24836	.	_	
118-79	24837-24839	1B	_	
118-80	24839-24840	)	_	
118-81	24840-24841	.	_	

#Text=As expected, participants had a higher likelihood of error on trials with longer stop signal delay (χ2(1) = 106,p < .001).
119-1	24842-24844	As	_	
119-2	24845-24853	expected	_	
119-3	24853-24854	,	_	
119-4	24855-24867	participants	_	
119-5	24868-24871	had	_	
119-6	24872-24873	a	_	
119-7	24874-24880	higher	_	
119-8	24881-24891	likelihood	_	
119-9	24892-24894	of	_	
119-10	24895-24900	error	_	
119-11	24901-24903	on	_	
119-12	24904-24910	trials	_	
119-13	24911-24915	with	_	
119-14	24916-24922	longer	_	
119-15	24923-24927	stop	_	
119-16	24928-24934	signal	_	
119-17	24935-24940	delay	_	
119-18	24941-24942	(	_	
119-19	24942-24944	χ2	_	
119-20	24944-24945	(	_	
119-21	24945-24946	1	_	
119-22	24946-24947	)	_	
119-23	24947-24948	 	_	
119-24	24948-24949	=	_	
119-25	24949-24950	 	_	
119-26	24950-24953	106	_	
119-27	24953-24954	,	_	
119-28	24954-24955	p	_	
119-29	24955-24956	 	_	
119-30	24956-24957	<	_	
119-31	24957-24958	 	_	
119-32	24958-24962	.001	_	
119-33	24962-24963	)	_	
119-34	24963-24964	.	_	

#Text=However, groups did not significantly differ in their average stop error rates (Group main effect: χ2(1) = 0.20,p = .66; Mean Error Rate = 0. 49).
120-1	24965-24972	However	_	
120-2	24972-24973	,	_	
120-3	24974-24980	groups	_	
120-4	24981-24984	did	_	
120-5	24985-24988	not	_	
120-6	24989-25002	significantly	_	
120-7	25003-25009	differ	_	
120-8	25010-25012	in	_	
120-9	25013-25018	their	_	
120-10	25019-25026	average	_	
120-11	25027-25031	stop	_	
120-12	25032-25037	error	_	
120-13	25038-25043	rates	_	
120-14	25044-25045	(	_	
120-15	25045-25050	Group	_	
120-16	25051-25055	main	_	
120-17	25056-25062	effect	_	
120-18	25062-25063	:	_	
120-19	25064-25066	χ2	_	
120-20	25066-25067	(	_	
120-21	25067-25068	1	_	
120-22	25068-25069	)	_	
120-23	25069-25070	 	_	
120-24	25070-25071	=	_	
120-25	25071-25072	 	_	
120-26	25072-25076	0.20	_	
120-27	25076-25077	,	_	
120-28	25077-25078	p	_	
120-29	25078-25079	 	_	
120-30	25079-25080	=	_	
120-31	25080-25081	 	_	
120-32	25081-25084	.66	_	
120-33	25084-25085	;	_	
120-34	25086-25090	Mean	_	
120-35	25091-25096	Error	_	
120-36	25097-25101	Rate	_	
120-37	25101-25102	 	_	
120-38	25102-25103	=	_	
120-39	25103-25104	 	_	
120-40	25104-25105	0	_	
120-41	25105-25106	.	_	
120-42	25107-25109	49	_	
120-43	25109-25110	)	_	
120-44	25110-25111	.	_	

#Text=The Group by SSD interaction was not statistically significant, but a trend was observed in the direction of steeper decline in accuracy for shorter SSD among relapsed individuals (χ2(1) = 3.3,p = .07).
121-1	25112-25115	The	_	
121-2	25116-25121	Group	_	
121-3	25122-25124	by	_	
121-4	25125-25128	SSD	_	
121-5	25129-25140	interaction	_	
121-6	25141-25144	was	_	
121-7	25145-25148	not	_	
121-8	25149-25162	statistically	_	
121-9	25163-25174	significant	_	
121-10	25174-25175	,	_	
121-11	25176-25179	but	_	
121-12	25180-25181	a	_	
121-13	25182-25187	trend	_	
121-14	25188-25191	was	_	
121-15	25192-25200	observed	_	
121-16	25201-25203	in	_	
121-17	25204-25207	the	_	
121-18	25208-25217	direction	_	
121-19	25218-25220	of	_	
121-20	25221-25228	steeper	_	
121-21	25229-25236	decline	_	
121-22	25237-25239	in	_	
121-23	25240-25248	accuracy	_	
121-24	25249-25252	for	_	
121-25	25253-25260	shorter	_	
121-26	25261-25264	SSD	_	
121-27	25265-25270	among	_	
121-28	25271-25279	relapsed	_	
121-29	25280-25291	individuals	_	
121-30	25292-25293	(	_	
121-31	25293-25295	χ2	_	
121-32	25295-25296	(	_	
121-33	25296-25297	1	_	
121-34	25297-25298	)	_	
121-35	25298-25299	 	_	
121-36	25299-25300	=	_	
121-37	25300-25301	 	_	
121-38	25301-25304	3.3	_	
121-39	25304-25305	,	_	
121-40	25305-25306	p	_	
121-41	25306-25307	 	_	
121-42	25307-25308	=	_	
121-43	25308-25309	 	_	
121-44	25309-25312	.07	_	
121-45	25312-25313	)	_	
121-46	25313-25314	.	_	

#Text=Importantly, as predicted by our ideal observer model and the observed RT adjustment, we found a negative relationship between error likelihood and P(stop), with higher P(stop) prompting a smaller likelihood of error (odds ratio = 0.48, Wald z = −3.04,p < .05; omnibus test: χ2(1) = 9.2, p < .05).
122-1	25315-25326	Importantly	_	
122-2	25326-25327	,	_	
122-3	25328-25330	as	_	
122-4	25331-25340	predicted	_	
122-5	25341-25343	by	_	
122-6	25344-25347	our	_	
122-7	25348-25353	ideal	_	
122-8	25354-25362	observer	_	
122-9	25363-25368	model	_	
122-10	25369-25372	and	_	
122-11	25373-25376	the	_	
122-12	25377-25385	observed	_	
122-13	25386-25388	RT	_	
122-14	25389-25399	adjustment	_	
122-15	25399-25400	,	_	
122-16	25401-25403	we	_	
122-17	25404-25409	found	_	
122-18	25410-25411	a	_	
122-19	25412-25420	negative	_	
122-20	25421-25433	relationship	_	
122-21	25434-25441	between	_	
122-22	25442-25447	error	_	
122-23	25448-25458	likelihood	_	
122-24	25459-25462	and	_	
122-25	25463-25464	P	_	
122-26	25464-25465	(	_	
122-27	25465-25469	stop	_	
122-28	25469-25470	)	_	
122-29	25470-25471	,	_	
122-30	25472-25476	with	_	
122-31	25477-25483	higher	_	
122-32	25484-25485	P	_	
122-33	25485-25486	(	_	
122-34	25486-25490	stop	_	
122-35	25490-25491	)	_	
122-36	25492-25501	prompting	_	
122-37	25502-25503	a	_	
122-38	25504-25511	smaller	_	
122-39	25512-25522	likelihood	_	
122-40	25523-25525	of	_	
122-41	25526-25531	error	_	
122-42	25532-25533	(	_	
122-43	25533-25537	odds	_	
122-44	25538-25543	ratio	_	
122-45	25543-25544	 	_	
122-46	25544-25545	=	_	
122-47	25545-25546	 	_	
122-48	25546-25550	0.48	_	
122-49	25550-25551	,	_	
122-50	25552-25556	Wald	_	
122-51	25557-25558	z	_	
122-52	25558-25559	 	_	
122-53	25559-25560	=	_	
122-54	25560-25561	 	_	
122-55	25561-25562	−	_	
122-56	25562-25566	3.04	_	
122-57	25566-25567	,	_	
122-58	25567-25568	p	_	
122-59	25568-25569	 	_	
122-60	25569-25570	<	_	
122-61	25570-25571	 	_	
122-62	25571-25574	.05	_	
122-63	25574-25575	;	_	
122-64	25576-25583	omnibus	_	
122-65	25584-25588	test	_	
122-66	25588-25589	:	_	
122-67	25590-25592	χ2	_	
122-68	25592-25593	(	_	
122-69	25593-25594	1	_	
122-70	25594-25595	)	_	
122-71	25595-25596	 	_	
122-72	25596-25597	=	_	
122-73	25597-25598	 	_	
122-74	25598-25601	9.2	_	
122-75	25601-25602	,	_	
122-76	25603-25604	p	_	
122-77	25604-25605	 	_	
122-78	25605-25606	<	_	
122-79	25606-25607	 	_	
122-80	25607-25610	.05	_	
122-81	25610-25611	)	_	
122-82	25611-25612	.	_	

#Text=There was no statistically significant group x P(stop) interaction (χ2(1) = 0.03,p = .85).
#Text=fMRI analyses
#Text=Bayesian prediction of inhibitory response (P(stop))
#Text=Group difference in neural activation to a Bayesian signed prediction error (SPE).
123-1	25613-25618	There	_	
123-2	25619-25622	was	_	
123-3	25623-25625	no	_	
123-4	25626-25639	statistically	_	
123-5	25640-25651	significant	_	
123-6	25652-25657	group	_	
123-7	25658-25659	x	_	
123-8	25660-25661	P	_	
123-9	25661-25662	(	_	
123-10	25662-25666	stop	_	
123-11	25666-25667	)	_	
123-12	25668-25679	interaction	_	
123-13	25680-25681	(	_	
123-14	25681-25683	χ2	_	
123-15	25683-25684	(	_	
123-16	25684-25685	1	_	
123-17	25685-25686	)	_	
123-18	25686-25687	 	_	
123-19	25687-25688	=	_	
123-20	25688-25689	 	_	
123-21	25689-25693	0.03	_	
123-22	25693-25694	,	_	
123-23	25694-25695	p	_	
123-24	25695-25696	 	_	
123-25	25696-25697	=	_	
123-26	25697-25698	 	_	
123-27	25698-25701	.85	_	
123-28	25701-25702	)	_	
123-29	25702-25703	.	_	
123-30	25704-25708	fMRI	_	
123-31	25709-25717	analyses	_	
123-32	25718-25726	Bayesian	_	
123-33	25727-25737	prediction	_	
123-34	25738-25740	of	_	
123-35	25741-25751	inhibitory	_	
123-36	25752-25760	response	_	
123-37	25761-25762	(	_	
123-38	25762-25763	P	_	
123-39	25763-25764	(	_	
123-40	25764-25768	stop	_	
123-41	25768-25769	)	_	
123-42	25769-25770	)	_	
123-43	25771-25776	Group	_	
123-44	25777-25787	difference	_	
123-45	25788-25790	in	_	
123-46	25791-25797	neural	_	
123-47	25798-25808	activation	_	
123-48	25809-25811	to	_	
123-49	25812-25813	a	_	
123-50	25814-25822	Bayesian	_	
123-51	25823-25829	signed	_	
123-52	25830-25840	prediction	_	
123-53	25841-25846	error	_	
123-54	25847-25848	(	_	
123-55	25848-25851	SPE	_	
123-56	25851-25852	)	_	
123-57	25852-25853	.	_	

#Text=A.
124-1	25854-25855	A	_	
124-2	25855-25856	.	_	

#Text=BOLD signal in the left middle frontal gyrus a showing group difference in the temporo-parietal junction (TPJ)/angular gyrus.
125-1	25857-25861	BOLD	_	
125-2	25862-25868	signal	_	
125-3	25869-25871	in	_	
125-4	25872-25875	the	_	
125-5	25876-25880	left	_	
125-6	25881-25887	middle	_	
125-7	25888-25895	frontal	_	
125-8	25896-25901	gyrus	_	
125-9	25902-25903	a	_	
125-10	25904-25911	showing	_	
125-11	25912-25917	group	_	
125-12	25918-25928	difference	_	
125-13	25929-25931	in	_	
125-14	25932-25935	the	_	
125-15	25936-25952	temporo-parietal	_	
125-16	25953-25961	junction	_	
125-17	25962-25963	(	_	
125-18	25963-25966	TPJ	_	
125-19	25966-25967	)	_	
125-20	25967-25968	/	_	
125-21	25968-25975	angular	_	
125-22	25976-25981	gyrus	_	
125-23	25981-25982	.	_	

#Text=B.
126-1	25983-25984	B	_	
126-2	25984-25985	.	_	

#Text=Bar graph displays average P(stop) modulation of percent signal change by trial type (Go vs Stop) and group (Abstinent: n = 38; Relapsed: n = 19; error bars indicate ±1 SEM).
127-1	25986-25989	Bar	_	
127-2	25990-25995	graph	_	
127-3	25996-26004	displays	_	
127-4	26005-26012	average	_	
127-5	26013-26014	P	_	
127-6	26014-26015	(	_	
127-7	26015-26019	stop	_	
127-8	26019-26020	)	_	
127-9	26021-26031	modulation	_	
127-10	26032-26034	of	_	
127-11	26035-26042	percent	_	
127-12	26043-26049	signal	_	
127-13	26050-26056	change	_	
127-14	26057-26059	by	_	
127-15	26060-26065	trial	_	
127-16	26066-26070	type	_	
127-17	26071-26072	(	_	
127-18	26072-26074	Go	_	
127-19	26075-26077	vs	_	
127-20	26078-26082	Stop	_	
127-21	26082-26083	)	_	
127-22	26084-26087	and	_	
127-23	26088-26093	group	_	
127-24	26094-26095	(	_	
127-25	26095-26104	Abstinent	_	
127-26	26104-26105	:	_	
127-27	26106-26107	n	_	
127-28	26107-26108	 	_	
127-29	26108-26109	=	_	
127-30	26109-26110	 	_	
127-31	26110-26112	38	_	
127-32	26112-26113	;	_	
127-33	26114-26122	Relapsed	_	
127-34	26122-26123	:	_	
127-35	26124-26125	n	_	
127-36	26125-26126	 	_	
127-37	26126-26127	=	_	
127-38	26127-26128	 	_	
127-39	26128-26130	19	_	
127-40	26130-26131	;	_	
127-41	26132-26137	error	_	
127-42	26138-26142	bars	_	
127-43	26143-26151	indicate	_	
127-44	26152-26153	±	_	
127-45	26153-26154	1	_	
127-46	26155-26158	SEM	_	
127-47	26158-26159	)	_	
127-48	26159-26160	.	_	

#Text=In this area, abstinent individuals (grey bars) demonstrated a neural response consistent with a significant de-activation to a signed prediction error (outcome − P(stop)), i.e., a positive correlation between percentage signal change and P(stop) on both Go and Stop trials, whereas relapsed participants (red/striped bars) do not show any significant P(stop) dependent activation on either Go or Stop trials.
128-1	26161-26163	In	_	
128-2	26164-26168	this	_	
128-3	26169-26173	area	_	
128-4	26173-26174	,	_	
128-5	26175-26184	abstinent	_	
128-6	26185-26196	individuals	_	
128-7	26197-26198	(	_	
128-8	26198-26202	grey	_	
128-9	26203-26207	bars	_	
128-10	26207-26208	)	_	
128-11	26209-26221	demonstrated	_	
128-12	26222-26223	a	_	
128-13	26224-26230	neural	_	
128-14	26231-26239	response	_	
128-15	26240-26250	consistent	_	
128-16	26251-26255	with	_	
128-17	26256-26257	a	_	
128-18	26258-26269	significant	_	
128-19	26270-26283	de-activation	_	
128-20	26284-26286	to	_	
128-21	26287-26288	a	_	
128-22	26289-26295	signed	_	
128-23	26296-26306	prediction	_	
128-24	26307-26312	error	_	
128-25	26313-26314	(	_	
128-26	26314-26321	outcome	_	
128-27	26322-26323	−	_	
128-28	26324-26325	P	_	
128-29	26325-26326	(	_	
128-30	26326-26330	stop	_	
128-31	26330-26331	)	_	
128-32	26331-26332	)	_	
128-33	26332-26333	,	_	
128-34	26334-26337	i.e	_	
128-35	26337-26338	.	_	
128-36	26338-26339	,	_	
128-37	26340-26341	a	_	
128-38	26342-26350	positive	_	
128-39	26351-26362	correlation	_	
128-40	26363-26370	between	_	
128-41	26371-26381	percentage	_	
128-42	26382-26388	signal	_	
128-43	26389-26395	change	_	
128-44	26396-26399	and	_	
128-45	26400-26401	P	_	
128-46	26401-26402	(	_	
128-47	26402-26406	stop	_	
128-48	26406-26407	)	_	
128-49	26408-26410	on	_	
128-50	26411-26415	both	_	
128-51	26416-26418	Go	_	
128-52	26419-26422	and	_	
128-53	26423-26427	Stop	_	
128-54	26428-26434	trials	_	
128-55	26434-26435	,	_	
128-56	26436-26443	whereas	_	
128-57	26444-26452	relapsed	_	
128-58	26453-26465	participants	_	
128-59	26466-26467	(	_	
128-60	26467-26470	red	_	
128-61	26470-26471	/	_	
128-62	26471-26478	striped	_	
128-63	26479-26483	bars	_	
128-64	26483-26484	)	_	
128-65	26485-26487	do	_	
128-66	26488-26491	not	_	
128-67	26492-26496	show	_	
128-68	26497-26500	any	_	
128-69	26501-26512	significant	_	
128-70	26513-26514	P	_	
128-71	26514-26515	(	_	
128-72	26515-26519	stop	_	
128-73	26519-26520	)	_	
128-74	26521-26530	dependent	_	
128-75	26531-26541	activation	_	
128-76	26542-26544	on	_	
128-77	26545-26551	either	_	
128-78	26552-26554	Go	_	
128-79	26555-26557	or	_	
128-80	26558-26562	Stop	_	
128-81	26563-26569	trials	_	
128-82	26569-26570	.	_	

#Text=C.
129-1	26571-26572	C	_	
129-2	26572-26573	.	_	

#Text=Average percent signal change correlation with a Bayesian SPE (outcome − P(stop) for each group (error bars: ±1 SEM).
130-1	26574-26581	Average	_	
130-2	26582-26589	percent	_	
130-3	26590-26596	signal	_	
130-4	26597-26603	change	_	
130-5	26604-26615	correlation	_	
130-6	26616-26620	with	_	
130-7	26621-26622	a	_	
130-8	26623-26631	Bayesian	_	
130-9	26632-26635	SPE	_	
130-10	26636-26637	(	_	
130-11	26637-26644	outcome	_	
130-12	26645-26646	−	_	
130-13	26647-26648	P	_	
130-14	26648-26649	(	_	
130-15	26649-26653	stop	_	
130-16	26653-26654	)	_	
130-17	26655-26658	for	_	
130-18	26659-26663	each	_	
130-19	26664-26669	group	_	
130-20	26670-26671	(	_	
130-21	26671-26676	error	_	
130-22	26677-26681	bars	_	
130-23	26681-26682	:	_	
130-24	26683-26684	±	_	
130-25	26684-26685	1	_	
130-26	26686-26689	SEM	_	
130-27	26689-26690	)	_	
130-28	26690-26691	.	_	

#Text=Relative to abstinent participants who show a strong deactivation to SPE (grey bar), relapsed individuals show an attenuated SPE-dependent activation, which was not significantly different from zero (p > .05).
131-1	26692-26700	Relative	_	
131-2	26701-26703	to	_	
131-3	26704-26713	abstinent	_	
131-4	26714-26726	participants	_	
131-5	26727-26730	who	_	
131-6	26731-26735	show	_	
131-7	26736-26737	a	_	
131-8	26738-26744	strong	_	
131-9	26745-26757	deactivation	_	
131-10	26758-26760	to	_	
131-11	26761-26764	SPE	_	
131-12	26765-26766	(	_	
131-13	26766-26770	grey	_	
131-14	26771-26774	bar	_	
131-15	26774-26775	)	_	
131-16	26775-26776	,	_	
131-17	26777-26785	relapsed	_	
131-18	26786-26797	individuals	_	
131-19	26798-26802	show	_	
131-20	26803-26805	an	_	
131-21	26806-26816	attenuated	_	
131-22	26817-26830	SPE-dependent	_	
131-23	26831-26841	activation	_	
131-24	26841-26842	,	_	
131-25	26843-26848	which	_	
131-26	26849-26852	was	_	
131-27	26853-26856	not	_	
131-28	26857-26870	significantly	_	
131-29	26871-26880	different	_	
131-30	26881-26885	from	_	
131-31	26886-26890	zero	_	
131-32	26891-26892	(	_	
131-33	26892-26893	p	_	
131-34	26893-26894	 	_	
131-35	26894-26895	>	_	
131-36	26895-26896	 	_	
131-37	26896-26899	.05	_	
131-38	26899-26900	)	_	
131-39	26900-26901	.	_	

#Text=Fig. 2
#Text=Testing for any group differences in brain activation associated with P(stop) irrespective of trial type, we found one area consistent with such neural pattern in the left the left temporoparietal junction including the angular gyrus (Brodmann Area 39; Volume = 23 voxels/1472 μL; Peak Voxel Coordinates:-40,-66,22; z = 3.49, p = .0005; see Fig. 2A).
132-1	26902-26905	Fig	_	
132-2	26905-26906	.	_	
132-3	26907-26908	2	_	
132-4	26909-26916	Testing	_	
132-5	26917-26920	for	_	
132-6	26921-26924	any	_	
132-7	26925-26930	group	_	
132-8	26931-26942	differences	_	
132-9	26943-26945	in	_	
132-10	26946-26951	brain	_	
132-11	26952-26962	activation	_	
132-12	26963-26973	associated	_	
132-13	26974-26978	with	_	
132-14	26979-26980	P	_	
132-15	26980-26981	(	_	
132-16	26981-26985	stop	_	
132-17	26985-26986	)	_	
132-18	26987-26999	irrespective	_	
132-19	27000-27002	of	_	
132-20	27003-27008	trial	_	
132-21	27009-27013	type	_	
132-22	27013-27014	,	_	
132-23	27015-27017	we	_	
132-24	27018-27023	found	_	
132-25	27024-27027	one	_	
132-26	27028-27032	area	_	
132-27	27033-27043	consistent	_	
132-28	27044-27048	with	_	
132-29	27049-27053	such	_	
132-30	27054-27060	neural	_	
132-31	27061-27068	pattern	_	
132-32	27069-27071	in	_	
132-33	27072-27075	the	_	
132-34	27076-27080	left	_	
132-35	27081-27084	the	_	
132-36	27085-27089	left	_	
132-37	27090-27105	temporoparietal	_	
132-38	27106-27114	junction	_	
132-39	27115-27124	including	_	
132-40	27125-27128	the	_	
132-41	27129-27136	angular	_	
132-42	27137-27142	gyrus	_	
132-43	27143-27144	(	_	
132-44	27144-27152	Brodmann	_	
132-45	27153-27157	Area	_	
132-46	27158-27160	39	_	
132-47	27160-27161	;	_	
132-48	27162-27168	Volume	_	
132-49	27168-27169	 	_	
132-50	27169-27170	=	_	
132-51	27170-27171	 	_	
132-52	27171-27173	23	_	
132-53	27174-27180	voxels	_	
132-54	27180-27181	/	_	
132-55	27181-27185	1472	_	
132-56	27185-27186	 	_	
132-57	27186-27188	μL	_	
132-58	27188-27189	;	_	
132-59	27190-27194	Peak	_	
132-60	27195-27200	Voxel	_	
132-61	27201-27212	Coordinates	_	
132-62	27212-27213	:	_	
132-63	27213-27214	-	_	
132-64	27214-27216	40	_	
132-65	27216-27217	,	_	
132-66	27217-27218	-	_	
132-67	27218-27223	66,22	_	
132-68	27223-27224	;	_	
132-69	27225-27226	z	_	
132-70	27226-27227	 	_	
132-71	27227-27228	=	_	
132-72	27228-27229	 	_	
132-73	27229-27233	3.49	_	
132-74	27233-27234	,	_	
132-75	27235-27236	p	_	
132-76	27236-27237	 	_	
132-77	27237-27238	=	_	
132-78	27238-27239	 	_	
132-79	27239-27244	.0005	_	
132-80	27244-27245	;	_	
132-81	27246-27249	see	_	
132-82	27250-27253	Fig	_	
132-83	27253-27254	.	_	
132-84	27255-27257	2A	_	
132-85	27257-27258	)	_	
132-86	27258-27259	.	_	

#Text=Specifically, statistically significantly positive P(stop) activations on both Go and Stop trials was observed in abstinent participants, whereas P(stop) activations were weaker and not different from zero in relapsed individuals (see Fig. 2B).
133-1	27260-27272	Specifically	_	
133-2	27272-27273	,	_	
133-3	27274-27287	statistically	_	
133-4	27288-27301	significantly	_	
133-5	27302-27310	positive	_	
133-6	27311-27312	P	_	
133-7	27312-27313	(	_	
133-8	27313-27317	stop	_	
133-9	27317-27318	)	_	
133-10	27319-27330	activations	_	
133-11	27331-27333	on	_	
133-12	27334-27338	both	_	
133-13	27339-27341	Go	_	
133-14	27342-27345	and	_	
133-15	27346-27350	Stop	_	
133-16	27351-27357	trials	_	
133-17	27358-27361	was	_	
133-18	27362-27370	observed	_	
133-19	27371-27373	in	_	
133-20	27374-27383	abstinent	_	
133-21	27384-27396	participants	_	
133-22	27396-27397	,	_	
133-23	27398-27405	whereas	_	
133-24	27406-27407	P	_	
133-25	27407-27408	(	_	
133-26	27408-27412	stop	_	
133-27	27412-27413	)	_	
133-28	27414-27425	activations	_	
133-29	27426-27430	were	_	
133-30	27431-27437	weaker	_	
133-31	27438-27441	and	_	
133-32	27442-27445	not	_	
133-33	27446-27455	different	_	
133-34	27456-27460	from	_	
133-35	27461-27465	zero	_	
133-36	27466-27468	in	_	
133-37	27469-27477	relapsed	_	
133-38	27478-27489	individuals	_	
133-39	27490-27491	(	_	
133-40	27491-27494	see	_	
133-41	27495-27498	Fig	_	
133-42	27498-27499	.	_	
133-43	27500-27502	2B	_	
133-44	27502-27503	)	_	
133-45	27503-27504	.	_	

#Text=Moreover, and consistent with this neural pattern, a group difference in SPE activation was observed based on ROI analyses with the 2nd GLM.
134-1	27505-27513	Moreover	_	
134-2	27513-27514	,	_	
134-3	27515-27518	and	_	
134-4	27519-27529	consistent	_	
134-5	27530-27534	with	_	
134-6	27535-27539	this	_	
134-7	27540-27546	neural	_	
134-8	27547-27554	pattern	_	
134-9	27554-27555	,	_	
134-10	27556-27557	a	_	
134-11	27558-27563	group	_	
134-12	27564-27574	difference	_	
134-13	27575-27577	in	_	
134-14	27578-27581	SPE	_	
134-15	27582-27592	activation	_	
134-16	27593-27596	was	_	
134-17	27597-27605	observed	_	
134-18	27606-27611	based	_	
134-19	27612-27614	on	_	
134-20	27615-27618	ROI	_	
134-21	27619-27627	analyses	_	
134-22	27628-27632	with	_	
134-23	27633-27636	the	_	
134-24	27637-27640	2nd	_	
134-25	27641-27644	GLM	_	
134-26	27644-27645	.	_	

#Text=That is, average %SC to SPE was significantly different from zero in self-reported abstinent (p < .05) but not relapsed individuals (p > .05; Mean Difference Cohen's d = 0.91; see Fig. 2C).
135-1	27646-27650	That	_	
135-2	27651-27653	is	_	
135-3	27653-27654	,	_	
135-4	27655-27662	average	_	
135-5	27663-27664	%	_	
135-6	27664-27666	SC	_	
135-7	27667-27669	to	_	
135-8	27670-27673	SPE	_	
135-9	27674-27677	was	_	
135-10	27678-27691	significantly	_	
135-11	27692-27701	different	_	
135-12	27702-27706	from	_	
135-13	27707-27711	zero	_	
135-14	27712-27714	in	_	
135-15	27715-27728	self-reported	_	
135-16	27729-27738	abstinent	_	
135-17	27739-27740	(	_	
135-18	27740-27741	p	_	
135-19	27741-27742	 	_	
135-20	27742-27743	<	_	
135-21	27743-27744	 	_	
135-22	27744-27747	.05	_	
135-23	27747-27748	)	_	
135-24	27749-27752	but	_	
135-25	27753-27756	not	_	
135-26	27757-27765	relapsed	_	
135-27	27766-27777	individuals	_	
135-28	27778-27779	(	_	
135-29	27779-27780	p	_	
135-30	27780-27781	 	_	
135-31	27781-27782	>	_	
135-32	27782-27783	 	_	
135-33	27783-27786	.05	_	
135-34	27786-27787	;	_	
135-35	27788-27792	Mean	_	
135-36	27793-27803	Difference	_	
135-37	27804-27811	Cohen's	_	
135-38	27812-27813	d	_	
135-39	27813-27814	 	_	
135-40	27814-27815	=	_	
135-41	27815-27816	 	_	
135-42	27816-27820	0.91	_	
135-43	27820-27821	;	_	
135-44	27822-27825	see	_	
135-45	27826-27829	Fig	_	
135-46	27829-27830	.	_	
135-47	27831-27833	2C	_	
135-48	27833-27834	)	_	
135-49	27834-27835	.	_	

#Text=Modulation of P(stop) by action trial type (stop vs go)
#Text=Testing for any significant interaction between clinical status (abstinent vs relapsed) and P(stop) modulated trial type [StopxP(stop) vs GoxP(stop)] across all trials, we found no areas consistent with such neural pattern.
136-1	27836-27846	Modulation	_	
136-2	27847-27849	of	_	
136-3	27850-27851	P	_	
136-4	27851-27852	(	_	
136-5	27852-27856	stop	_	
136-6	27856-27857	)	_	
136-7	27858-27860	by	_	
136-8	27861-27867	action	_	
136-9	27868-27873	trial	_	
136-10	27874-27878	type	_	
136-11	27879-27880	(	_	
136-12	27880-27884	stop	_	
136-13	27885-27887	vs	_	
136-14	27888-27890	go	_	
136-15	27890-27891	)	_	
136-16	27892-27899	Testing	_	
136-17	27900-27903	for	_	
136-18	27904-27907	any	_	
136-19	27908-27919	significant	_	
136-20	27920-27931	interaction	_	
136-21	27932-27939	between	_	
136-22	27940-27948	clinical	_	
136-23	27949-27955	status	_	
136-24	27956-27957	(	_	
136-25	27957-27966	abstinent	_	
136-26	27967-27969	vs	_	
136-27	27970-27978	relapsed	_	
136-28	27978-27979	)	_	
136-29	27980-27983	and	_	
136-30	27984-27985	P	_	
136-31	27985-27986	(	_	
136-32	27986-27990	stop	_	
136-33	27990-27991	)	_	
136-34	27992-28001	modulated	_	
136-35	28002-28007	trial	_	
136-36	28008-28012	type	_	
136-37	28013-28014	[	_	
136-38	28014-28020	StopxP	_	
136-39	28020-28021	(	_	
136-40	28021-28025	stop	_	
136-41	28025-28026	)	_	
136-42	28027-28029	vs	_	
136-43	28030-28034	GoxP	_	
136-44	28034-28035	(	_	
136-45	28035-28039	stop	_	
136-46	28039-28040	)	_	
136-47	28040-28041	]	_	
136-48	28042-28048	across	_	
136-49	28049-28052	all	_	
136-50	28053-28059	trials	_	
136-51	28059-28060	,	_	
136-52	28061-28063	we	_	
136-53	28064-28069	found	_	
136-54	28070-28072	no	_	
136-55	28073-28078	areas	_	
136-56	28079-28089	consistent	_	
136-57	28090-28094	with	_	
136-58	28095-28099	such	_	
136-59	28100-28106	neural	_	
136-60	28107-28114	pattern	_	
136-61	28114-28115	.	_	

#Text=Modulation of P(stop) by stop trial accuracy (SS vs SE)
#Text=Group difference in the modulation of neural activation correlated with P(stop) by inhibitory success.
137-1	28116-28126	Modulation	_	
137-2	28127-28129	of	_	
137-3	28130-28131	P	_	
137-4	28131-28132	(	_	
137-5	28132-28136	stop	_	
137-6	28136-28137	)	_	
137-7	28138-28140	by	_	
137-8	28141-28145	stop	_	
137-9	28146-28151	trial	_	
137-10	28152-28160	accuracy	_	
137-11	28161-28162	(	_	
137-12	28162-28164	SS	_	
137-13	28165-28167	vs	_	
137-14	28168-28170	SE	_	
137-15	28170-28171	)	_	
137-16	28172-28177	Group	_	
137-17	28178-28188	difference	_	
137-18	28189-28191	in	_	
137-19	28192-28195	the	_	
137-20	28196-28206	modulation	_	
137-21	28207-28209	of	_	
137-22	28210-28216	neural	_	
137-23	28217-28227	activation	_	
137-24	28228-28238	correlated	_	
137-25	28239-28243	with	_	
137-26	28244-28245	P	_	
137-27	28245-28246	(	_	
137-28	28246-28250	stop	_	
137-29	28250-28251	)	_	
137-30	28252-28254	by	_	
137-31	28255-28265	inhibitory	_	
137-32	28266-28273	success	_	
137-33	28273-28274	.	_	

#Text=A.
138-1	28275-28276	A	_	
138-2	28276-28277	.	_	

#Text=BOLD signal regions representing a significant interaction between group and P(stop)-modulated activation for Stop Success (SS) versus Stop Error (SE) in the left Inferior Frontal Gyrus (IFG).
139-1	28278-28282	BOLD	_	
139-2	28283-28289	signal	_	
139-3	28290-28297	regions	_	
139-4	28298-28310	representing	_	
139-5	28311-28312	a	_	
139-6	28313-28324	significant	_	
139-7	28325-28336	interaction	_	
139-8	28337-28344	between	_	
139-9	28345-28350	group	_	
139-10	28351-28354	and	_	
139-11	28355-28356	P	_	
139-12	28356-28357	(	_	
139-13	28357-28361	stop	_	
139-14	28361-28362	)	_	
139-15	28362-28363	-	_	
139-16	28363-28372	modulated	_	
139-17	28373-28383	activation	_	
139-18	28384-28387	for	_	
139-19	28388-28392	Stop	_	
139-20	28393-28400	Success	_	
139-21	28401-28402	(	_	
139-22	28402-28404	SS	_	
139-23	28404-28405	)	_	
139-24	28406-28412	versus	_	
139-25	28413-28417	Stop	_	
139-26	28418-28423	Error	_	
139-27	28424-28425	(	_	
139-28	28425-28427	SE	_	
139-29	28427-28428	)	_	
139-30	28429-28431	in	_	
139-31	28432-28435	the	_	
139-32	28436-28440	left	_	
139-33	28441-28449	Inferior	_	
139-34	28450-28457	Frontal	_	
139-35	28458-28463	Gyrus	_	
139-36	28464-28465	(	_	
139-37	28465-28468	IFG	_	
139-38	28468-28469	)	_	
139-39	28469-28470	.	_	

#Text=B.
140-1	28471-28472	B	_	
140-2	28472-28473	.	_	

#Text=Bar graphs represent average percent signal change for parametric regressors SE × P(stop, and SS × P(stop) in Abstinent (n = 39) and Relapsed individuals (n = 19).
141-1	28474-28477	Bar	_	
141-2	28478-28484	graphs	_	
141-3	28485-28494	represent	_	
141-4	28495-28502	average	_	
141-5	28503-28510	percent	_	
141-6	28511-28517	signal	_	
141-7	28518-28524	change	_	
141-8	28525-28528	for	_	
141-9	28529-28539	parametric	_	
141-10	28540-28550	regressors	_	
141-11	28551-28553	SE	_	
141-12	28553-28554	 	_	
141-13	28554-28555	×	_	
141-14	28555-28556	 	_	
141-15	28556-28557	P	_	
141-16	28557-28558	(	_	
141-17	28558-28562	stop	_	
141-18	28562-28563	,	_	
141-19	28564-28567	and	_	
141-20	28568-28570	SS	_	
141-21	28570-28571	 	_	
141-22	28571-28572	×	_	
141-23	28572-28573	 	_	
141-24	28573-28574	P	_	
141-25	28574-28575	(	_	
141-26	28575-28579	stop	_	
141-27	28579-28580	)	_	
141-28	28581-28583	in	_	
141-29	28584-28593	Abstinent	_	
141-30	28594-28595	(	_	
141-31	28595-28596	n	_	
141-32	28596-28597	 	_	
141-33	28597-28598	=	_	
141-34	28598-28599	 	_	
141-35	28599-28601	39	_	
141-36	28601-28602	)	_	
141-37	28603-28606	and	_	
141-38	28607-28615	Relapsed	_	
141-39	28616-28627	individuals	_	
141-40	28628-28629	(	_	
141-41	28629-28630	n	_	
141-42	28630-28631	 	_	
141-43	28631-28632	=	_	
141-44	28632-28633	 	_	
141-45	28633-28635	19	_	
141-46	28635-28636	)	_	
141-47	28636-28637	.	_	

#Text=Percent signal change in the abstinent group (grey bars) was positively correlated with P(stop) on successful stop (SS) trials and not on stop error (SE) trials, whereas relapsed participants (red striped bars) show a positive P(stop)-modulated activation on stop error SE but not SS trials.
142-1	28638-28645	Percent	_	
142-2	28646-28652	signal	_	
142-3	28653-28659	change	_	
142-4	28660-28662	in	_	
142-5	28663-28666	the	_	
142-6	28667-28676	abstinent	_	
142-7	28677-28682	group	_	
142-8	28683-28684	(	_	
142-9	28684-28688	grey	_	
142-10	28689-28693	bars	_	
142-11	28693-28694	)	_	
142-12	28695-28698	was	_	
142-13	28699-28709	positively	_	
142-14	28710-28720	correlated	_	
142-15	28721-28725	with	_	
142-16	28726-28727	P	_	
142-17	28727-28728	(	_	
142-18	28728-28732	stop	_	
142-19	28732-28733	)	_	
142-20	28734-28736	on	_	
142-21	28737-28747	successful	_	
142-22	28748-28752	stop	_	
142-23	28753-28754	(	_	
142-24	28754-28756	SS	_	
142-25	28756-28757	)	_	
142-26	28758-28764	trials	_	
142-27	28765-28768	and	_	
142-28	28769-28772	not	_	
142-29	28773-28775	on	_	
142-30	28776-28780	stop	_	
142-31	28781-28786	error	_	
142-32	28787-28788	(	_	
142-33	28788-28790	SE	_	
142-34	28790-28791	)	_	
142-35	28792-28798	trials	_	
142-36	28798-28799	,	_	
142-37	28800-28807	whereas	_	
142-38	28808-28816	relapsed	_	
142-39	28817-28829	participants	_	
142-40	28830-28831	(	_	
142-41	28831-28834	red	_	
142-42	28835-28842	striped	_	
142-43	28843-28847	bars	_	
142-44	28847-28848	)	_	
142-45	28849-28853	show	_	
142-46	28854-28855	a	_	
142-47	28856-28864	positive	_	
142-48	28865-28866	P	_	
142-49	28866-28867	(	_	
142-50	28867-28871	stop	_	
142-51	28871-28872	)	_	
142-52	28872-28873	-	_	
142-53	28873-28882	modulated	_	
142-54	28883-28893	activation	_	
142-55	28894-28896	on	_	
142-56	28897-28901	stop	_	
142-57	28902-28907	error	_	
142-58	28908-28910	SE	_	
142-59	28911-28914	but	_	
142-60	28915-28918	not	_	
142-61	28919-28921	SS	_	
142-62	28922-28928	trials	_	
142-63	28928-28929	.	_	

#Text=C.
143-1	28930-28931	C	_	
143-2	28931-28932	.	_	

#Text=Consistent with this pattern of activation, in this region, percent signal change was selectively anti-correlated with a Bayesian UPE (i.e., |outcome-P(stop)|) on SS but not on SE trials in abstinent participants (grey bars).
144-1	28933-28943	Consistent	_	
144-2	28944-28948	with	_	
144-3	28949-28953	this	_	
144-4	28954-28961	pattern	_	
144-5	28962-28964	of	_	
144-6	28965-28975	activation	_	
144-7	28975-28976	,	_	
144-8	28977-28979	in	_	
144-9	28980-28984	this	_	
144-10	28985-28991	region	_	
144-11	28991-28992	,	_	
144-12	28993-29000	percent	_	
144-13	29001-29007	signal	_	
144-14	29008-29014	change	_	
144-15	29015-29018	was	_	
144-16	29019-29030	selectively	_	
144-17	29031-29046	anti-correlated	_	
144-18	29047-29051	with	_	
144-19	29052-29053	a	_	
144-20	29054-29062	Bayesian	_	
144-21	29063-29066	UPE	_	
144-22	29067-29068	(	_	
144-23	29068-29071	i.e	_	
144-24	29071-29072	.	_	
144-25	29072-29073	,	_	
144-26	29074-29075	|	_	
144-27	29075-29084	outcome-P	_	
144-28	29084-29085	(	_	
144-29	29085-29089	stop	_	
144-30	29089-29090	)	_	
144-31	29090-29091	|	_	
144-32	29091-29092	)	_	
144-33	29093-29095	on	_	
144-34	29096-29098	SS	_	
144-35	29099-29102	but	_	
144-36	29103-29106	not	_	
144-37	29107-29109	on	_	
144-38	29110-29112	SE	_	
144-39	29113-29119	trials	_	
144-40	29120-29122	in	_	
144-41	29123-29132	abstinent	_	
144-42	29133-29145	participants	_	
144-43	29146-29147	(	_	
144-44	29147-29151	grey	_	
144-45	29152-29156	bars	_	
144-46	29156-29157	)	_	
144-47	29157-29158	.	_	

#Text=In contrast, a significant UPE-dependent deactivation was observed in relapsed participants on SE trials only; error bars indicate ±1 SEM.
145-1	29159-29161	In	_	
145-2	29162-29170	contrast	_	
145-3	29170-29171	,	_	
145-4	29172-29173	a	_	
145-5	29174-29185	significant	_	
145-6	29186-29199	UPE-dependent	_	
145-7	29200-29212	deactivation	_	
145-8	29213-29216	was	_	
145-9	29217-29225	observed	_	
145-10	29226-29228	in	_	
145-11	29229-29237	relapsed	_	
145-12	29238-29250	participants	_	
145-13	29251-29253	on	_	
145-14	29254-29256	SE	_	
145-15	29257-29263	trials	_	
145-16	29264-29268	only	_	
145-17	29268-29269	;	_	
145-18	29270-29275	error	_	
145-19	29276-29280	bars	_	
145-20	29281-29289	indicate	_	
145-21	29290-29291	±	_	
145-22	29291-29292	1	_	
145-23	29293-29296	SEM	_	
145-24	29296-29297	.	_	

#Text=D.
146-1	29298-29299	D	_	
146-2	29299-29300	.	_	

#Text=BOLD signal regions representing a significant interaction between group and P(stop)-modulated activation for Stop Success (SS) versus Stop Error (SE) in the left Anterior Insula.
147-1	29301-29305	BOLD	_	
147-2	29306-29312	signal	_	
147-3	29313-29320	regions	_	
147-4	29321-29333	representing	_	
147-5	29334-29335	a	_	
147-6	29336-29347	significant	_	
147-7	29348-29359	interaction	_	
147-8	29360-29367	between	_	
147-9	29368-29373	group	_	
147-10	29374-29377	and	_	
147-11	29378-29379	P	_	
147-12	29379-29380	(	_	
147-13	29380-29384	stop	_	
147-14	29384-29385	)	_	
147-15	29385-29386	-	_	
147-16	29386-29395	modulated	_	
147-17	29396-29406	activation	_	
147-18	29407-29410	for	_	
147-19	29411-29415	Stop	_	
147-20	29416-29423	Success	_	
147-21	29424-29425	(	_	
147-22	29425-29427	SS	_	
147-23	29427-29428	)	_	
147-24	29429-29435	versus	_	
147-25	29436-29440	Stop	_	
147-26	29441-29446	Error	_	
147-27	29447-29448	(	_	
147-28	29448-29450	SE	_	
147-29	29450-29451	)	_	
147-30	29452-29454	in	_	
147-31	29455-29458	the	_	
147-32	29459-29463	left	_	
147-33	29464-29472	Anterior	_	
147-34	29473-29479	Insula	_	
147-35	29479-29480	.	_	

#Text=E.
148-1	29481-29482	E	_	
148-2	29482-29483	.	_	

#Text=Bar graphs represent average percent signal change for parametric regressors SE × P(stop, and SS × P(stop)) in Abstinent (n = 39) and Relapsed individuals (n = 19).
149-1	29484-29487	Bar	_	
149-2	29488-29494	graphs	_	
149-3	29495-29504	represent	_	
149-4	29505-29512	average	_	
149-5	29513-29520	percent	_	
149-6	29521-29527	signal	_	
149-7	29528-29534	change	_	
149-8	29535-29538	for	_	
149-9	29539-29549	parametric	_	
149-10	29550-29560	regressors	_	
149-11	29561-29563	SE	_	
149-12	29563-29564	 	_	
149-13	29564-29565	×	_	
149-14	29565-29566	 	_	
149-15	29566-29567	P	_	
149-16	29567-29568	(	_	
149-17	29568-29572	stop	_	
149-18	29572-29573	,	_	
149-19	29574-29577	and	_	
149-20	29578-29580	SS	_	
149-21	29580-29581	 	_	
149-22	29581-29582	×	_	
149-23	29582-29583	 	_	
149-24	29583-29584	P	_	
149-25	29584-29585	(	_	
149-26	29585-29589	stop	_	
149-27	29589-29590	)	_	
149-28	29590-29591	)	_	
149-29	29592-29594	in	_	
149-30	29595-29604	Abstinent	_	
149-31	29605-29606	(	_	
149-32	29606-29607	n	_	
149-33	29607-29608	 	_	
149-34	29608-29609	=	_	
149-35	29609-29610	 	_	
149-36	29610-29612	39	_	
149-37	29612-29613	)	_	
149-38	29614-29617	and	_	
149-39	29618-29626	Relapsed	_	
149-40	29627-29638	individuals	_	
149-41	29639-29640	(	_	
149-42	29640-29641	n	_	
149-43	29641-29642	 	_	
149-44	29642-29643	=	_	
149-45	29643-29644	 	_	
149-46	29644-29646	19	_	
149-47	29646-29647	)	_	
149-48	29647-29648	.	_	

#Text=Percent signal change in the abstinent group (grey bars) was positively correlated with P(stop) on SS but not SE trials, whereas relapsed participants (red striped bars) show a positive P(stop)-modulated activation on SE but not SS trials.
150-1	29649-29656	Percent	_	
150-2	29657-29663	signal	_	
150-3	29664-29670	change	_	
150-4	29671-29673	in	_	
150-5	29674-29677	the	_	
150-6	29678-29687	abstinent	_	
150-7	29688-29693	group	_	
150-8	29694-29695	(	_	
150-9	29695-29699	grey	_	
150-10	29700-29704	bars	_	
150-11	29704-29705	)	_	
150-12	29706-29709	was	_	
150-13	29710-29720	positively	_	
150-14	29721-29731	correlated	_	
150-15	29732-29736	with	_	
150-16	29737-29738	P	_	
150-17	29738-29739	(	_	
150-18	29739-29743	stop	_	
150-19	29743-29744	)	_	
150-20	29745-29747	on	_	
150-21	29748-29750	SS	_	
150-22	29751-29754	but	_	
150-23	29755-29758	not	_	
150-24	29759-29761	SE	_	
150-25	29762-29768	trials	_	
150-26	29768-29769	,	_	
150-27	29770-29777	whereas	_	
150-28	29778-29786	relapsed	_	
150-29	29787-29799	participants	_	
150-30	29800-29801	(	_	
150-31	29801-29804	red	_	
150-32	29805-29812	striped	_	
150-33	29813-29817	bars	_	
150-34	29817-29818	)	_	
150-35	29819-29823	show	_	
150-36	29824-29825	a	_	
150-37	29826-29834	positive	_	
150-38	29835-29836	P	_	
150-39	29836-29837	(	_	
150-40	29837-29841	stop	_	
150-41	29841-29842	)	_	
150-42	29842-29843	-	_	
150-43	29843-29852	modulated	_	
150-44	29853-29863	activation	_	
150-45	29864-29866	on	_	
150-46	29867-29869	SE	_	
150-47	29870-29873	but	_	
150-48	29874-29877	not	_	
150-49	29878-29880	SS	_	
150-50	29881-29887	trials	_	
150-51	29887-29888	.	_	

#Text=F.
151-1	29889-29890	F	_	
151-2	29890-29891	.	_	

#Text=Consistent with this pattern of activation, in this region, percent signal change was selectively negatively correlated with a Bayesian UPE (i.e., |outcome-P(stop)|) on SS but not on SE trials in abstinent participants (grey bars).
152-1	29892-29902	Consistent	_	
152-2	29903-29907	with	_	
152-3	29908-29912	this	_	
152-4	29913-29920	pattern	_	
152-5	29921-29923	of	_	
152-6	29924-29934	activation	_	
152-7	29934-29935	,	_	
152-8	29936-29938	in	_	
152-9	29939-29943	this	_	
152-10	29944-29950	region	_	
152-11	29950-29951	,	_	
152-12	29952-29959	percent	_	
152-13	29960-29966	signal	_	
152-14	29967-29973	change	_	
152-15	29974-29977	was	_	
152-16	29978-29989	selectively	_	
152-17	29990-30000	negatively	_	
152-18	30001-30011	correlated	_	
152-19	30012-30016	with	_	
152-20	30017-30018	a	_	
152-21	30019-30027	Bayesian	_	
152-22	30028-30031	UPE	_	
152-23	30032-30033	(	_	
152-24	30033-30036	i.e	_	
152-25	30036-30037	.	_	
152-26	30037-30038	,	_	
152-27	30039-30040	|	_	
152-28	30040-30049	outcome-P	_	
152-29	30049-30050	(	_	
152-30	30050-30054	stop	_	
152-31	30054-30055	)	_	
152-32	30055-30056	|	_	
152-33	30056-30057	)	_	
152-34	30058-30060	on	_	
152-35	30061-30063	SS	_	
152-36	30064-30067	but	_	
152-37	30068-30071	not	_	
152-38	30072-30074	on	_	
152-39	30075-30077	SE	_	
152-40	30078-30084	trials	_	
152-41	30085-30087	in	_	
152-42	30088-30097	abstinent	_	
152-43	30098-30110	participants	_	
152-44	30111-30112	(	_	
152-45	30112-30116	grey	_	
152-46	30117-30121	bars	_	
152-47	30121-30122	)	_	
152-48	30122-30123	.	_	

#Text=In contrast, a significant UPE-dependent deactivation was observed in relapsed participants on SE but not SS trials; error bars indicate ±1 SEM.
153-1	30124-30126	In	_	
153-2	30127-30135	contrast	_	
153-3	30135-30136	,	_	
153-4	30137-30138	a	_	
153-5	30139-30150	significant	_	
153-6	30151-30164	UPE-dependent	_	
153-7	30165-30177	deactivation	_	
153-8	30178-30181	was	_	
153-9	30182-30190	observed	_	
153-10	30191-30193	in	_	
153-11	30194-30202	relapsed	_	
153-12	30203-30215	participants	_	
153-13	30216-30218	on	_	
153-14	30219-30221	SE	_	
153-15	30222-30225	but	_	
153-16	30226-30229	not	_	
153-17	30230-30232	SS	_	
153-18	30233-30239	trials	_	
153-19	30239-30240	;	_	
153-20	30241-30246	error	_	
153-21	30247-30251	bars	_	
153-22	30252-30260	indicate	_	
153-23	30261-30262	±	_	
153-24	30262-30263	1	_	
153-25	30264-30267	SEM	_	
153-26	30267-30268	.	_	

#Text=Fig. 3
#Text=Activation in two neural regions were associated with a significant interaction between clinical status and P(stop) modulated stop accuracy (SS vs SE trials).
154-1	30269-30272	Fig	_	
154-2	30272-30273	.	_	
154-3	30274-30275	3	_	
154-4	30276-30286	Activation	_	
154-5	30287-30289	in	_	
154-6	30290-30293	two	_	
154-7	30294-30300	neural	_	
154-8	30301-30308	regions	_	
154-9	30309-30313	were	_	
154-10	30314-30324	associated	_	
154-11	30325-30329	with	_	
154-12	30330-30331	a	_	
154-13	30332-30343	significant	_	
154-14	30344-30355	interaction	_	
154-15	30356-30363	between	_	
154-16	30364-30372	clinical	_	
154-17	30373-30379	status	_	
154-18	30380-30383	and	_	
154-19	30384-30385	P	_	
154-20	30385-30386	(	_	
154-21	30386-30390	stop	_	
154-22	30390-30391	)	_	
154-23	30392-30401	modulated	_	
154-24	30402-30406	stop	_	
154-25	30407-30415	accuracy	_	
154-26	30416-30417	(	_	
154-27	30417-30419	SS	_	
154-28	30420-30422	vs	_	
154-29	30423-30425	SE	_	
154-30	30426-30432	trials	_	
154-31	30432-30433	)	_	
154-32	30433-30434	.	_	

#Text=In a first region, identified in the left IFG (Brodmann Area 45; Volume = 15 voxels/960 μL; Peak Voxel Coordinates: −44,21,23; z = 3.19, p = .0001; see Fig. 3A), abstinent participants exhibited a significant positive activation to P(stop) on successful stop (SS) trials (p < .05), but no significant activation or deactivation with P(stop) on stop error (SE) trials (p > .05).
155-1	30435-30437	In	_	
155-2	30438-30439	a	_	
155-3	30440-30445	first	_	
155-4	30446-30452	region	_	
155-5	30452-30453	,	_	
155-6	30454-30464	identified	_	
155-7	30465-30467	in	_	
155-8	30468-30471	the	_	
155-9	30472-30476	left	_	
155-10	30477-30480	IFG	_	
155-11	30481-30482	(	_	
155-12	30482-30490	Brodmann	_	
155-13	30491-30495	Area	_	
155-14	30496-30498	45	_	
155-15	30498-30499	;	_	
155-16	30500-30506	Volume	_	
155-17	30506-30507	 	_	
155-18	30507-30508	=	_	
155-19	30508-30509	 	_	
155-20	30509-30511	15	_	
155-21	30512-30518	voxels	_	
155-22	30518-30519	/	_	
155-23	30519-30522	960	_	
155-24	30522-30523	 	_	
155-25	30523-30525	μL	_	
155-26	30525-30526	;	_	
155-27	30527-30531	Peak	_	
155-28	30532-30537	Voxel	_	
155-29	30538-30549	Coordinates	_	
155-30	30549-30550	:	_	
155-31	30551-30552	−	_	
155-32	30552-30560	44,21,23	_	
155-33	30560-30561	;	_	
155-34	30562-30563	z	_	
155-35	30563-30564	 	_	
155-36	30564-30565	=	_	
155-37	30565-30566	 	_	
155-38	30566-30570	3.19	_	
155-39	30570-30571	,	_	
155-40	30572-30573	p	_	
155-41	30573-30574	 	_	
155-42	30574-30575	=	_	
155-43	30575-30576	 	_	
155-44	30576-30581	.0001	_	
155-45	30581-30582	;	_	
155-46	30583-30586	see	_	
155-47	30587-30590	Fig	_	
155-48	30590-30591	.	_	
155-49	30592-30594	3A	_	
155-50	30594-30595	)	_	
155-51	30595-30596	,	_	
155-52	30597-30606	abstinent	_	
155-53	30607-30619	participants	_	
155-54	30620-30629	exhibited	_	
155-55	30630-30631	a	_	
155-56	30632-30643	significant	_	
155-57	30644-30652	positive	_	
155-58	30653-30663	activation	_	
155-59	30664-30666	to	_	
155-60	30667-30668	P	_	
155-61	30668-30669	(	_	
155-62	30669-30673	stop	_	
155-63	30673-30674	)	_	
155-64	30675-30677	on	_	
155-65	30678-30688	successful	_	
155-66	30689-30693	stop	_	
155-67	30694-30695	(	_	
155-68	30695-30697	SS	_	
155-69	30697-30698	)	_	
155-70	30699-30705	trials	_	
155-71	30706-30707	(	_	
155-72	30707-30708	p	_	
155-73	30708-30709	 	_	
155-74	30709-30710	<	_	
155-75	30710-30711	 	_	
155-76	30711-30714	.05	_	
155-77	30714-30715	)	_	
155-78	30715-30716	,	_	
155-79	30717-30720	but	_	
155-80	30721-30723	no	_	
155-81	30724-30735	significant	_	
155-82	30736-30746	activation	_	
155-83	30747-30749	or	_	
155-84	30750-30762	deactivation	_	
155-85	30763-30767	with	_	
155-86	30768-30769	P	_	
155-87	30769-30770	(	_	
155-88	30770-30774	stop	_	
155-89	30774-30775	)	_	
155-90	30776-30778	on	_	
155-91	30779-30783	stop	_	
155-92	30784-30789	error	_	
155-93	30790-30791	(	_	
155-94	30791-30793	SE	_	
155-95	30793-30794	)	_	
155-96	30795-30801	trials	_	
155-97	30802-30803	(	_	
155-98	30803-30804	p	_	
155-99	30804-30805	 	_	
155-100	30805-30806	>	_	
155-101	30806-30807	 	_	
155-102	30807-30810	.05	_	
155-103	30810-30811	)	_	
155-104	30811-30812	.	_	

#Text=In contrast, relapsed individuals showed a significant positive activation to P(stop) on SE trials (p < .05) but not P(stop) activation was observed on SS trials (p > .05; see Fig. 3B).
156-1	30813-30815	In	_	
156-2	30816-30824	contrast	_	
156-3	30824-30825	,	_	
156-4	30826-30834	relapsed	_	
156-5	30835-30846	individuals	_	
156-6	30847-30853	showed	_	
156-7	30854-30855	a	_	
156-8	30856-30867	significant	_	
156-9	30868-30876	positive	_	
156-10	30877-30887	activation	_	
156-11	30888-30890	to	_	
156-12	30891-30892	P	_	
156-13	30892-30893	(	_	
156-14	30893-30897	stop	_	
156-15	30897-30898	)	_	
156-16	30899-30901	on	_	
156-17	30902-30904	SE	_	
156-18	30905-30911	trials	_	
156-19	30912-30913	(	_	
156-20	30913-30914	p	_	
156-21	30914-30915	 	_	
156-22	30915-30916	<	_	
156-23	30916-30917	 	_	
156-24	30917-30920	.05	_	
156-25	30920-30921	)	_	
156-26	30922-30925	but	_	
156-27	30926-30929	not	_	
156-28	30930-30931	P	_	
156-29	30931-30932	(	_	
156-30	30932-30936	stop	_	
156-31	30936-30937	)	_	
156-32	30938-30948	activation	_	
156-33	30949-30952	was	_	
156-34	30953-30961	observed	_	
156-35	30962-30964	on	_	
156-36	30965-30967	SS	_	
156-37	30968-30974	trials	_	
156-38	30975-30976	(	_	
156-39	30976-30977	p	_	
156-40	30977-30978	 	_	
156-41	30978-30979	>	_	
156-42	30979-30980	 	_	
156-43	30980-30983	.05	_	
156-44	30983-30984	;	_	
156-45	30985-30988	see	_	
156-46	30989-30992	Fig	_	
156-47	30992-30993	.	_	
156-48	30994-30996	3B	_	
156-49	30996-30997	)	_	
156-50	30997-30998	.	_	

#Text=Importantly, consistent with the positive activation to P(stop) on stop trials, this was reflected by percent signal change to a Bayesian UPE.
157-1	30999-31010	Importantly	_	
157-2	31010-31011	,	_	
157-3	31012-31022	consistent	_	
157-4	31023-31027	with	_	
157-5	31028-31031	the	_	
157-6	31032-31040	positive	_	
157-7	31041-31051	activation	_	
157-8	31052-31054	to	_	
157-9	31055-31056	P	_	
157-10	31056-31057	(	_	
157-11	31057-31061	stop	_	
157-12	31061-31062	)	_	
157-13	31063-31065	on	_	
157-14	31066-31070	stop	_	
157-15	31071-31077	trials	_	
157-16	31077-31078	,	_	
157-17	31079-31083	this	_	
157-18	31084-31087	was	_	
157-19	31088-31097	reflected	_	
157-20	31098-31100	by	_	
157-21	31101-31108	percent	_	
157-22	31109-31115	signal	_	
157-23	31116-31122	change	_	
157-24	31123-31125	to	_	
157-25	31126-31127	a	_	
157-26	31128-31136	Bayesian	_	
157-27	31137-31140	UPE	_	
157-28	31140-31141	.	_	

#Text=Specifically, on successful stop trials (SS), abstinent individuals showed a significant deactivation to UPE (p < .05), which was not significantly difference from zero in relapsed individuals (p > .05; Group Difference Cohen's d = 0.57, p = .03).
158-1	31142-31154	Specifically	_	
158-2	31154-31155	,	_	
158-3	31156-31158	on	_	
158-4	31159-31169	successful	_	
158-5	31170-31174	stop	_	
158-6	31175-31181	trials	_	
158-7	31182-31183	(	_	
158-8	31183-31185	SS	_	
158-9	31185-31186	)	_	
158-10	31186-31187	,	_	
158-11	31188-31197	abstinent	_	
158-12	31198-31209	individuals	_	
158-13	31210-31216	showed	_	
158-14	31217-31218	a	_	
158-15	31219-31230	significant	_	
158-16	31231-31243	deactivation	_	
158-17	31244-31246	to	_	
158-18	31247-31250	UPE	_	
158-19	31251-31252	(	_	
158-20	31252-31253	p	_	
158-21	31253-31254	 	_	
158-22	31254-31255	<	_	
158-23	31255-31256	 	_	
158-24	31256-31259	.05	_	
158-25	31259-31260	)	_	
158-26	31260-31261	,	_	
158-27	31262-31267	which	_	
158-28	31268-31271	was	_	
158-29	31272-31275	not	_	
158-30	31276-31289	significantly	_	
158-31	31290-31300	difference	_	
158-32	31301-31305	from	_	
158-33	31306-31310	zero	_	
158-34	31311-31313	in	_	
158-35	31314-31322	relapsed	_	
158-36	31323-31334	individuals	_	
158-37	31335-31336	(	_	
158-38	31336-31337	p	_	
158-39	31337-31338	 	_	
158-40	31338-31339	>	_	
158-41	31339-31340	 	_	
158-42	31340-31343	.05	_	
158-43	31343-31344	;	_	
158-44	31345-31350	Group	_	
158-45	31351-31361	Difference	_	
158-46	31362-31369	Cohen's	_	
158-47	31370-31371	d	_	
158-48	31371-31372	 	_	
158-49	31372-31373	=	_	
158-50	31373-31374	 	_	
158-51	31374-31378	0.57	_	
158-52	31378-31379	,	_	
158-53	31380-31381	p	_	
158-54	31381-31382	 	_	
158-55	31382-31383	=	_	
158-56	31383-31384	 	_	
158-57	31384-31387	.03	_	
158-58	31387-31388	)	_	
158-59	31388-31389	.	_	

#Text=In contrast, on SE trials, the opposite pattern was seen in that the relapsed group showed a significant deactivation to UPE (p < .05), which was not significant in abstinent individuals (p > .05; Group Difference Cohen's d = 0.72, p = .02; see Fig. 3C).
159-1	31390-31392	In	_	
159-2	31393-31401	contrast	_	
159-3	31401-31402	,	_	
159-4	31403-31405	on	_	
159-5	31406-31408	SE	_	
159-6	31409-31415	trials	_	
159-7	31415-31416	,	_	
159-8	31417-31420	the	_	
159-9	31421-31429	opposite	_	
159-10	31430-31437	pattern	_	
159-11	31438-31441	was	_	
159-12	31442-31446	seen	_	
159-13	31447-31449	in	_	
159-14	31450-31454	that	_	
159-15	31455-31458	the	_	
159-16	31459-31467	relapsed	_	
159-17	31468-31473	group	_	
159-18	31474-31480	showed	_	
159-19	31481-31482	a	_	
159-20	31483-31494	significant	_	
159-21	31495-31507	deactivation	_	
159-22	31508-31510	to	_	
159-23	31511-31514	UPE	_	
159-24	31515-31516	(	_	
159-25	31516-31517	p	_	
159-26	31517-31518	 	_	
159-27	31518-31519	<	_	
159-28	31519-31520	 	_	
159-29	31520-31523	.05	_	
159-30	31523-31524	)	_	
159-31	31524-31525	,	_	
159-32	31526-31531	which	_	
159-33	31532-31535	was	_	
159-34	31536-31539	not	_	
159-35	31540-31551	significant	_	
159-36	31552-31554	in	_	
159-37	31555-31564	abstinent	_	
159-38	31565-31576	individuals	_	
159-39	31577-31578	(	_	
159-40	31578-31579	p	_	
159-41	31579-31580	 	_	
159-42	31580-31581	>	_	
159-43	31581-31582	 	_	
159-44	31582-31585	.05	_	
159-45	31585-31586	;	_	
159-46	31587-31592	Group	_	
159-47	31593-31603	Difference	_	
159-48	31604-31611	Cohen's	_	
159-49	31612-31613	d	_	
159-50	31613-31614	 	_	
159-51	31614-31615	=	_	
159-52	31615-31616	 	_	
159-53	31616-31620	0.72	_	
159-54	31620-31621	,	_	
159-55	31622-31623	p	_	
159-56	31623-31624	 	_	
159-57	31624-31625	=	_	
159-58	31625-31626	 	_	
159-59	31626-31629	.02	_	
159-60	31629-31630	;	_	
159-61	31631-31634	see	_	
159-62	31635-31638	Fig	_	
159-63	31638-31639	.	_	
159-64	31640-31642	3C	_	
159-65	31642-31643	)	_	
159-66	31643-31644	.	_	

#Text=In the second region, identified in the left anterior insula (Brodmann Area 13; Volume = 15 voxels/960 μL; Peak Voxel Coordinates: −28,28,4; z = 3.70, p = .0002; see Fig. 3D), a similar pattern was observed.
160-1	31645-31647	In	_	
160-2	31648-31651	the	_	
160-3	31652-31658	second	_	
160-4	31659-31665	region	_	
160-5	31665-31666	,	_	
160-6	31667-31677	identified	_	
160-7	31678-31680	in	_	
160-8	31681-31684	the	_	
160-9	31685-31689	left	_	
160-10	31690-31698	anterior	_	
160-11	31699-31705	insula	_	
160-12	31706-31707	(	_	
160-13	31707-31715	Brodmann	_	
160-14	31716-31720	Area	_	
160-15	31721-31723	13	_	
160-16	31723-31724	;	_	
160-17	31725-31731	Volume	_	
160-18	31731-31732	 	_	
160-19	31732-31733	=	_	
160-20	31733-31734	 	_	
160-21	31734-31736	15	_	
160-22	31737-31743	voxels	_	
160-23	31743-31744	/	_	
160-24	31744-31747	960	_	
160-25	31747-31748	 	_	
160-26	31748-31750	μL	_	
160-27	31750-31751	;	_	
160-28	31752-31756	Peak	_	
160-29	31757-31762	Voxel	_	
160-30	31763-31774	Coordinates	_	
160-31	31774-31775	:	_	
160-32	31776-31777	−	_	
160-33	31777-31784	28,28,4	_	
160-34	31784-31785	;	_	
160-35	31786-31787	z	_	
160-36	31787-31788	 	_	
160-37	31788-31789	=	_	
160-38	31789-31790	 	_	
160-39	31790-31794	3.70	_	
160-40	31794-31795	,	_	
160-41	31796-31797	p	_	
160-42	31797-31798	 	_	
160-43	31798-31799	=	_	
160-44	31799-31800	 	_	
160-45	31800-31805	.0002	_	
160-46	31805-31806	;	_	
160-47	31807-31810	see	_	
160-48	31811-31814	Fig	_	
160-49	31814-31815	.	_	
160-50	31816-31818	3D	_	
160-51	31818-31819	)	_	
160-52	31819-31820	,	_	
160-53	31821-31822	a	_	
160-54	31823-31830	similar	_	
160-55	31831-31838	pattern	_	
160-56	31839-31842	was	_	
160-57	31843-31851	observed	_	
160-58	31851-31852	.	_	

#Text=The abstinent group exhibited a significant positive activation to P(stop) on successful stop (SS) trials (p < .05), but no significant activation or deactivation with P(stop) on stop error (SE) trials (p > .05).
161-1	31853-31856	The	_	
161-2	31857-31866	abstinent	_	
161-3	31867-31872	group	_	
161-4	31873-31882	exhibited	_	
161-5	31883-31884	a	_	
161-6	31885-31896	significant	_	
161-7	31897-31905	positive	_	
161-8	31906-31916	activation	_	
161-9	31917-31919	to	_	
161-10	31920-31921	P	_	
161-11	31921-31922	(	_	
161-12	31922-31926	stop	_	
161-13	31926-31927	)	_	
161-14	31928-31930	on	_	
161-15	31931-31941	successful	_	
161-16	31942-31946	stop	_	
161-17	31947-31948	(	_	
161-18	31948-31950	SS	_	
161-19	31950-31951	)	_	
161-20	31952-31958	trials	_	
161-21	31959-31960	(	_	
161-22	31960-31961	p	_	
161-23	31961-31962	 	_	
161-24	31962-31963	<	_	
161-25	31963-31964	 	_	
161-26	31964-31967	.05	_	
161-27	31967-31968	)	_	
161-28	31968-31969	,	_	
161-29	31970-31973	but	_	
161-30	31974-31976	no	_	
161-31	31977-31988	significant	_	
161-32	31989-31999	activation	_	
161-33	32000-32002	or	_	
161-34	32003-32015	deactivation	_	
161-35	32016-32020	with	_	
161-36	32021-32022	P	_	
161-37	32022-32023	(	_	
161-38	32023-32027	stop	_	
161-39	32027-32028	)	_	
161-40	32029-32031	on	_	
161-41	32032-32036	stop	_	
161-42	32037-32042	error	_	
161-43	32043-32044	(	_	
161-44	32044-32046	SE	_	
161-45	32046-32047	)	_	
161-46	32048-32054	trials	_	
161-47	32055-32056	(	_	
161-48	32056-32057	p	_	
161-49	32057-32058	 	_	
161-50	32058-32059	>	_	
161-51	32059-32060	 	_	
161-52	32060-32063	.05	_	
161-53	32063-32064	)	_	
161-54	32064-32065	.	_	

#Text=In contrast, relapsed participants showed a significant positive activation to P(stop) on SE trials (p < .05) but not on SS trials (p > .05; see Fig. 3E).
162-1	32066-32068	In	_	
162-2	32069-32077	contrast	_	
162-3	32077-32078	,	_	
162-4	32079-32087	relapsed	_	
162-5	32088-32100	participants	_	
162-6	32101-32107	showed	_	
162-7	32108-32109	a	_	
162-8	32110-32121	significant	_	
162-9	32122-32130	positive	_	
162-10	32131-32141	activation	_	
162-11	32142-32144	to	_	
162-12	32145-32146	P	_	
162-13	32146-32147	(	_	
162-14	32147-32151	stop	_	
162-15	32151-32152	)	_	
162-16	32153-32155	on	_	
162-17	32156-32158	SE	_	
162-18	32159-32165	trials	_	
162-19	32166-32167	(	_	
162-20	32167-32168	p	_	
162-21	32168-32169	 	_	
162-22	32169-32170	<	_	
162-23	32170-32171	 	_	
162-24	32171-32174	.05	_	
162-25	32174-32175	)	_	
162-26	32176-32179	but	_	
162-27	32180-32183	not	_	
162-28	32184-32186	on	_	
162-29	32187-32189	SS	_	
162-30	32190-32196	trials	_	
162-31	32197-32198	(	_	
162-32	32198-32199	p	_	
162-33	32199-32200	 	_	
162-34	32200-32201	>	_	
162-35	32201-32202	 	_	
162-36	32202-32205	.05	_	
162-37	32205-32206	;	_	
162-38	32207-32210	see	_	
162-39	32211-32214	Fig	_	
162-40	32214-32215	.	_	
162-41	32216-32218	3E	_	
162-42	32218-32219	)	_	
162-43	32219-32220	.	_	

#Text=Again, this was reflected by the group difference in percent signal change to a Bayesian UPE.
163-1	32221-32226	Again	_	
163-2	32226-32227	,	_	
163-3	32228-32232	this	_	
163-4	32233-32236	was	_	
163-5	32237-32246	reflected	_	
163-6	32247-32249	by	_	
163-7	32250-32253	the	_	
163-8	32254-32259	group	_	
163-9	32260-32270	difference	_	
163-10	32271-32273	in	_	
163-11	32274-32281	percent	_	
163-12	32282-32288	signal	_	
163-13	32289-32295	change	_	
163-14	32296-32298	to	_	
163-15	32299-32300	a	_	
163-16	32301-32309	Bayesian	_	
163-17	32310-32313	UPE	_	
163-18	32313-32314	.	_	

#Text=Specifically, on successful stop trials (SS), abstinent individuals showed a significant deactivation to UPE (p < .05), which was not significantly difference from zero in relapsed individuals (p > .05; Group Difference Cohen's d = 0.63, p = .02).
164-1	32315-32327	Specifically	_	
164-2	32327-32328	,	_	
164-3	32329-32331	on	_	
164-4	32332-32342	successful	_	
164-5	32343-32347	stop	_	
164-6	32348-32354	trials	_	
164-7	32355-32356	(	_	
164-8	32356-32358	SS	_	
164-9	32358-32359	)	_	
164-10	32359-32360	,	_	
164-11	32361-32370	abstinent	_	
164-12	32371-32382	individuals	_	
164-13	32383-32389	showed	_	
164-14	32390-32391	a	_	
164-15	32392-32403	significant	_	
164-16	32404-32416	deactivation	_	
164-17	32417-32419	to	_	
164-18	32420-32423	UPE	_	
164-19	32424-32425	(	_	
164-20	32425-32426	p	_	
164-21	32426-32427	 	_	
164-22	32427-32428	<	_	
164-23	32428-32429	 	_	
164-24	32429-32432	.05	_	
164-25	32432-32433	)	_	
164-26	32433-32434	,	_	
164-27	32435-32440	which	_	
164-28	32441-32444	was	_	
164-29	32445-32448	not	_	
164-30	32449-32462	significantly	_	
164-31	32463-32473	difference	_	
164-32	32474-32478	from	_	
164-33	32479-32483	zero	_	
164-34	32484-32486	in	_	
164-35	32487-32495	relapsed	_	
164-36	32496-32507	individuals	_	
164-37	32508-32509	(	_	
164-38	32509-32510	p	_	
164-39	32510-32511	 	_	
164-40	32511-32512	>	_	
164-41	32512-32513	 	_	
164-42	32513-32516	.05	_	
164-43	32516-32517	;	_	
164-44	32518-32523	Group	_	
164-45	32524-32534	Difference	_	
164-46	32535-32542	Cohen's	_	
164-47	32543-32544	d	_	
164-48	32544-32545	 	_	
164-49	32545-32546	=	_	
164-50	32546-32547	 	_	
164-51	32547-32551	0.63	_	
164-52	32551-32552	,	_	
164-53	32553-32554	p	_	
164-54	32554-32555	 	_	
164-55	32555-32556	=	_	
164-56	32556-32557	 	_	
164-57	32557-32560	.02	_	
164-58	32560-32561	)	_	
164-59	32561-32562	.	_	

#Text=In contrast, on SE trials, the relapsed group showed a significant deactivation to UPE (p = .05), which was not significant in abstinent individuals (p > .05; Group Difference was not significant: Cohen's d = 0.31, p = .26; see Fig. 3C).
165-1	32563-32565	In	_	
165-2	32566-32574	contrast	_	
165-3	32574-32575	,	_	
165-4	32576-32578	on	_	
165-5	32579-32581	SE	_	
165-6	32582-32588	trials	_	
165-7	32588-32589	,	_	
165-8	32590-32593	the	_	
165-9	32594-32602	relapsed	_	
165-10	32603-32608	group	_	
165-11	32609-32615	showed	_	
165-12	32616-32617	a	_	
165-13	32618-32629	significant	_	
165-14	32630-32642	deactivation	_	
165-15	32643-32645	to	_	
165-16	32646-32649	UPE	_	
165-17	32650-32651	(	_	
165-18	32651-32652	p	_	
165-19	32652-32653	 	_	
165-20	32653-32654	=	_	
165-21	32654-32655	 	_	
165-22	32655-32658	.05	_	
165-23	32658-32659	)	_	
165-24	32659-32660	,	_	
165-25	32661-32666	which	_	
165-26	32667-32670	was	_	
165-27	32671-32674	not	_	
165-28	32675-32686	significant	_	
165-29	32687-32689	in	_	
165-30	32690-32699	abstinent	_	
165-31	32700-32711	individuals	_	
165-32	32712-32713	(	_	
165-33	32713-32714	p	_	
165-34	32714-32715	 	_	
165-35	32715-32716	>	_	
165-36	32716-32717	 	_	
165-37	32717-32720	.05	_	
165-38	32720-32721	;	_	
165-39	32722-32727	Group	_	
165-40	32728-32738	Difference	_	
165-41	32739-32742	was	_	
165-42	32743-32746	not	_	
165-43	32747-32758	significant	_	
165-44	32758-32759	:	_	
165-45	32760-32767	Cohen's	_	
165-46	32768-32769	d	_	
165-47	32769-32770	 	_	
165-48	32770-32771	=	_	
165-49	32771-32772	 	_	
165-50	32772-32776	0.31	_	
165-51	32776-32777	,	_	
165-52	32778-32779	p	_	
165-53	32779-32780	 	_	
165-54	32780-32781	=	_	
165-55	32781-32782	 	_	
165-56	32782-32785	.26	_	
165-57	32785-32786	;	_	
165-58	32787-32790	see	_	
165-59	32791-32794	Fig	_	
165-60	32794-32795	.	_	
165-61	32796-32798	3C	_	
165-62	32798-32799	)	_	
165-63	32799-32800	.	_	

#Text=Non-computational task regressors
#Text=We conducted two similar LME analyses with the categorical regressors (Go, SS, SE) to assess whether clinical groups differed in their neural responses to trial type after regressing out any variance correlated with the P(stop)-modulated predictors.
166-1	32801-32818	Non-computational	_	
166-2	32819-32823	task	_	
166-3	32824-32834	regressors	_	
166-4	32835-32837	We	_	
166-5	32838-32847	conducted	_	
166-6	32848-32851	two	_	
166-7	32852-32859	similar	_	
166-8	32860-32863	LME	_	
166-9	32864-32872	analyses	_	
166-10	32873-32877	with	_	
166-11	32878-32881	the	_	
166-12	32882-32893	categorical	_	
166-13	32894-32904	regressors	_	
166-14	32905-32906	(	_	
166-15	32906-32908	Go	_	
166-16	32908-32909	,	_	
166-17	32910-32912	SS	_	
166-18	32912-32913	,	_	
166-19	32914-32916	SE	_	
166-20	32916-32917	)	_	
166-21	32918-32920	to	_	
166-22	32921-32927	assess	_	
166-23	32928-32935	whether	_	
166-24	32936-32944	clinical	_	
166-25	32945-32951	groups	_	
166-26	32952-32960	differed	_	
166-27	32961-32963	in	_	
166-28	32964-32969	their	_	
166-29	32970-32976	neural	_	
166-30	32977-32986	responses	_	
166-31	32987-32989	to	_	
166-32	32990-32995	trial	_	
166-33	32996-33000	type	_	
166-34	33001-33006	after	_	
166-35	33007-33017	regressing	_	
166-36	33018-33021	out	_	
166-37	33022-33025	any	_	
166-38	33026-33034	variance	_	
166-39	33035-33045	correlated	_	
166-40	33046-33050	with	_	
166-41	33051-33054	the	_	
166-42	33055-33056	P	_	
166-43	33056-33057	(	_	
166-44	33057-33061	stop	_	
166-45	33061-33062	)	_	
166-46	33062-33063	-	_	
166-47	33063-33072	modulated	_	
166-48	33073-33083	predictors	_	
166-49	33083-33084	.	_	

#Text=We specifically looked at the interaction of clinical status with the Go - Stop contrast (SS and SE averaged), as well as with the SS – SE contrast.
167-1	33085-33087	We	_	
167-2	33088-33100	specifically	_	
167-3	33101-33107	looked	_	
167-4	33108-33110	at	_	
167-5	33111-33114	the	_	
167-6	33115-33126	interaction	_	
167-7	33127-33129	of	_	
167-8	33130-33138	clinical	_	
167-9	33139-33145	status	_	
167-10	33146-33150	with	_	
167-11	33151-33154	the	_	
167-12	33155-33157	Go	_	
167-13	33158-33159	-	_	
167-14	33160-33164	Stop	_	
167-15	33165-33173	contrast	_	
167-16	33174-33175	(	_	
167-17	33175-33177	SS	_	
167-18	33178-33181	and	_	
167-19	33182-33184	SE	_	
167-20	33185-33193	averaged	_	
167-21	33193-33194	)	_	
167-22	33194-33195	,	_	
167-23	33196-33198	as	_	
167-24	33199-33203	well	_	
167-25	33204-33206	as	_	
167-26	33207-33211	with	_	
167-27	33212-33215	the	_	
167-28	33216-33218	SS	_	
167-29	33219-33220	–	_	
167-30	33221-33223	SE	_	
167-31	33224-33232	contrast	_	
167-32	33232-33233	.	_	

#Text=We found not regions consistent with either a significant group by Go-Stop contrast, or a significant group by SS-SE contrast.
168-1	33234-33236	We	_	
168-2	33237-33242	found	_	
168-3	33243-33246	not	_	
168-4	33247-33254	regions	_	
168-5	33255-33265	consistent	_	
168-6	33266-33270	with	_	
168-7	33271-33277	either	_	
168-8	33278-33279	a	_	
168-9	33280-33291	significant	_	
168-10	33292-33297	group	_	
168-11	33298-33300	by	_	
168-12	33301-33308	Go-Stop	_	
168-13	33309-33317	contrast	_	
168-14	33317-33318	,	_	
168-15	33319-33321	or	_	
168-16	33322-33323	a	_	
168-17	33324-33335	significant	_	
168-18	33336-33341	group	_	
168-19	33342-33344	by	_	
168-20	33345-33350	SS-SE	_	
168-21	33351-33359	contrast	_	
168-22	33359-33360	.	_	

#Text=Discussion
#Text=We aimed to identify neural markers of relapse to methamphetamine use, combining behavioral, neuroimaging, and computational approaches.
169-1	33361-33371	Discussion	_	
169-2	33372-33374	We	_	
169-3	33375-33380	aimed	_	
169-4	33381-33383	to	_	
169-5	33384-33392	identify	_	
169-6	33393-33399	neural	_	
169-7	33400-33407	markers	_	
169-8	33408-33410	of	_	
169-9	33411-33418	relapse	_	
169-10	33419-33421	to	_	
169-11	33422-33437	methamphetamine	_	
169-12	33438-33441	use	_	
169-13	33441-33442	,	_	
169-14	33443-33452	combining	_	
169-15	33453-33463	behavioral	_	
169-16	33463-33464	,	_	
169-17	33465-33477	neuroimaging	_	
169-18	33477-33478	,	_	
169-19	33479-33482	and	_	
169-20	33483-33496	computational	_	
169-21	33497-33507	approaches	_	
169-22	33507-33508	.	_	

#Text=We used a Bayesian ideal observer model to infer expectations of inhibitory response in a stop-signal task among fifty-eight methamphetamine-dependent individuals.
170-1	33509-33511	We	_	
170-2	33512-33516	used	_	
170-3	33517-33518	a	_	
170-4	33519-33527	Bayesian	_	
170-5	33528-33533	ideal	_	
170-6	33534-33542	observer	_	
170-7	33543-33548	model	_	
170-8	33549-33551	to	_	
170-9	33552-33557	infer	_	
170-10	33558-33570	expectations	_	
170-11	33571-33573	of	_	
170-12	33574-33584	inhibitory	_	
170-13	33585-33593	response	_	
170-14	33594-33596	in	_	
170-15	33597-33598	a	_	
170-16	33599-33610	stop-signal	_	
170-17	33611-33615	task	_	
170-18	33616-33621	among	_	
170-19	33622-33633	fifty-eight	_	
170-20	33634-33659	methamphetamine-dependent	_	
170-21	33660-33671	individuals	_	
170-22	33671-33672	.	_	

#Text=We found that, relative to those MDI who remained abstinent, relapsed individuals failed to exhibit a deactivation to a signed prediction error (SPE) in the left temporoparietal junction.
171-1	33673-33675	We	_	
171-2	33676-33681	found	_	
171-3	33682-33686	that	_	
171-4	33686-33687	,	_	
171-5	33688-33696	relative	_	
171-6	33697-33699	to	_	
171-7	33700-33705	those	_	
171-8	33706-33709	MDI	_	
171-9	33710-33713	who	_	
171-10	33714-33722	remained	_	
171-11	33723-33732	abstinent	_	
171-12	33732-33733	,	_	
171-13	33734-33742	relapsed	_	
171-14	33743-33754	individuals	_	
171-15	33755-33761	failed	_	
171-16	33762-33764	to	_	
171-17	33765-33772	exhibit	_	
171-18	33773-33774	a	_	
171-19	33775-33787	deactivation	_	
171-20	33788-33790	to	_	
171-21	33791-33792	a	_	
171-22	33793-33799	signed	_	
171-23	33800-33810	prediction	_	
171-24	33811-33816	error	_	
171-25	33817-33818	(	_	
171-26	33818-33821	SPE	_	
171-27	33821-33822	)	_	
171-28	33823-33825	in	_	
171-29	33826-33829	the	_	
171-30	33830-33834	left	_	
171-31	33835-33850	temporoparietal	_	
171-32	33851-33859	junction	_	
171-33	33859-33860	.	_	

#Text=In addition, while abstinent individuals exhibited significant neural responses to P(stop) and an unsigned prediction error (UPE) on successfully inhibited trials in the left IFG and left anterior insula, relapsed individuals showed abnormalities in the tracking of UPE in those regions, with stronger UPE activation on failed but not successful trials.
172-1	33861-33863	In	_	
172-2	33864-33872	addition	_	
172-3	33872-33873	,	_	
172-4	33874-33879	while	_	
172-5	33880-33889	abstinent	_	
172-6	33890-33901	individuals	_	
172-7	33902-33911	exhibited	_	
172-8	33912-33923	significant	_	
172-9	33924-33930	neural	_	
172-10	33931-33940	responses	_	
172-11	33941-33943	to	_	
172-12	33944-33945	P	_	
172-13	33945-33946	(	_	
172-14	33946-33950	stop	_	
172-15	33950-33951	)	_	
172-16	33952-33955	and	_	
172-17	33956-33958	an	_	
172-18	33959-33967	unsigned	_	
172-19	33968-33978	prediction	_	
172-20	33979-33984	error	_	
172-21	33985-33986	(	_	
172-22	33986-33989	UPE	_	
172-23	33989-33990	)	_	
172-24	33991-33993	on	_	
172-25	33994-34006	successfully	_	
172-26	34007-34016	inhibited	_	
172-27	34017-34023	trials	_	
172-28	34024-34026	in	_	
172-29	34027-34030	the	_	
172-30	34031-34035	left	_	
172-31	34036-34039	IFG	_	
172-32	34040-34043	and	_	
172-33	34044-34048	left	_	
172-34	34049-34057	anterior	_	
172-35	34058-34064	insula	_	
172-36	34064-34065	,	_	
172-37	34066-34074	relapsed	_	
172-38	34075-34086	individuals	_	
172-39	34087-34093	showed	_	
172-40	34094-34107	abnormalities	_	
172-41	34108-34110	in	_	
172-42	34111-34114	the	_	
172-43	34115-34123	tracking	_	
172-44	34124-34126	of	_	
172-45	34127-34130	UPE	_	
172-46	34131-34133	in	_	
172-47	34134-34139	those	_	
172-48	34140-34147	regions	_	
172-49	34147-34148	,	_	
172-50	34149-34153	with	_	
172-51	34154-34162	stronger	_	
172-52	34163-34166	UPE	_	
172-53	34167-34177	activation	_	
172-54	34178-34180	on	_	
172-55	34181-34187	failed	_	
172-56	34188-34191	but	_	
172-57	34192-34195	not	_	
172-58	34196-34206	successful	_	
172-59	34207-34213	trials	_	
172-60	34213-34214	.	_	

#Text=In contrast to these neural differences, no other baseline predictors, such as reported lifetime drug use or non-model based neural predictors, predicted relapse.
173-1	34215-34217	In	_	
173-2	34218-34226	contrast	_	
173-3	34227-34229	to	_	
173-4	34230-34235	these	_	
173-5	34236-34242	neural	_	
173-6	34243-34254	differences	_	
173-7	34254-34255	,	_	
173-8	34256-34258	no	_	
173-9	34259-34264	other	_	
173-10	34265-34273	baseline	_	
173-11	34274-34284	predictors	_	
173-12	34284-34285	,	_	
173-13	34286-34290	such	_	
173-14	34291-34293	as	_	
173-15	34294-34302	reported	_	
173-16	34303-34311	lifetime	_	
173-17	34312-34316	drug	_	
173-18	34317-34320	use	_	
173-19	34321-34323	or	_	
173-20	34324-34333	non-model	_	
173-21	34334-34339	based	_	
173-22	34340-34346	neural	_	
173-23	34347-34357	predictors	_	
173-24	34357-34358	,	_	
173-25	34359-34368	predicted	_	
173-26	34369-34376	relapse	_	
173-27	34376-34377	.	_	

#Text=These two types of prediction errors (SPE and UPE) carry different yet complementary relevance to behavior adjustment, as discussed below.
174-1	34378-34383	These	_	
174-2	34384-34387	two	_	
174-3	34388-34393	types	_	
174-4	34394-34396	of	_	
174-5	34397-34407	prediction	_	
174-6	34408-34414	errors	_	
174-7	34415-34416	(	_	
174-8	34416-34419	SPE	_	
174-9	34420-34423	and	_	
174-10	34424-34427	UPE	_	
174-11	34427-34428	)	_	
174-12	34429-34434	carry	_	
174-13	34435-34444	different	_	
174-14	34445-34448	yet	_	
174-15	34449-34462	complementary	_	
174-16	34463-34472	relevance	_	
174-17	34473-34475	to	_	
174-18	34476-34484	behavior	_	
174-19	34485-34495	adjustment	_	
174-20	34495-34496	,	_	
174-21	34497-34499	as	_	
174-22	34500-34509	discussed	_	
174-23	34510-34515	below	_	
174-24	34515-34516	.	_	

#Text=The SPE (outcome-P(stop)) is proportional to the degree of Dynamic Belief Model (DBM) belief updating following a given trial outcome, and quantifies how much the directional difference between expecting and observing a stop signal update prior beliefs to modify the internal model.
175-1	34517-34520	The	_	
175-2	34521-34524	SPE	_	
175-3	34525-34526	(	_	
175-4	34526-34535	outcome-P	_	
175-5	34535-34536	(	_	
175-6	34536-34540	stop	_	
175-7	34540-34541	)	_	
175-8	34541-34542	)	_	
175-9	34543-34545	is	_	
175-10	34546-34558	proportional	_	
175-11	34559-34561	to	_	
175-12	34562-34565	the	_	
175-13	34566-34572	degree	_	
175-14	34573-34575	of	_	
175-15	34576-34583	Dynamic	_	
175-16	34584-34590	Belief	_	
175-17	34591-34596	Model	_	
175-18	34597-34598	(	_	
175-19	34598-34601	DBM	_	
175-20	34601-34602	)	_	
175-21	34603-34609	belief	_	
175-22	34610-34618	updating	_	
175-23	34619-34628	following	_	
175-24	34629-34630	a	_	
175-25	34631-34636	given	_	
175-26	34637-34642	trial	_	
175-27	34643-34650	outcome	_	
175-28	34650-34651	,	_	
175-29	34652-34655	and	_	
175-30	34656-34666	quantifies	_	
175-31	34667-34670	how	_	
175-32	34671-34675	much	_	
175-33	34676-34679	the	_	
175-34	34680-34691	directional	_	
175-35	34692-34702	difference	_	
175-36	34703-34710	between	_	
175-37	34711-34720	expecting	_	
175-38	34721-34724	and	_	
175-39	34725-34734	observing	_	
175-40	34735-34736	a	_	
175-41	34737-34741	stop	_	
175-42	34742-34748	signal	_	
175-43	34749-34755	update	_	
175-44	34756-34761	prior	_	
175-45	34762-34769	beliefs	_	
175-46	34770-34772	to	_	
175-47	34773-34779	modify	_	
175-48	34780-34783	the	_	
175-49	34784-34792	internal	_	
175-50	34793-34798	model	_	
175-51	34798-34799	.	_	

#Text=The fact that individuals with weaker Bayesian SPE activations in the left angular gyrus appear more likely to relapse suggests that these individuals may be less efficient at learning, i.e., updating expectations, in the task.
176-1	34800-34803	The	_	
176-2	34804-34808	fact	_	
176-3	34809-34813	that	_	
176-4	34814-34825	individuals	_	
176-5	34826-34830	with	_	
176-6	34831-34837	weaker	_	
176-7	34838-34846	Bayesian	_	
176-8	34847-34850	SPE	_	
176-9	34851-34862	activations	_	
176-10	34863-34865	in	_	
176-11	34866-34869	the	_	
176-12	34870-34874	left	_	
176-13	34875-34882	angular	_	
176-14	34883-34888	gyrus	_	
176-15	34889-34895	appear	_	
176-16	34896-34900	more	_	
176-17	34901-34907	likely	_	
176-18	34908-34910	to	_	
176-19	34911-34918	relapse	_	
176-20	34919-34927	suggests	_	
176-21	34928-34932	that	_	
176-22	34933-34938	these	_	
176-23	34939-34950	individuals	_	
176-24	34951-34954	may	_	
176-25	34955-34957	be	_	
176-26	34958-34962	less	_	
176-27	34963-34972	efficient	_	
176-28	34973-34975	at	_	
176-29	34976-34984	learning	_	
176-30	34984-34985	,	_	
176-31	34986-34989	i.e	_	
176-32	34989-34990	.	_	
176-33	34990-34991	,	_	
176-34	34992-35000	updating	_	
176-35	35001-35013	expectations	_	
176-36	35013-35014	,	_	
176-37	35015-35017	in	_	
176-38	35018-35021	the	_	
176-39	35022-35026	task	_	
176-40	35026-35027	.	_	

#Text=With extensive connections to prefrontal and temporal lobes, the left angular gyrus has been implicated in encoding prediction errors and event frequencies within a Bayesian learning context, highlighting the role of this region in computationally-based learning.
177-1	35028-35032	With	_	
177-2	35033-35042	extensive	_	
177-3	35043-35054	connections	_	
177-4	35055-35057	to	_	
177-5	35058-35068	prefrontal	_	
177-6	35069-35072	and	_	
177-7	35073-35081	temporal	_	
177-8	35082-35087	lobes	_	
177-9	35087-35088	,	_	
177-10	35089-35092	the	_	
177-11	35093-35097	left	_	
177-12	35098-35105	angular	_	
177-13	35106-35111	gyrus	_	
177-14	35112-35115	has	_	
177-15	35116-35120	been	_	
177-16	35121-35131	implicated	_	
177-17	35132-35134	in	_	
177-18	35135-35143	encoding	_	
177-19	35144-35154	prediction	_	
177-20	35155-35161	errors	_	
177-21	35162-35165	and	_	
177-22	35166-35171	event	_	
177-23	35172-35183	frequencies	_	
177-24	35184-35190	within	_	
177-25	35191-35192	a	_	
177-26	35193-35201	Bayesian	_	
177-27	35202-35210	learning	_	
177-28	35211-35218	context	_	
177-29	35218-35219	,	_	
177-30	35220-35232	highlighting	_	
177-31	35233-35236	the	_	
177-32	35237-35241	role	_	
177-33	35242-35244	of	_	
177-34	35245-35249	this	_	
177-35	35250-35256	region	_	
177-36	35257-35259	in	_	
177-37	35260-35281	computationally-based	_	
177-38	35282-35290	learning	_	
177-39	35290-35291	.	_	

#Text=The observed negative as opposed to positive correlation between SPE and neural activity in this region highlights the relevance for relapse prediction of tracking this signed discrepancy specifically when observed stop frequency is lower than expectations (negative SPE).
178-1	35292-35295	The	_	
178-2	35296-35304	observed	_	
178-3	35305-35313	negative	_	
178-4	35314-35316	as	_	
178-5	35317-35324	opposed	_	
178-6	35325-35327	to	_	
178-7	35328-35336	positive	_	
178-8	35337-35348	correlation	_	
178-9	35349-35356	between	_	
178-10	35357-35360	SPE	_	
178-11	35361-35364	and	_	
178-12	35365-35371	neural	_	
178-13	35372-35380	activity	_	
178-14	35381-35383	in	_	
178-15	35384-35388	this	_	
178-16	35389-35395	region	_	
178-17	35396-35406	highlights	_	
178-18	35407-35410	the	_	
178-19	35411-35420	relevance	_	
178-20	35421-35424	for	_	
178-21	35425-35432	relapse	_	
178-22	35433-35443	prediction	_	
178-23	35444-35446	of	_	
178-24	35447-35455	tracking	_	
178-25	35456-35460	this	_	
178-26	35461-35467	signed	_	
178-27	35468-35479	discrepancy	_	
178-28	35480-35492	specifically	_	
178-29	35493-35497	when	_	
178-30	35498-35506	observed	_	
178-31	35507-35511	stop	_	
178-32	35512-35521	frequency	_	
178-33	35522-35524	is	_	
178-34	35525-35530	lower	_	
178-35	35531-35535	than	_	
178-36	35536-35548	expectations	_	
178-37	35549-35550	(	_	
178-38	35550-35558	negative	_	
178-39	35559-35562	SPE	_	
178-40	35562-35563	)	_	
178-41	35563-35564	.	_	

#Text=That is, because of its specific relevance to inhibitory/stop action tendency following belief adjustment, negative SPE activation may point to a specific vulnerability in flexibly implementing such action in relapsers.
179-1	35565-35569	That	_	
179-2	35570-35572	is	_	
179-3	35572-35573	,	_	
179-4	35574-35581	because	_	
179-5	35582-35584	of	_	
179-6	35585-35588	its	_	
179-7	35589-35597	specific	_	
179-8	35598-35607	relevance	_	
179-9	35608-35610	to	_	
179-10	35611-35621	inhibitory	_	
179-11	35621-35622	/	_	
179-12	35622-35626	stop	_	
179-13	35627-35633	action	_	
179-14	35634-35642	tendency	_	
179-15	35643-35652	following	_	
179-16	35653-35659	belief	_	
179-17	35660-35670	adjustment	_	
179-18	35670-35671	,	_	
179-19	35672-35680	negative	_	
179-20	35681-35684	SPE	_	
179-21	35685-35695	activation	_	
179-22	35696-35699	may	_	
179-23	35700-35705	point	_	
179-24	35706-35708	to	_	
179-25	35709-35710	a	_	
179-26	35711-35719	specific	_	
179-27	35720-35733	vulnerability	_	
179-28	35734-35736	in	_	
179-29	35737-35745	flexibly	_	
179-30	35746-35758	implementing	_	
179-31	35759-35763	such	_	
179-32	35764-35770	action	_	
179-33	35771-35773	in	_	
179-34	35774-35783	relapsers	_	
179-35	35783-35784	.	_	

#Text=Interestingly, there is evidence pointing to structural abnormalities in the superior temporal region (i.e., lower grey matter volumes) as potential biological vulnerability to stimulant addiction.
180-1	35785-35798	Interestingly	_	
180-2	35798-35799	,	_	
180-3	35800-35805	there	_	
180-4	35806-35808	is	_	
180-5	35809-35817	evidence	_	
180-6	35818-35826	pointing	_	
180-7	35827-35829	to	_	
180-8	35830-35840	structural	_	
180-9	35841-35854	abnormalities	_	
180-10	35855-35857	in	_	
180-11	35858-35861	the	_	
180-12	35862-35870	superior	_	
180-13	35871-35879	temporal	_	
180-14	35880-35886	region	_	
180-15	35887-35888	(	_	
180-16	35888-35891	i.e	_	
180-17	35891-35892	.	_	
180-18	35892-35893	,	_	
180-19	35894-35899	lower	_	
180-20	35900-35904	grey	_	
180-21	35905-35911	matter	_	
180-22	35912-35919	volumes	_	
180-23	35919-35920	)	_	
180-24	35921-35923	as	_	
180-25	35924-35933	potential	_	
180-26	35934-35944	biological	_	
180-27	35945-35958	vulnerability	_	
180-28	35959-35961	to	_	
180-29	35962-35971	stimulant	_	
180-30	35972-35981	addiction	_	
180-31	35981-35982	.	_	

#Text=Overall, these results are congruent with extensive evidence of difficulties learning and integrating new information to adjust behavioral performance in methamphetamine users, and with recent computational work pointing reduced prefrontal recruitment during model-based decision-making among alcohol relapsers.
181-1	35983-35990	Overall	_	
181-2	35990-35991	,	_	
181-3	35992-35997	these	_	
181-4	35998-36005	results	_	
181-5	36006-36009	are	_	
181-6	36010-36019	congruent	_	
181-7	36020-36024	with	_	
181-8	36025-36034	extensive	_	
181-9	36035-36043	evidence	_	
181-10	36044-36046	of	_	
181-11	36047-36059	difficulties	_	
181-12	36060-36068	learning	_	
181-13	36069-36072	and	_	
181-14	36073-36084	integrating	_	
181-15	36085-36088	new	_	
181-16	36089-36100	information	_	
181-17	36101-36103	to	_	
181-18	36104-36110	adjust	_	
181-19	36111-36121	behavioral	_	
181-20	36122-36133	performance	_	
181-21	36134-36136	in	_	
181-22	36137-36152	methamphetamine	_	
181-23	36153-36158	users	_	
181-24	36158-36159	,	_	
181-25	36160-36163	and	_	
181-26	36164-36168	with	_	
181-27	36169-36175	recent	_	
181-28	36176-36189	computational	_	
181-29	36190-36194	work	_	
181-30	36195-36203	pointing	_	
181-31	36204-36211	reduced	_	
181-32	36212-36222	prefrontal	_	
181-33	36223-36234	recruitment	_	
181-34	36235-36241	during	_	
181-35	36242-36253	model-based	_	
181-36	36254-36269	decision-making	_	
181-37	36270-36275	among	_	
181-38	36276-36283	alcohol	_	
181-39	36284-36293	relapsers	_	
181-40	36293-36294	.	_	

#Text=In contrast, the UPE (|outcome-P(stop)|) represents an overall degree of discrepancy between one's internal model prediction and actual outcome, and can be understood as a “goodness of fit” estimate of one's internal predictive model.
182-1	36295-36297	In	_	
182-2	36298-36306	contrast	_	
182-3	36306-36307	,	_	
182-4	36308-36311	the	_	
182-5	36312-36315	UPE	_	
182-6	36316-36317	(	_	
182-7	36317-36318	|	_	
182-8	36318-36327	outcome-P	_	
182-9	36327-36328	(	_	
182-10	36328-36332	stop	_	
182-11	36332-36333	)	_	
182-12	36333-36334	|	_	
182-13	36334-36335	)	_	
182-14	36336-36346	represents	_	
182-15	36347-36349	an	_	
182-16	36350-36357	overall	_	
182-17	36358-36364	degree	_	
182-18	36365-36367	of	_	
182-19	36368-36379	discrepancy	_	
182-20	36380-36387	between	_	
182-21	36388-36393	one's	_	
182-22	36394-36402	internal	_	
182-23	36403-36408	model	_	
182-24	36409-36419	prediction	_	
182-25	36420-36423	and	_	
182-26	36424-36430	actual	_	
182-27	36431-36438	outcome	_	
182-28	36438-36439	,	_	
182-29	36440-36443	and	_	
182-30	36444-36447	can	_	
182-31	36448-36450	be	_	
182-32	36451-36461	understood	_	
182-33	36462-36464	as	_	
182-34	36465-36466	a	_	
182-35	36467-36468	“	_	
182-36	36468-36476	goodness	_	
182-37	36477-36479	of	_	
182-38	36480-36483	fit	_	
182-39	36483-36484	”	_	
182-40	36485-36493	estimate	_	
182-41	36494-36496	of	_	
182-42	36497-36502	one's	_	
182-43	36503-36511	internal	_	
182-44	36512-36522	predictive	_	
182-45	36523-36528	model	_	
182-46	36528-36529	.	_	

#Text=Larger UPE deactivations, as observed in the left IFG and anterior insula, may thus reflect a stronger tracking of expectancy violation as unexpected changes in the environment statistics are being monitored.
183-1	36530-36536	Larger	_	
183-2	36537-36540	UPE	_	
183-3	36541-36554	deactivations	_	
183-4	36554-36555	,	_	
183-5	36556-36558	as	_	
183-6	36559-36567	observed	_	
183-7	36568-36570	in	_	
183-8	36571-36574	the	_	
183-9	36575-36579	left	_	
183-10	36580-36583	IFG	_	
183-11	36584-36587	and	_	
183-12	36588-36596	anterior	_	
183-13	36597-36603	insula	_	
183-14	36603-36604	,	_	
183-15	36605-36608	may	_	
183-16	36609-36613	thus	_	
183-17	36614-36621	reflect	_	
183-18	36622-36623	a	_	
183-19	36624-36632	stronger	_	
183-20	36633-36641	tracking	_	
183-21	36642-36644	of	_	
183-22	36645-36655	expectancy	_	
183-23	36656-36665	violation	_	
183-24	36666-36668	as	_	
183-25	36669-36679	unexpected	_	
183-26	36680-36687	changes	_	
183-27	36688-36690	in	_	
183-28	36691-36694	the	_	
183-29	36695-36706	environment	_	
183-30	36707-36717	statistics	_	
183-31	36718-36721	are	_	
183-32	36722-36727	being	_	
183-33	36728-36737	monitored	_	
183-34	36737-36738	.	_	

#Text=In both left IFG and left anterior insula, while abstinent individuals exhibited significant deactivations UPE, relapsed participants failed to show neural tracking of UPE when successfully inhibiting a motor response, but they instead exhibited such neural responses when failing to inhibit.
184-1	36739-36741	In	_	
184-2	36742-36746	both	_	
184-3	36747-36751	left	_	
184-4	36752-36755	IFG	_	
184-5	36756-36759	and	_	
184-6	36760-36764	left	_	
184-7	36765-36773	anterior	_	
184-8	36774-36780	insula	_	
184-9	36780-36781	,	_	
184-10	36782-36787	while	_	
184-11	36788-36797	abstinent	_	
184-12	36798-36809	individuals	_	
184-13	36810-36819	exhibited	_	
184-14	36820-36831	significant	_	
184-15	36832-36845	deactivations	_	
184-16	36846-36849	UPE	_	
184-17	36849-36850	,	_	
184-18	36851-36859	relapsed	_	
184-19	36860-36872	participants	_	
184-20	36873-36879	failed	_	
184-21	36880-36882	to	_	
184-22	36883-36887	show	_	
184-23	36888-36894	neural	_	
184-24	36895-36903	tracking	_	
184-25	36904-36906	of	_	
184-26	36907-36910	UPE	_	
184-27	36911-36915	when	_	
184-28	36916-36928	successfully	_	
184-29	36929-36939	inhibiting	_	
184-30	36940-36941	a	_	
184-31	36942-36947	motor	_	
184-32	36948-36956	response	_	
184-33	36956-36957	,	_	
184-34	36958-36961	but	_	
184-35	36962-36966	they	_	
184-36	36967-36974	instead	_	
184-37	36975-36984	exhibited	_	
184-38	36985-36989	such	_	
184-39	36990-36996	neural	_	
184-40	36997-37006	responses	_	
184-41	37007-37011	when	_	
184-42	37012-37019	failing	_	
184-43	37020-37022	to	_	
184-44	37023-37030	inhibit	_	
184-45	37030-37031	.	_	

#Text=This could suggest two things.
185-1	37032-37036	This	_	
185-2	37037-37042	could	_	
185-3	37043-37050	suggest	_	
185-4	37051-37054	two	_	
185-5	37055-37061	things	_	
185-6	37061-37062	.	_	

#Text=First, relative to individuals who remained abstinent, relapsed individuals may be less efficient at maintaining internal monitoring of unexpected uncertainty in the environment while preforming well on the task.
186-1	37063-37068	First	_	
186-2	37068-37069	,	_	
186-3	37070-37078	relative	_	
186-4	37079-37081	to	_	
186-5	37082-37093	individuals	_	
186-6	37094-37097	who	_	
186-7	37098-37106	remained	_	
186-8	37107-37116	abstinent	_	
186-9	37116-37117	,	_	
186-10	37118-37126	relapsed	_	
186-11	37127-37138	individuals	_	
186-12	37139-37142	may	_	
186-13	37143-37145	be	_	
186-14	37146-37150	less	_	
186-15	37151-37160	efficient	_	
186-16	37161-37163	at	_	
186-17	37164-37175	maintaining	_	
186-18	37176-37184	internal	_	
186-19	37185-37195	monitoring	_	
186-20	37196-37198	of	_	
186-21	37199-37209	unexpected	_	
186-22	37210-37221	uncertainty	_	
186-23	37222-37224	in	_	
186-24	37225-37228	the	_	
186-25	37229-37240	environment	_	
186-26	37241-37246	while	_	
186-27	37247-37257	preforming	_	
186-28	37258-37262	well	_	
186-29	37263-37265	on	_	
186-30	37266-37269	the	_	
186-31	37270-37274	task	_	
186-32	37274-37275	.	_	

#Text=Second, failure to successfully inhibit motor response may more specifically prompt neural tracking of uncertainty in those regions among relapsed individuals, which could point to a more selective tracking of uncertainty and higher attentional threshold to trigger strategic shifts and adapt behavior in this subset of individuals.
187-1	37276-37282	Second	_	
187-2	37282-37283	,	_	
187-3	37284-37291	failure	_	
187-4	37292-37294	to	_	
187-5	37295-37307	successfully	_	
187-6	37308-37315	inhibit	_	
187-7	37316-37321	motor	_	
187-8	37322-37330	response	_	
187-9	37331-37334	may	_	
187-10	37335-37339	more	_	
187-11	37340-37352	specifically	_	
187-12	37353-37359	prompt	_	
187-13	37360-37366	neural	_	
187-14	37367-37375	tracking	_	
187-15	37376-37378	of	_	
187-16	37379-37390	uncertainty	_	
187-17	37391-37393	in	_	
187-18	37394-37399	those	_	
187-19	37400-37407	regions	_	
187-20	37408-37413	among	_	
187-21	37414-37422	relapsed	_	
187-22	37423-37434	individuals	_	
187-23	37434-37435	,	_	
187-24	37436-37441	which	_	
187-25	37442-37447	could	_	
187-26	37448-37453	point	_	
187-27	37454-37456	to	_	
187-28	37457-37458	a	_	
187-29	37459-37463	more	_	
187-30	37464-37473	selective	_	
187-31	37474-37482	tracking	_	
187-32	37483-37485	of	_	
187-33	37486-37497	uncertainty	_	
187-34	37498-37501	and	_	
187-35	37502-37508	higher	_	
187-36	37509-37520	attentional	_	
187-37	37521-37530	threshold	_	
187-38	37531-37533	to	_	
187-39	37534-37541	trigger	_	
187-40	37542-37551	strategic	_	
187-41	37552-37558	shifts	_	
187-42	37559-37562	and	_	
187-43	37563-37568	adapt	_	
187-44	37569-37577	behavior	_	
187-45	37578-37580	in	_	
187-46	37581-37585	this	_	
187-47	37586-37592	subset	_	
187-48	37593-37595	of	_	
187-49	37596-37607	individuals	_	
187-50	37607-37608	.	_	

#Text=Indeed, several studies suggest that, while the right IFG is more robustly recruited during inhibitory control, the left IFG is also critical to response inhibition in SST and Go-NoGo tasks.
188-1	37609-37615	Indeed	_	
188-2	37615-37616	,	_	
188-3	37617-37624	several	_	
188-4	37625-37632	studies	_	
188-5	37633-37640	suggest	_	
188-6	37641-37645	that	_	
188-7	37645-37646	,	_	
188-8	37647-37652	while	_	
188-9	37653-37656	the	_	
188-10	37657-37662	right	_	
188-11	37663-37666	IFG	_	
188-12	37667-37669	is	_	
188-13	37670-37674	more	_	
188-14	37675-37683	robustly	_	
188-15	37684-37693	recruited	_	
188-16	37694-37700	during	_	
188-17	37701-37711	inhibitory	_	
188-18	37712-37719	control	_	
188-19	37719-37720	,	_	
188-20	37721-37724	the	_	
188-21	37725-37729	left	_	
188-22	37730-37733	IFG	_	
188-23	37734-37736	is	_	
188-24	37737-37741	also	_	
188-25	37742-37750	critical	_	
188-26	37751-37753	to	_	
188-27	37754-37762	response	_	
188-28	37763-37773	inhibition	_	
188-29	37774-37776	in	_	
188-30	37777-37780	SST	_	
188-31	37781-37784	and	_	
188-32	37785-37792	Go-NoGo	_	
188-33	37793-37798	tasks	_	
188-34	37798-37799	.	_	

#Text=Consistent with greater experienced expectancy violation, the left IFG has been shown to encode prediction errors, including those associated with Bayesian posterior probabilities, and with the ability to “switch” strategy when no longer task-relevant.
189-1	37800-37810	Consistent	_	
189-2	37811-37815	with	_	
189-3	37816-37823	greater	_	
189-4	37824-37835	experienced	_	
189-5	37836-37846	expectancy	_	
189-6	37847-37856	violation	_	
189-7	37856-37857	,	_	
189-8	37858-37861	the	_	
189-9	37862-37866	left	_	
189-10	37867-37870	IFG	_	
189-11	37871-37874	has	_	
189-12	37875-37879	been	_	
189-13	37880-37885	shown	_	
189-14	37886-37888	to	_	
189-15	37889-37895	encode	_	
189-16	37896-37906	prediction	_	
189-17	37907-37913	errors	_	
189-18	37913-37914	,	_	
189-19	37915-37924	including	_	
189-20	37925-37930	those	_	
189-21	37931-37941	associated	_	
189-22	37942-37946	with	_	
189-23	37947-37955	Bayesian	_	
189-24	37956-37965	posterior	_	
189-25	37966-37979	probabilities	_	
189-26	37979-37980	,	_	
189-27	37981-37984	and	_	
189-28	37985-37989	with	_	
189-29	37990-37993	the	_	
189-30	37994-38001	ability	_	
189-31	38002-38004	to	_	
189-32	38005-38006	“	_	
189-33	38006-38012	switch	_	
189-34	38012-38013	”	_	
189-35	38014-38022	strategy	_	
189-36	38023-38027	when	_	
189-37	38028-38030	no	_	
189-38	38031-38037	longer	_	
189-39	38038-38051	task-relevant	_	
189-40	38051-38052	.	_	

#Text=Similarly, prediction error and expectancy violation signals in reinforcement learning paradigms have been robustly observed in the insular cortex, and this region has been implicated in interoception and error-based learning within complex, uncertain environment.
190-1	38053-38062	Similarly	_	
190-2	38062-38063	,	_	
190-3	38064-38074	prediction	_	
190-4	38075-38080	error	_	
190-5	38081-38084	and	_	
190-6	38085-38095	expectancy	_	
190-7	38096-38105	violation	_	
190-8	38106-38113	signals	_	
190-9	38114-38116	in	_	
190-10	38117-38130	reinforcement	_	
190-11	38131-38139	learning	_	
190-12	38140-38149	paradigms	_	
190-13	38150-38154	have	_	
190-14	38155-38159	been	_	
190-15	38160-38168	robustly	_	
190-16	38169-38177	observed	_	
190-17	38178-38180	in	_	
190-18	38181-38184	the	_	
190-19	38185-38192	insular	_	
190-20	38193-38199	cortex	_	
190-21	38199-38200	,	_	
190-22	38201-38204	and	_	
190-23	38205-38209	this	_	
190-24	38210-38216	region	_	
190-25	38217-38220	has	_	
190-26	38221-38225	been	_	
190-27	38226-38236	implicated	_	
190-28	38237-38239	in	_	
190-29	38240-38253	interoception	_	
190-30	38254-38257	and	_	
190-31	38258-38269	error-based	_	
190-32	38270-38278	learning	_	
190-33	38279-38285	within	_	
190-34	38286-38293	complex	_	
190-35	38293-38294	,	_	
190-36	38295-38304	uncertain	_	
190-37	38305-38316	environment	_	
190-38	38316-38317	.	_	

#Text=Again, the observed deactivation vs positive activation pattern, consistent with previous evidence of negative relationships between unsigned prediction errors and activity in cingulate cortex and IFG, is congruent with a downstream inhibitory role of UPE activation in this region, which may be relevant to prompt de-engagement from the current behavioral strategy.
191-1	38318-38323	Again	_	
191-2	38323-38324	,	_	
191-3	38325-38328	the	_	
191-4	38329-38337	observed	_	
191-5	38338-38350	deactivation	_	
191-6	38351-38353	vs	_	
191-7	38354-38362	positive	_	
191-8	38363-38373	activation	_	
191-9	38374-38381	pattern	_	
191-10	38381-38382	,	_	
191-11	38383-38393	consistent	_	
191-12	38394-38398	with	_	
191-13	38399-38407	previous	_	
191-14	38408-38416	evidence	_	
191-15	38417-38419	of	_	
191-16	38420-38428	negative	_	
191-17	38429-38442	relationships	_	
191-18	38443-38450	between	_	
191-19	38451-38459	unsigned	_	
191-20	38460-38470	prediction	_	
191-21	38471-38477	errors	_	
191-22	38478-38481	and	_	
191-23	38482-38490	activity	_	
191-24	38491-38493	in	_	
191-25	38494-38503	cingulate	_	
191-26	38504-38510	cortex	_	
191-27	38511-38514	and	_	
191-28	38515-38518	IFG	_	
191-29	38518-38519	,	_	
191-30	38520-38522	is	_	
191-31	38523-38532	congruent	_	
191-32	38533-38537	with	_	
191-33	38538-38539	a	_	
191-34	38540-38550	downstream	_	
191-35	38551-38561	inhibitory	_	
191-36	38562-38566	role	_	
191-37	38567-38569	of	_	
191-38	38570-38573	UPE	_	
191-39	38574-38584	activation	_	
191-40	38585-38587	in	_	
191-41	38588-38592	this	_	
191-42	38593-38599	region	_	
191-43	38599-38600	,	_	
191-44	38601-38606	which	_	
191-45	38607-38610	may	_	
191-46	38611-38613	be	_	
191-47	38614-38622	relevant	_	
191-48	38623-38625	to	_	
191-49	38626-38632	prompt	_	
191-50	38633-38646	de-engagement	_	
191-51	38647-38651	from	_	
191-52	38652-38655	the	_	
191-53	38656-38663	current	_	
191-54	38664-38674	behavioral	_	
191-55	38675-38683	strategy	_	
191-56	38683-38684	.	_	

#Text=That is, those individuals prone to relapse show increased tracking of expectancy violation (i.e., appropriateness of the internal belief model guiding behavior), which is critical to guide shifts in attention away from an ineffective prediction strategy, in the face of failure, i.e., in a more reactive manner.
192-1	38685-38689	That	_	
192-2	38690-38692	is	_	
192-3	38692-38693	,	_	
192-4	38694-38699	those	_	
192-5	38700-38711	individuals	_	
192-6	38712-38717	prone	_	
192-7	38718-38720	to	_	
192-8	38721-38728	relapse	_	
192-9	38729-38733	show	_	
192-10	38734-38743	increased	_	
192-11	38744-38752	tracking	_	
192-12	38753-38755	of	_	
192-13	38756-38766	expectancy	_	
192-14	38767-38776	violation	_	
192-15	38777-38778	(	_	
192-16	38778-38781	i.e	_	
192-17	38781-38782	.	_	
192-18	38782-38783	,	_	
192-19	38784-38799	appropriateness	_	
192-20	38800-38802	of	_	
192-21	38803-38806	the	_	
192-22	38807-38815	internal	_	
192-23	38816-38822	belief	_	
192-24	38823-38828	model	_	
192-25	38829-38836	guiding	_	
192-26	38837-38845	behavior	_	
192-27	38845-38846	)	_	
192-28	38846-38847	,	_	
192-29	38848-38853	which	_	
192-30	38854-38856	is	_	
192-31	38857-38865	critical	_	
192-32	38866-38868	to	_	
192-33	38869-38874	guide	_	
192-34	38875-38881	shifts	_	
192-35	38882-38884	in	_	
192-36	38885-38894	attention	_	
192-37	38895-38899	away	_	
192-38	38900-38904	from	_	
192-39	38905-38907	an	_	
192-40	38908-38919	ineffective	_	
192-41	38920-38930	prediction	_	
192-42	38931-38939	strategy	_	
192-43	38939-38940	,	_	
192-44	38941-38943	in	_	
192-45	38944-38947	the	_	
192-46	38948-38952	face	_	
192-47	38953-38955	of	_	
192-48	38956-38963	failure	_	
192-49	38963-38964	,	_	
192-50	38965-38968	i.e	_	
192-51	38968-38969	.	_	
192-52	38969-38970	,	_	
192-53	38971-38973	in	_	
192-54	38974-38975	a	_	
192-55	38976-38980	more	_	
192-56	38981-38989	reactive	_	
192-57	38990-38996	manner	_	
192-58	38996-38997	.	_	

#Text=In contrast, those more likely to remain abstinent appear to more consistently track this discrepancy between model-based beliefs and actual outcome when they are successfully performing, i.e., in a more pro-active manner.
193-1	38998-39000	In	_	
193-2	39001-39009	contrast	_	
193-3	39009-39010	,	_	
193-4	39011-39016	those	_	
193-5	39017-39021	more	_	
193-6	39022-39028	likely	_	
193-7	39029-39031	to	_	
193-8	39032-39038	remain	_	
193-9	39039-39048	abstinent	_	
193-10	39049-39055	appear	_	
193-11	39056-39058	to	_	
193-12	39059-39063	more	_	
193-13	39064-39076	consistently	_	
193-14	39077-39082	track	_	
193-15	39083-39087	this	_	
193-16	39088-39099	discrepancy	_	
193-17	39100-39107	between	_	
193-18	39108-39119	model-based	_	
193-19	39120-39127	beliefs	_	
193-20	39128-39131	and	_	
193-21	39132-39138	actual	_	
193-22	39139-39146	outcome	_	
193-23	39147-39151	when	_	
193-24	39152-39156	they	_	
193-25	39157-39160	are	_	
193-26	39161-39173	successfully	_	
193-27	39174-39184	performing	_	
193-28	39184-39185	,	_	
193-29	39186-39189	i.e	_	
193-30	39189-39190	.	_	
193-31	39190-39191	,	_	
193-32	39192-39194	in	_	
193-33	39195-39196	a	_	
193-34	39197-39201	more	_	
193-35	39202-39212	pro-active	_	
193-36	39213-39219	manner	_	
193-37	39219-39220	.	_	

#Text=In light of recent computational work suggesting that individuals' decisions are partly guided by minimizing surprise through maximizing entropy over outcomes to “keep their options open”, such belief-based process may be particularly informative/predictive in individuals vulnerable to relapse.
194-1	39221-39223	In	_	
194-2	39224-39229	light	_	
194-3	39230-39232	of	_	
194-4	39233-39239	recent	_	
194-5	39240-39253	computational	_	
194-6	39254-39258	work	_	
194-7	39259-39269	suggesting	_	
194-8	39270-39274	that	_	
194-9	39275-39286	individuals	_	
194-10	39286-39287	'	_	
194-11	39288-39297	decisions	_	
194-12	39298-39301	are	_	
194-13	39302-39308	partly	_	
194-14	39309-39315	guided	_	
194-15	39316-39318	by	_	
194-16	39319-39329	minimizing	_	
194-17	39330-39338	surprise	_	
194-18	39339-39346	through	_	
194-19	39347-39357	maximizing	_	
194-20	39358-39365	entropy	_	
194-21	39366-39370	over	_	
194-22	39371-39379	outcomes	_	
194-23	39380-39382	to	_	
194-24	39383-39384	“	_	
194-25	39384-39388	keep	_	
194-26	39389-39394	their	_	
194-27	39395-39402	options	_	
194-28	39403-39407	open	_	
194-29	39407-39408	”	_	
194-30	39408-39409	,	_	
194-31	39410-39414	such	_	
194-32	39415-39427	belief-based	_	
194-33	39428-39435	process	_	
194-34	39436-39439	may	_	
194-35	39440-39442	be	_	
194-36	39443-39455	particularly	_	
194-37	39456-39467	informative	_	
194-38	39467-39468	/	_	
194-39	39468-39478	predictive	_	
194-40	39479-39481	in	_	
194-41	39482-39493	individuals	_	
194-42	39494-39504	vulnerable	_	
194-43	39505-39507	to	_	
194-44	39508-39515	relapse	_	
194-45	39515-39516	.	_	

#Text=Overall, these neural findings suggest that methamphetamine-dependent individuals more likely to relapse one year after treatment are less efficient at tracking unexpected uncertainty and updating their internal belief model when presented with new information.
195-1	39517-39524	Overall	_	
195-2	39524-39525	,	_	
195-3	39526-39531	these	_	
195-4	39532-39538	neural	_	
195-5	39539-39547	findings	_	
195-6	39548-39555	suggest	_	
195-7	39556-39560	that	_	
195-8	39561-39586	methamphetamine-dependent	_	
195-9	39587-39598	individuals	_	
195-10	39599-39603	more	_	
195-11	39604-39610	likely	_	
195-12	39611-39613	to	_	
195-13	39614-39621	relapse	_	
195-14	39622-39625	one	_	
195-15	39626-39630	year	_	
195-16	39631-39636	after	_	
195-17	39637-39646	treatment	_	
195-18	39647-39650	are	_	
195-19	39651-39655	less	_	
195-20	39656-39665	efficient	_	
195-21	39666-39668	at	_	
195-22	39669-39677	tracking	_	
195-23	39678-39688	unexpected	_	
195-24	39689-39700	uncertainty	_	
195-25	39701-39704	and	_	
195-26	39705-39713	updating	_	
195-27	39714-39719	their	_	
195-28	39720-39728	internal	_	
195-29	39729-39735	belief	_	
195-30	39736-39741	model	_	
195-31	39742-39746	when	_	
195-32	39747-39756	presented	_	
195-33	39757-39761	with	_	
195-34	39762-39765	new	_	
195-35	39766-39777	information	_	
195-36	39777-39778	.	_	

#Text=This highlights the importance of distinguishing belief updating processes from expectancy violation and uncertainty monitoring, with growing computational evidence of distinct neural substrates.
196-1	39779-39783	This	_	
196-2	39784-39794	highlights	_	
196-3	39795-39798	the	_	
196-4	39799-39809	importance	_	
196-5	39810-39812	of	_	
196-6	39813-39827	distinguishing	_	
196-7	39828-39834	belief	_	
196-8	39835-39843	updating	_	
196-9	39844-39853	processes	_	
196-10	39854-39858	from	_	
196-11	39859-39869	expectancy	_	
196-12	39870-39879	violation	_	
196-13	39880-39883	and	_	
196-14	39884-39895	uncertainty	_	
196-15	39896-39906	monitoring	_	
196-16	39906-39907	,	_	
196-17	39908-39912	with	_	
196-18	39913-39920	growing	_	
196-19	39921-39934	computational	_	
196-20	39935-39943	evidence	_	
196-21	39944-39946	of	_	
196-22	39947-39955	distinct	_	
196-23	39956-39962	neural	_	
196-24	39963-39973	substrates	_	
196-25	39973-39974	.	_	

#Text=Interestingly, this pattern echoes a recent meta-analysis of reward prediction in substance abusers, pointing to weaker anticipation of reward and higher prediction error signals when receiving unexpected rewards.
197-1	39975-39988	Interestingly	_	
197-2	39988-39989	,	_	
197-3	39990-39994	this	_	
197-4	39995-40002	pattern	_	
197-5	40003-40009	echoes	_	
197-6	40010-40011	a	_	
197-7	40012-40018	recent	_	
197-8	40019-40032	meta-analysis	_	
197-9	40033-40035	of	_	
197-10	40036-40042	reward	_	
197-11	40043-40053	prediction	_	
197-12	40054-40056	in	_	
197-13	40057-40066	substance	_	
197-14	40067-40074	abusers	_	
197-15	40074-40075	,	_	
197-16	40076-40084	pointing	_	
197-17	40085-40087	to	_	
197-18	40088-40094	weaker	_	
197-19	40095-40107	anticipation	_	
197-20	40108-40110	of	_	
197-21	40111-40117	reward	_	
197-22	40118-40121	and	_	
197-23	40122-40128	higher	_	
197-24	40129-40139	prediction	_	
197-25	40140-40145	error	_	
197-26	40146-40153	signals	_	
197-27	40154-40158	when	_	
197-28	40159-40168	receiving	_	
197-29	40169-40179	unexpected	_	
197-30	40180-40187	rewards	_	
197-31	40187-40188	.	_	

#Text=The similarity between this meta-analysis and our results further supports a learning impairment hypothesis, i.e. a problem of adapting behavior to a changing environment, generally consistent with a shift from model-based, goal-directed behavior to habitual decision-making associated with inflexible learning.
198-1	40189-40192	The	_	
198-2	40193-40203	similarity	_	
198-3	40204-40211	between	_	
198-4	40212-40216	this	_	
198-5	40217-40230	meta-analysis	_	
198-6	40231-40234	and	_	
198-7	40235-40238	our	_	
198-8	40239-40246	results	_	
198-9	40247-40254	further	_	
198-10	40255-40263	supports	_	
198-11	40264-40265	a	_	
198-12	40266-40274	learning	_	
198-13	40275-40285	impairment	_	
198-14	40286-40296	hypothesis	_	
198-15	40296-40297	,	_	
198-16	40298-40301	i.e	_	
198-17	40301-40302	.	_	
198-18	40303-40304	a	_	
198-19	40305-40312	problem	_	
198-20	40313-40315	of	_	
198-21	40316-40324	adapting	_	
198-22	40325-40333	behavior	_	
198-23	40334-40336	to	_	
198-24	40337-40338	a	_	
198-25	40339-40347	changing	_	
198-26	40348-40359	environment	_	
198-27	40359-40360	,	_	
198-28	40361-40370	generally	_	
198-29	40371-40381	consistent	_	
198-30	40382-40386	with	_	
198-31	40387-40388	a	_	
198-32	40389-40394	shift	_	
198-33	40395-40399	from	_	
198-34	40400-40411	model-based	_	
198-35	40411-40412	,	_	
198-36	40413-40426	goal-directed	_	
198-37	40427-40435	behavior	_	
198-38	40436-40438	to	_	
198-39	40439-40447	habitual	_	
198-40	40448-40463	decision-making	_	
198-41	40464-40474	associated	_	
198-42	40475-40479	with	_	
198-43	40480-40490	inflexible	_	
198-44	40491-40499	learning	_	
198-45	40499-40500	.	_	

#Text=We note, however, that this study has several limitations, including a small sample size, the fact that relapse/abstinence status was based on self-report, and that alcohol, prescription drugs, and other secondary drugs of abuse were not monitored after treatment.
199-1	40501-40503	We	_	
199-2	40504-40508	note	_	
199-3	40508-40509	,	_	
199-4	40510-40517	however	_	
199-5	40517-40518	,	_	
199-6	40519-40523	that	_	
199-7	40524-40528	this	_	
199-8	40529-40534	study	_	
199-9	40535-40538	has	_	
199-10	40539-40546	several	_	
199-11	40547-40558	limitations	_	
199-12	40558-40559	,	_	
199-13	40560-40569	including	_	
199-14	40570-40571	a	_	
199-15	40572-40577	small	_	
199-16	40578-40584	sample	_	
199-17	40585-40589	size	_	
199-18	40589-40590	,	_	
199-19	40591-40594	the	_	
199-20	40595-40599	fact	_	
199-21	40600-40604	that	_	
199-22	40605-40612	relapse	_	
199-23	40612-40613	/	_	
199-24	40613-40623	abstinence	_	
199-25	40624-40630	status	_	
199-26	40631-40634	was	_	
199-27	40635-40640	based	_	
199-28	40641-40643	on	_	
199-29	40644-40655	self-report	_	
199-30	40655-40656	,	_	
199-31	40657-40660	and	_	
199-32	40661-40665	that	_	
199-33	40666-40673	alcohol	_	
199-34	40673-40674	,	_	
199-35	40675-40687	prescription	_	
199-36	40688-40693	drugs	_	
199-37	40693-40694	,	_	
199-38	40695-40698	and	_	
199-39	40699-40704	other	_	
199-40	40705-40714	secondary	_	
199-41	40715-40720	drugs	_	
199-42	40721-40723	of	_	
199-43	40724-40729	abuse	_	
199-44	40730-40734	were	_	
199-45	40735-40738	not	_	
199-46	40739-40748	monitored	_	
199-47	40749-40754	after	_	
199-48	40755-40764	treatment	_	
199-49	40764-40765	.	_	

#Text=In addition, medical status, hospitalizations, and psychiatric comorbidities were not assessed during the follow-up interval.
200-1	40766-40768	In	_	
200-2	40769-40777	addition	_	
200-3	40777-40778	,	_	
200-4	40779-40786	medical	_	
200-5	40787-40793	status	_	
200-6	40793-40794	,	_	
200-7	40795-40811	hospitalizations	_	
200-8	40811-40812	,	_	
200-9	40813-40816	and	_	
200-10	40817-40828	psychiatric	_	
200-11	40829-40842	comorbidities	_	
200-12	40843-40847	were	_	
200-13	40848-40851	not	_	
200-14	40852-40860	assessed	_	
200-15	40861-40867	during	_	
200-16	40868-40871	the	_	
200-17	40872-40881	follow-up	_	
200-18	40882-40890	interval	_	
200-19	40890-40891	.	_	

#Text=The latter limits our ability to evaluate the specificity of the neurocognitive markers identified to methamphetamine dependence and the role of psychiatric comorbidities in this predictive model.
201-1	40892-40895	The	_	
201-2	40896-40902	latter	_	
201-3	40903-40909	limits	_	
201-4	40910-40913	our	_	
201-5	40914-40921	ability	_	
201-6	40922-40924	to	_	
201-7	40925-40933	evaluate	_	
201-8	40934-40937	the	_	
201-9	40938-40949	specificity	_	
201-10	40950-40952	of	_	
201-11	40953-40956	the	_	
201-12	40957-40971	neurocognitive	_	
201-13	40972-40979	markers	_	
201-14	40980-40990	identified	_	
201-15	40991-40993	to	_	
201-16	40994-41009	methamphetamine	_	
201-17	41010-41020	dependence	_	
201-18	41021-41024	and	_	
201-19	41025-41028	the	_	
201-20	41029-41033	role	_	
201-21	41034-41036	of	_	
201-22	41037-41048	psychiatric	_	
201-23	41049-41062	comorbidities	_	
201-24	41063-41065	in	_	
201-25	41066-41070	this	_	
201-26	41071-41081	predictive	_	
201-27	41082-41087	model	_	
201-28	41087-41088	.	_	

#Text=Future research should include a more in-depth clinical assessment to tease apart those factors.
202-1	41089-41095	Future	_	
202-2	41096-41104	research	_	
202-3	41105-41111	should	_	
202-4	41112-41119	include	_	
202-5	41120-41121	a	_	
202-6	41122-41126	more	_	
202-7	41127-41135	in-depth	_	
202-8	41136-41144	clinical	_	
202-9	41145-41155	assessment	_	
202-10	41156-41158	to	_	
202-11	41159-41164	tease	_	
202-12	41165-41170	apart	_	
202-13	41171-41176	those	_	
202-14	41177-41184	factors	_	
202-15	41184-41185	.	_	

#Text=In addition, we acknowledge the group differences in Bayesian model-based neural responses were observed in the absence of statistically significant group difference in behavioral performance.
203-1	41186-41188	In	_	
203-2	41189-41197	addition	_	
203-3	41197-41198	,	_	
203-4	41199-41201	we	_	
203-5	41202-41213	acknowledge	_	
203-6	41214-41217	the	_	
203-7	41218-41223	group	_	
203-8	41224-41235	differences	_	
203-9	41236-41238	in	_	
203-10	41239-41247	Bayesian	_	
203-11	41248-41259	model-based	_	
203-12	41260-41266	neural	_	
203-13	41267-41276	responses	_	
203-14	41277-41281	were	_	
203-15	41282-41290	observed	_	
203-16	41291-41293	in	_	
203-17	41294-41297	the	_	
203-18	41298-41305	absence	_	
203-19	41306-41308	of	_	
203-20	41309-41322	statistically	_	
203-21	41323-41334	significant	_	
203-22	41335-41340	group	_	
203-23	41341-41351	difference	_	
203-24	41352-41354	in	_	
203-25	41355-41365	behavioral	_	
203-26	41366-41377	performance	_	
203-27	41377-41378	.	_	

#Text=However, the group by SSD interaction contrast predicting accuracy was marginally significant and pointing to more marked decline in performance as SSD shortens (i.e., more challenging) among relapsed individuals.
204-1	41379-41386	However	_	
204-2	41386-41387	,	_	
204-3	41388-41391	the	_	
204-4	41392-41397	group	_	
204-5	41398-41400	by	_	
204-6	41401-41404	SSD	_	
204-7	41405-41416	interaction	_	
204-8	41417-41425	contrast	_	
204-9	41426-41436	predicting	_	
204-10	41437-41445	accuracy	_	
204-11	41446-41449	was	_	
204-12	41450-41460	marginally	_	
204-13	41461-41472	significant	_	
204-14	41473-41476	and	_	
204-15	41477-41485	pointing	_	
204-16	41486-41488	to	_	
204-17	41489-41493	more	_	
204-18	41494-41500	marked	_	
204-19	41501-41508	decline	_	
204-20	41509-41511	in	_	
204-21	41512-41523	performance	_	
204-22	41524-41526	as	_	
204-23	41527-41530	SSD	_	
204-24	41531-41539	shortens	_	
204-25	41540-41541	(	_	
204-26	41541-41544	i.e	_	
204-27	41544-41545	.	_	
204-28	41545-41546	,	_	
204-29	41547-41551	more	_	
204-30	41552-41563	challenging	_	
204-31	41563-41564	)	_	
204-32	41565-41570	among	_	
204-33	41571-41579	relapsed	_	
204-34	41580-41591	individuals	_	
204-35	41591-41592	.	_	

#Text=Moreover, this lack of strong behavioral findings does not preclude the relevance of such subtle neural differences to inhibitory learning and/or the worsening of behavioral inhibitory performance as individuals progress towards relapse.
205-1	41593-41601	Moreover	_	
205-2	41601-41602	,	_	
205-3	41603-41607	this	_	
205-4	41608-41612	lack	_	
205-5	41613-41615	of	_	
205-6	41616-41622	strong	_	
205-7	41623-41633	behavioral	_	
205-8	41634-41642	findings	_	
205-9	41643-41647	does	_	
205-10	41648-41651	not	_	
205-11	41652-41660	preclude	_	
205-12	41661-41664	the	_	
205-13	41665-41674	relevance	_	
205-14	41675-41677	of	_	
205-15	41678-41682	such	_	
205-16	41683-41689	subtle	_	
205-17	41690-41696	neural	_	
205-18	41697-41708	differences	_	
205-19	41709-41711	to	_	
205-20	41712-41722	inhibitory	_	
205-21	41723-41731	learning	_	
205-22	41732-41735	and	_	
205-23	41735-41736	/	_	
205-24	41736-41738	or	_	
205-25	41739-41742	the	_	
205-26	41743-41752	worsening	_	
205-27	41753-41755	of	_	
205-28	41756-41766	behavioral	_	
205-29	41767-41777	inhibitory	_	
205-30	41778-41789	performance	_	
205-31	41790-41792	as	_	
205-32	41793-41804	individuals	_	
205-33	41805-41813	progress	_	
205-34	41814-41821	towards	_	
205-35	41822-41829	relapse	_	
205-36	41829-41830	.	_	

#Text=It would thus be critical to assess behavioral performance at follow-up in future studies to assess the evolution of neural changes in anticipatory processes as it impacts performance.
206-1	41831-41833	It	_	
206-2	41834-41839	would	_	
206-3	41840-41844	thus	_	
206-4	41845-41847	be	_	
206-5	41848-41856	critical	_	
206-6	41857-41859	to	_	
206-7	41860-41866	assess	_	
206-8	41867-41877	behavioral	_	
206-9	41878-41889	performance	_	
206-10	41890-41892	at	_	
206-11	41893-41902	follow-up	_	
206-12	41903-41905	in	_	
206-13	41906-41912	future	_	
206-14	41913-41920	studies	_	
206-15	41921-41923	to	_	
206-16	41924-41930	assess	_	
206-17	41931-41934	the	_	
206-18	41935-41944	evolution	_	
206-19	41945-41947	of	_	
206-20	41948-41954	neural	_	
206-21	41955-41962	changes	_	
206-22	41963-41965	in	_	
206-23	41966-41978	anticipatory	_	
206-24	41979-41988	processes	_	
206-25	41989-41991	as	_	
206-26	41992-41994	it	_	
206-27	41995-42002	impacts	_	
206-28	42003-42014	performance	_	
206-29	42014-42015	.	_	

#Text=In conclusion, the combination of functional neuroimaging and Bayesian cognitive modeling may be helpful in identifying finer neural markers for methamphetamine use disorder relapse, which can provide a mechanistic explanation of more subtle processing deficits.
207-1	42016-42018	In	_	
207-2	42019-42029	conclusion	_	
207-3	42029-42030	,	_	
207-4	42031-42034	the	_	
207-5	42035-42046	combination	_	
207-6	42047-42049	of	_	
207-7	42050-42060	functional	_	
207-8	42061-42073	neuroimaging	_	
207-9	42074-42077	and	_	
207-10	42078-42086	Bayesian	_	
207-11	42087-42096	cognitive	_	
207-12	42097-42105	modeling	_	
207-13	42106-42109	may	_	
207-14	42110-42112	be	_	
207-15	42113-42120	helpful	_	
207-16	42121-42123	in	_	
207-17	42124-42135	identifying	_	
207-18	42136-42141	finer	_	
207-19	42142-42148	neural	_	
207-20	42149-42156	markers	_	
207-21	42157-42160	for	_	
207-22	42161-42176	methamphetamine	_	
207-23	42177-42180	use	_	
207-24	42181-42189	disorder	_	
207-25	42190-42197	relapse	_	
207-26	42197-42198	,	_	
207-27	42199-42204	which	_	
207-28	42205-42208	can	_	
207-29	42209-42216	provide	_	
207-30	42217-42218	a	_	
207-31	42219-42230	mechanistic	_	
207-32	42231-42242	explanation	_	
207-33	42243-42245	of	_	
207-34	42246-42250	more	_	
207-35	42251-42257	subtle	_	
207-36	42258-42268	processing	_	
207-37	42269-42277	deficits	_	
207-38	42277-42278	.	_	

#Text=We note, however, that a group model fitting approach was adopted in this study to identify potential neurocognitive predictors of relapse at the individual level, and thus a more in-depth study of clinical prediction utility is warranted.
208-1	42279-42281	We	_	
208-2	42282-42286	note	_	
208-3	42286-42287	,	_	
208-4	42288-42295	however	_	
208-5	42295-42296	,	_	
208-6	42297-42301	that	_	
208-7	42302-42303	a	_	
208-8	42304-42309	group	_	
208-9	42310-42315	model	_	
208-10	42316-42323	fitting	_	
208-11	42324-42332	approach	_	
208-12	42333-42336	was	_	
208-13	42337-42344	adopted	_	
208-14	42345-42347	in	_	
208-15	42348-42352	this	_	
208-16	42353-42358	study	_	
208-17	42359-42361	to	_	
208-18	42362-42370	identify	_	
208-19	42371-42380	potential	_	
208-20	42381-42395	neurocognitive	_	
208-21	42396-42406	predictors	_	
208-22	42407-42409	of	_	
208-23	42410-42417	relapse	_	
208-24	42418-42420	at	_	
208-25	42421-42424	the	_	
208-26	42425-42435	individual	_	
208-27	42436-42441	level	_	
208-28	42441-42442	,	_	
208-29	42443-42446	and	_	
208-30	42447-42451	thus	_	
208-31	42452-42453	a	_	
208-32	42454-42458	more	_	
208-33	42459-42467	in-depth	_	
208-34	42468-42473	study	_	
208-35	42474-42476	of	_	
208-36	42477-42485	clinical	_	
208-37	42486-42496	prediction	_	
208-38	42497-42504	utility	_	
208-39	42505-42507	is	_	
208-40	42508-42517	warranted	_	
208-41	42517-42518	.	_	

#Text=Nonetheless, such generative embedding approach is a first step to help bridge the clinical predictive utility and the scientific requirement of mechanistic insight into cognition, which for instance is not realistically attainable with standard multivariate classification algorithms.
209-1	42519-42530	Nonetheless	_	
209-2	42530-42531	,	_	
209-3	42532-42536	such	_	
209-4	42537-42547	generative	_	
209-5	42548-42557	embedding	_	
209-6	42558-42566	approach	_	
209-7	42567-42569	is	_	
209-8	42570-42571	a	_	
209-9	42572-42577	first	_	
209-10	42578-42582	step	_	
209-11	42583-42585	to	_	
209-12	42586-42590	help	_	
209-13	42591-42597	bridge	_	
209-14	42598-42601	the	_	
209-15	42602-42610	clinical	_	
209-16	42611-42621	predictive	_	
209-17	42622-42629	utility	_	
209-18	42630-42633	and	_	
209-19	42634-42637	the	_	
209-20	42638-42648	scientific	_	
209-21	42649-42660	requirement	_	
209-22	42661-42663	of	_	
209-23	42664-42675	mechanistic	_	
209-24	42676-42683	insight	_	
209-25	42684-42688	into	_	
209-26	42689-42698	cognition	_	
209-27	42698-42699	,	_	
209-28	42700-42705	which	_	
209-29	42706-42709	for	_	
209-30	42710-42718	instance	_	
209-31	42719-42721	is	_	
209-32	42722-42725	not	_	
209-33	42726-42739	realistically	_	
209-34	42740-42750	attainable	_	
209-35	42751-42755	with	_	
209-36	42756-42764	standard	_	
209-37	42765-42777	multivariate	_	
209-38	42778-42792	classification	_	
209-39	42793-42803	algorithms	_	
209-40	42803-42804	.	_	

#Text=Specifically, if robust to replication, and with the hope to refine such neurocomputational test to be more subpopulation- and individual-specific, this cognitive modeling approach may be useful to predict long-term relapse status at the individual level.
210-1	42805-42817	Specifically	_	
210-2	42817-42818	,	_	
210-3	42819-42821	if	_	
210-4	42822-42828	robust	_	
210-5	42829-42831	to	_	
210-6	42832-42843	replication	_	
210-7	42843-42844	,	_	
210-8	42845-42848	and	_	
210-9	42849-42853	with	_	
210-10	42854-42857	the	_	
210-11	42858-42862	hope	_	
210-12	42863-42865	to	_	
210-13	42866-42872	refine	_	
210-14	42873-42877	such	_	
210-15	42878-42896	neurocomputational	_	
210-16	42897-42901	test	_	
210-17	42902-42904	to	_	
210-18	42905-42907	be	_	
210-19	42908-42912	more	_	
210-20	42913-42926	subpopulation	_	
210-21	42926-42927	-	_	
210-22	42928-42931	and	_	
210-23	42932-42951	individual-specific	_	
210-24	42951-42952	,	_	
210-25	42953-42957	this	_	
210-26	42958-42967	cognitive	_	
210-27	42968-42976	modeling	_	
210-28	42977-42985	approach	_	
210-29	42986-42989	may	_	
210-30	42990-42992	be	_	
210-31	42993-42999	useful	_	
210-32	43000-43002	to	_	
210-33	43003-43010	predict	_	
210-34	43011-43020	long-term	_	
210-35	43021-43028	relapse	_	
210-36	43029-43035	status	_	
210-37	43036-43038	at	_	
210-38	43039-43042	the	_	
210-39	43043-43053	individual	_	
210-40	43054-43059	level	_	
210-41	43059-43060	.	_	

#Text=Such approach may further be able to pinpoint specific predisposing deficits in a) the adequacy of individuals' internal predictive model, and/or b) the efficiency of experience-based learning.
211-1	43061-43065	Such	_	
211-2	43066-43074	approach	_	
211-3	43075-43078	may	_	
211-4	43079-43086	further	_	
211-5	43087-43089	be	_	
211-6	43090-43094	able	_	
211-7	43095-43097	to	_	
211-8	43098-43106	pinpoint	_	
211-9	43107-43115	specific	_	
211-10	43116-43128	predisposing	_	
211-11	43129-43137	deficits	_	
211-12	43138-43140	in	_	
211-13	43141-43142	a	_	
211-14	43142-43143	)	_	
211-15	43144-43147	the	_	
211-16	43148-43156	adequacy	_	
211-17	43157-43159	of	_	
211-18	43160-43171	individuals	_	
211-19	43171-43172	'	_	
211-20	43173-43181	internal	_	
211-21	43182-43192	predictive	_	
211-22	43193-43198	model	_	
211-23	43198-43199	,	_	
211-24	43200-43203	and	_	
211-25	43203-43204	/	_	
211-26	43204-43206	or	_	
211-27	43207-43208	b	_	
211-28	43208-43209	)	_	
211-29	43210-43213	the	_	
211-30	43214-43224	efficiency	_	
211-31	43225-43227	of	_	
211-32	43228-43244	experience-based	_	
211-33	43245-43253	learning	_	
211-34	43253-43254	.	_	

#Text=Given their relevance to addictive behavior and recent developments in computational psychiatry, such Bayesian computational framework could be further strengthened by considering: the degree of precision/confidence about goal attainment, which may further modulate the influence of expectancies on choice, and the balance between model-free vs model-based/goal-directed control in relation to Pavlovian-instrumental transfer effects.
212-1	43255-43260	Given	_	
212-2	43261-43266	their	_	
212-3	43267-43276	relevance	_	
212-4	43277-43279	to	_	
212-5	43280-43289	addictive	_	
212-6	43290-43298	behavior	_	
212-7	43299-43302	and	_	
212-8	43303-43309	recent	_	
212-9	43310-43322	developments	_	
212-10	43323-43325	in	_	
212-11	43326-43339	computational	_	
212-12	43340-43350	psychiatry	_	
212-13	43350-43351	,	_	
212-14	43352-43356	such	_	
212-15	43357-43365	Bayesian	_	
212-16	43366-43379	computational	_	
212-17	43380-43389	framework	_	
212-18	43390-43395	could	_	
212-19	43396-43398	be	_	
212-20	43399-43406	further	_	
212-21	43407-43419	strengthened	_	
212-22	43420-43422	by	_	
212-23	43423-43434	considering	_	
212-24	43434-43435	:	_	
212-25	43436-43439	the	_	
212-26	43440-43446	degree	_	
212-27	43447-43449	of	_	
212-28	43450-43459	precision	_	
212-29	43459-43460	/	_	
212-30	43460-43470	confidence	_	
212-31	43471-43476	about	_	
212-32	43477-43481	goal	_	
212-33	43482-43492	attainment	_	
212-34	43492-43493	,	_	
212-35	43494-43499	which	_	
212-36	43500-43503	may	_	
212-37	43504-43511	further	_	
212-38	43512-43520	modulate	_	
212-39	43521-43524	the	_	
212-40	43525-43534	influence	_	
212-41	43535-43537	of	_	
212-42	43538-43550	expectancies	_	
212-43	43551-43553	on	_	
212-44	43554-43560	choice	_	
212-45	43560-43561	,	_	
212-46	43562-43565	and	_	
212-47	43566-43569	the	_	
212-48	43570-43577	balance	_	
212-49	43578-43585	between	_	
212-50	43586-43596	model-free	_	
212-51	43597-43599	vs	_	
212-52	43600-43611	model-based	_	
212-53	43611-43612	/	_	
212-54	43612-43625	goal-directed	_	
212-55	43626-43633	control	_	
212-56	43634-43636	in	_	
212-57	43637-43645	relation	_	
212-58	43646-43648	to	_	
212-59	43649-43671	Pavlovian-instrumental	_	
212-60	43672-43680	transfer	_	
212-61	43681-43688	effects	_	
212-62	43688-43689	.	_	

#Text=The observed computational markers may provide new avenues in the prevention of stimulant addiction and the development of personalized treatments.
213-1	43690-43693	The	_	
213-2	43694-43702	observed	_	
213-3	43703-43716	computational	_	
213-4	43717-43724	markers	_	
213-5	43725-43728	may	_	
213-6	43729-43736	provide	_	
213-7	43737-43740	new	_	
213-8	43741-43748	avenues	_	
213-9	43749-43751	in	_	
213-10	43752-43755	the	_	
213-11	43756-43766	prevention	_	
213-12	43767-43769	of	_	
213-13	43770-43779	stimulant	_	
213-14	43780-43789	addiction	_	
213-15	43790-43793	and	_	
213-16	43794-43797	the	_	
213-17	43798-43809	development	_	
213-18	43810-43812	of	_	
213-19	43813-43825	personalized	_	
213-20	43826-43836	treatments	_	
213-21	43836-43837	.	_	

#Text=For instance, cognitive training and biofeedback may be used to specifically target the computational learning processes showing evidence of neural inefficiencies in combination with standard addiction rehabilitation programs for those individuals identified at risk of relapse.
214-1	43838-43841	For	_	
214-2	43842-43850	instance	_	
214-3	43850-43851	,	_	
214-4	43852-43861	cognitive	_	
214-5	43862-43870	training	_	
214-6	43871-43874	and	_	
214-7	43875-43886	biofeedback	_	
214-8	43887-43890	may	_	
214-9	43891-43893	be	_	
214-10	43894-43898	used	_	
214-11	43899-43901	to	_	
214-12	43902-43914	specifically	_	
214-13	43915-43921	target	_	
214-14	43922-43925	the	_	
214-15	43926-43939	computational	_	
214-16	43940-43948	learning	_	
214-17	43949-43958	processes	_	
214-18	43959-43966	showing	_	
214-19	43967-43975	evidence	_	
214-20	43976-43978	of	_	
214-21	43979-43985	neural	_	
214-22	43986-44000	inefficiencies	_	
214-23	44001-44003	in	_	
214-24	44004-44015	combination	_	
214-25	44016-44020	with	_	
214-26	44021-44029	standard	_	
214-27	44030-44039	addiction	_	
214-28	44040-44054	rehabilitation	_	
214-29	44055-44063	programs	_	
214-30	44064-44067	for	_	
214-31	44068-44073	those	_	
214-32	44074-44085	individuals	_	
214-33	44086-44096	identified	_	
214-34	44097-44099	at	_	
214-35	44100-44104	risk	_	
214-36	44105-44107	of	_	
214-37	44108-44115	relapse	_	
214-38	44115-44116	.	_	

#Text=References
#Text=From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses
#Text=Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use
#Text=A componential analysis of task-switching deficits associated with lesions of left and right frontal cortex
#Text=Triangulating a cognitive control network using diffusion-weighted magnetic resonance imaging (MRI) and functional MRI
#Text=An inventory for measuring depression
#Text=Learning the value of information in an uncertain world
#Text=Risk and risk prediction error signals in anterior insula
#Text=Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors
#Text=Generative embedding for model-based classification of fMRI data
#Text=Behavioral control in alcohol use disorders: relationships with severity
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=Neural correlates of risk prediction error during reinforcement learning in humans
#Text=The human brain encodes event frequencies while forming subjective beliefs
#Text=The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment
#Text=Abnormal brain structure implicated in stimulant drug addiction
#Text=States versus rewards: dissociable neural prediction error signals underlying model-based and model-free reinforcement learning
#Text=The role of the right inferior frontal gyrus: inhibition and attentional control
#Text=Altered neural processing of the need to stop in young adults at risk for stimulant dependence
#Text=Bayesian neural adjustment of inhibitory control predicts emergence of problem stimulant use
#Text=Reduced neural recruitment for Bayesian adjustment of inhibitory control in methamphetamine dependence
#Text=Surprise signals in anterior cingulate cortex: neuronal encoding of unsigned reward prediction errors driving adjustment in behavior
#Text=Targeted intervention: computational approaches to elucidate and predict relapse in alcoholism
#Text=A validity study of the SSAGA--a comparison with the SCAN
#Text=Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity
#Text=Bayesian prediction and evaluation in the anterior cingulate cortex
#Text=An insula-frontostriatal network mediates flexible cognitive control by adaptively predicting changing control demands
#Text=Double dissociation of value computations in orbitofrontal and anterior cingulate neurons
#Text=Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity
#Text=Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers
#Text=Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies
#Text=Dissociating prefrontal and parietal cortex activation during arithmetic processing
#Text=Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects
#Text=Factor structure of the Barratt impulsiveness scale
#Text=Decision-making dysfunctions in psychiatry--altered homeostatic processing?
215-1	44117-44127	References	_	
215-2	44128-44132	From	_	
215-3	44133-44141	reactive	_	
215-4	44142-44144	to	_	
215-5	44145-44154	proactive	_	
215-6	44155-44158	and	_	
215-7	44159-44168	selective	_	
215-8	44169-44176	control	_	
215-9	44176-44177	:	_	
215-10	44178-44188	developing	_	
215-11	44189-44190	a	_	
215-12	44191-44197	richer	_	
215-13	44198-44203	model	_	
215-14	44204-44207	for	_	
215-15	44208-44216	stopping	_	
215-16	44217-44230	inappropriate	_	
215-17	44231-44240	responses	_	
215-18	44241-44249	Location	_	
215-19	44249-44250	,	_	
215-20	44251-44259	location	_	
215-21	44259-44260	:	_	
215-22	44261-44266	using	_	
215-23	44267-44277	functional	_	
215-24	44278-44286	magnetic	_	
215-25	44287-44296	resonance	_	
215-26	44297-44304	imaging	_	
215-27	44305-44307	to	_	
215-28	44308-44316	pinpoint	_	
215-29	44317-44322	brain	_	
215-30	44323-44334	differences	_	
215-31	44335-44343	relevant	_	
215-32	44344-44346	to	_	
215-33	44347-44356	stimulant	_	
215-34	44357-44360	use	_	
215-35	44361-44362	A	_	
215-36	44363-44375	componential	_	
215-37	44376-44384	analysis	_	
215-38	44385-44387	of	_	
215-39	44388-44402	task-switching	_	
215-40	44403-44411	deficits	_	
215-41	44412-44422	associated	_	
215-42	44423-44427	with	_	
215-43	44428-44435	lesions	_	
215-44	44436-44438	of	_	
215-45	44439-44443	left	_	
215-46	44444-44447	and	_	
215-47	44448-44453	right	_	
215-48	44454-44461	frontal	_	
215-49	44462-44468	cortex	_	
215-50	44469-44482	Triangulating	_	
215-51	44483-44484	a	_	
215-52	44485-44494	cognitive	_	
215-53	44495-44502	control	_	
215-54	44503-44510	network	_	
215-55	44511-44516	using	_	
215-56	44517-44535	diffusion-weighted	_	
215-57	44536-44544	magnetic	_	
215-58	44545-44554	resonance	_	
215-59	44555-44562	imaging	_	
215-60	44563-44564	(	_	
215-61	44564-44567	MRI	_	
215-62	44567-44568	)	_	
215-63	44569-44572	and	_	
215-64	44573-44583	functional	_	
215-65	44584-44587	MRI	_	
215-66	44588-44590	An	_	
215-67	44591-44600	inventory	_	
215-68	44601-44604	for	_	
215-69	44605-44614	measuring	_	
215-70	44615-44625	depression	_	
215-71	44626-44634	Learning	_	
215-72	44635-44638	the	_	
215-73	44639-44644	value	_	
215-74	44645-44647	of	_	
215-75	44648-44659	information	_	
215-76	44660-44662	in	_	
215-77	44663-44665	an	_	
215-78	44666-44675	uncertain	_	
215-79	44676-44681	world	_	
215-80	44682-44686	Risk	_	
215-81	44687-44690	and	_	
215-82	44691-44695	risk	_	
215-83	44696-44706	prediction	_	
215-84	44707-44712	error	_	
215-85	44713-44720	signals	_	
215-86	44721-44723	in	_	
215-87	44724-44732	anterior	_	
215-88	44733-44739	insula	_	
215-89	44740-44744	Time	_	
215-90	44745-44747	to	_	
215-91	44748-44755	relapse	_	
215-92	44756-44765	following	_	
215-93	44766-44775	treatment	_	
215-94	44776-44779	for	_	
215-95	44780-44795	methamphetamine	_	
215-96	44796-44799	use	_	
215-97	44799-44800	:	_	
215-98	44801-44802	a	_	
215-99	44803-44812	long-term	_	
215-100	44813-44824	perspective	_	
215-101	44825-44827	on	_	
215-102	44828-44836	patterns	_	
215-103	44837-44840	and	_	
215-104	44841-44851	predictors	_	
215-105	44852-44862	Generative	_	
215-106	44863-44872	embedding	_	
215-107	44873-44876	for	_	
215-108	44877-44888	model-based	_	
215-109	44889-44903	classification	_	
215-110	44904-44906	of	_	
215-111	44907-44911	fMRI	_	
215-112	44912-44916	data	_	
215-113	44917-44927	Behavioral	_	
215-114	44928-44935	control	_	
215-115	44936-44938	in	_	
215-116	44939-44946	alcohol	_	
215-117	44947-44950	use	_	
215-118	44951-44960	disorders	_	
215-119	44960-44961	:	_	
215-120	44962-44975	relationships	_	
215-121	44976-44980	with	_	
215-122	44981-44989	severity	_	
215-123	44990-44994	AFNI	_	
215-124	44994-44995	:	_	
215-125	44996-45004	software	_	
215-126	45005-45008	for	_	
215-127	45009-45017	analysis	_	
215-128	45018-45021	and	_	
215-129	45022-45035	visualization	_	
215-130	45036-45038	of	_	
215-131	45039-45049	functional	_	
215-132	45050-45058	magnetic	_	
215-133	45059-45068	resonance	_	
215-134	45069-45080	neuroimages	_	
215-135	45081-45087	Neural	_	
215-136	45088-45098	correlates	_	
215-137	45099-45101	of	_	
215-138	45102-45106	risk	_	
215-139	45107-45117	prediction	_	
215-140	45118-45123	error	_	
215-141	45124-45130	during	_	
215-142	45131-45144	reinforcement	_	
215-143	45145-45153	learning	_	
215-144	45154-45156	in	_	
215-145	45157-45163	humans	_	
215-146	45164-45167	The	_	
215-147	45168-45173	human	_	
215-148	45174-45179	brain	_	
215-149	45180-45187	encodes	_	
215-150	45188-45193	event	_	
215-151	45194-45205	frequencies	_	
215-152	45206-45211	while	_	
215-153	45212-45219	forming	_	
215-154	45220-45230	subjective	_	
215-155	45231-45238	beliefs	_	
215-156	45239-45242	The	_	
215-157	45243-45247	role	_	
215-158	45248-45250	of	_	
215-159	45251-45261	depression	_	
215-160	45262-45270	symptoms	_	
215-161	45271-45273	in	_	
215-162	45274-45284	predicting	_	
215-163	45285-45289	drug	_	
215-164	45290-45300	abstinence	_	
215-165	45301-45303	in	_	
215-166	45304-45314	outpatient	_	
215-167	45315-45324	substance	_	
215-168	45325-45330	abuse	_	
215-169	45331-45340	treatment	_	
215-170	45341-45349	Abnormal	_	
215-171	45350-45355	brain	_	
215-172	45356-45365	structure	_	
215-173	45366-45376	implicated	_	
215-174	45377-45379	in	_	
215-175	45380-45389	stimulant	_	
215-176	45390-45394	drug	_	
215-177	45395-45404	addiction	_	
215-178	45405-45411	States	_	
215-179	45412-45418	versus	_	
215-180	45419-45426	rewards	_	
215-181	45426-45427	:	_	
215-182	45428-45439	dissociable	_	
215-183	45440-45446	neural	_	
215-184	45447-45457	prediction	_	
215-185	45458-45463	error	_	
215-186	45464-45471	signals	_	
215-187	45472-45482	underlying	_	
215-188	45483-45494	model-based	_	
215-189	45495-45498	and	_	
215-190	45499-45509	model-free	_	
215-191	45510-45523	reinforcement	_	
215-192	45524-45532	learning	_	
215-193	45533-45536	The	_	
215-194	45537-45541	role	_	
215-195	45542-45544	of	_	
215-196	45545-45548	the	_	
215-197	45549-45554	right	_	
215-198	45555-45563	inferior	_	
215-199	45564-45571	frontal	_	
215-200	45572-45577	gyrus	_	
215-201	45577-45578	:	_	
215-202	45579-45589	inhibition	_	
215-203	45590-45593	and	_	
215-204	45594-45605	attentional	_	
215-205	45606-45613	control	_	
215-206	45614-45621	Altered	_	
215-207	45622-45628	neural	_	
215-208	45629-45639	processing	_	
215-209	45640-45642	of	_	
215-210	45643-45646	the	_	
215-211	45647-45651	need	_	
215-212	45652-45654	to	_	
215-213	45655-45659	stop	_	
215-214	45660-45662	in	_	
215-215	45663-45668	young	_	
215-216	45669-45675	adults	_	
215-217	45676-45678	at	_	
215-218	45679-45683	risk	_	
215-219	45684-45687	for	_	
215-220	45688-45697	stimulant	_	
215-221	45698-45708	dependence	_	
215-222	45709-45717	Bayesian	_	
215-223	45718-45724	neural	_	
215-224	45725-45735	adjustment	_	
215-225	45736-45738	of	_	
215-226	45739-45749	inhibitory	_	
215-227	45750-45757	control	_	
215-228	45758-45766	predicts	_	
215-229	45767-45776	emergence	_	
215-230	45777-45779	of	_	
215-231	45780-45787	problem	_	
215-232	45788-45797	stimulant	_	
215-233	45798-45801	use	_	
215-234	45802-45809	Reduced	_	
215-235	45810-45816	neural	_	
215-236	45817-45828	recruitment	_	
215-237	45829-45832	for	_	
215-238	45833-45841	Bayesian	_	
215-239	45842-45852	adjustment	_	
215-240	45853-45855	of	_	
215-241	45856-45866	inhibitory	_	
215-242	45867-45874	control	_	
215-243	45875-45877	in	_	
215-244	45878-45893	methamphetamine	_	
215-245	45894-45904	dependence	_	
215-246	45905-45913	Surprise	_	
215-247	45914-45921	signals	_	
215-248	45922-45924	in	_	
215-249	45925-45933	anterior	_	
215-250	45934-45943	cingulate	_	
215-251	45944-45950	cortex	_	
215-252	45950-45951	:	_	
215-253	45952-45960	neuronal	_	
215-254	45961-45969	encoding	_	
215-255	45970-45972	of	_	
215-256	45973-45981	unsigned	_	
215-257	45982-45988	reward	_	
215-258	45989-45999	prediction	_	
215-259	46000-46006	errors	_	
215-260	46007-46014	driving	_	
215-261	46015-46025	adjustment	_	
215-262	46026-46028	in	_	
215-263	46029-46037	behavior	_	
215-264	46038-46046	Targeted	_	
215-265	46047-46059	intervention	_	
215-266	46059-46060	:	_	
215-267	46061-46074	computational	_	
215-268	46075-46085	approaches	_	
215-269	46086-46088	to	_	
215-270	46089-46098	elucidate	_	
215-271	46099-46102	and	_	
215-272	46103-46110	predict	_	
215-273	46111-46118	relapse	_	
215-274	46119-46121	in	_	
215-275	46122-46132	alcoholism	_	
215-276	46133-46134	A	_	
215-277	46135-46143	validity	_	
215-278	46144-46149	study	_	
215-279	46150-46152	of	_	
215-280	46153-46156	the	_	
215-281	46157-46162	SSAGA	_	
215-282	46162-46163	-	_	
215-283	46163-46164	-	_	
215-284	46164-46165	a	_	
215-285	46166-46176	comparison	_	
215-286	46177-46181	with	_	
215-287	46182-46185	the	_	
215-288	46186-46190	SCAN	_	
215-289	46191-46200	Executive	_	
215-290	46201-46212	dysfunction	_	
215-291	46213-46215	in	_	
215-292	46216-46223	cocaine	_	
215-293	46224-46233	addiction	_	
215-294	46233-46234	:	_	
215-295	46235-46243	evidence	_	
215-296	46244-46247	for	_	
215-297	46248-46258	discordant	_	
215-298	46259-46266	frontal	_	
215-299	46266-46267	,	_	
215-300	46268-46277	cingulate	_	
215-301	46277-46278	,	_	
215-302	46279-46282	and	_	
215-303	46283-46293	cerebellar	_	
215-304	46294-46302	activity	_	
215-305	46303-46311	Bayesian	_	
215-306	46312-46322	prediction	_	
215-307	46323-46326	and	_	
215-308	46327-46337	evaluation	_	
215-309	46338-46340	in	_	
215-310	46341-46344	the	_	
215-311	46345-46353	anterior	_	
215-312	46354-46363	cingulate	_	
215-313	46364-46370	cortex	_	
215-314	46371-46373	An	_	
215-315	46374-46395	insula-frontostriatal	_	
215-316	46396-46403	network	_	
215-317	46404-46412	mediates	_	
215-318	46413-46421	flexible	_	
215-319	46422-46431	cognitive	_	
215-320	46432-46439	control	_	
215-321	46440-46442	by	_	
215-322	46443-46453	adaptively	_	
215-323	46454-46464	predicting	_	
215-324	46465-46473	changing	_	
215-325	46474-46481	control	_	
215-326	46482-46489	demands	_	
215-327	46490-46496	Double	_	
215-328	46497-46509	dissociation	_	
215-329	46510-46512	of	_	
215-330	46513-46518	value	_	
215-331	46519-46531	computations	_	
215-332	46532-46534	in	_	
215-333	46535-46548	orbitofrontal	_	
215-334	46549-46552	and	_	
215-335	46553-46561	anterior	_	
215-336	46562-46571	cingulate	_	
215-337	46572-46579	neurons	_	
215-338	46580-46588	Striatal	_	
215-339	46589-46597	dopamine	_	
215-340	46598-46600	d2	_	
215-341	46600-46601	/	_	
215-342	46601-46603	d3	_	
215-343	46604-46612	receptor	_	
215-344	46613-46625	availability	_	
215-345	46626-46628	is	_	
215-346	46629-46636	reduced	_	
215-347	46637-46639	in	_	
215-348	46640-46655	methamphetamine	_	
215-349	46656-46666	dependence	_	
215-350	46667-46670	and	_	
215-351	46671-46673	is	_	
215-352	46674-46680	linked	_	
215-353	46681-46683	to	_	
215-354	46684-46695	impulsivity	_	
215-355	46696-46700	Mood	_	
215-356	46701-46713	disturbances	_	
215-357	46714-46717	and	_	
215-358	46718-46726	regional	_	
215-359	46727-46735	cerebral	_	
215-360	46736-46745	metabolic	_	
215-361	46746-46759	abnormalities	_	
215-362	46760-46762	in	_	
215-363	46763-46771	recently	_	
215-364	46772-46781	abstinent	_	
215-365	46782-46797	methamphetamine	_	
215-366	46798-46805	abusers	_	
215-367	46806-46816	Disruption	_	
215-368	46817-46819	of	_	
215-369	46820-46826	reward	_	
215-370	46827-46837	processing	_	
215-371	46838-46840	in	_	
215-372	46841-46850	addiction	_	
215-373	46850-46851	:	_	
215-374	46852-46854	an	_	
215-375	46855-46866	image-based	_	
215-376	46867-46880	meta-analysis	_	
215-377	46881-46883	of	_	
215-378	46884-46894	functional	_	
215-379	46895-46903	magnetic	_	
215-380	46904-46913	resonance	_	
215-381	46914-46921	imaging	_	
215-382	46922-46929	studies	_	
215-383	46930-46942	Dissociating	_	
215-384	46943-46953	prefrontal	_	
215-385	46954-46957	and	_	
215-386	46958-46966	parietal	_	
215-387	46967-46973	cortex	_	
215-388	46974-46984	activation	_	
215-389	46985-46991	during	_	
215-390	46992-47002	arithmetic	_	
215-391	47003-47013	processing	_	
215-392	47014-47024	Prefrontal	_	
215-393	47025-47039	hypoactivation	_	
215-394	47040-47046	during	_	
215-395	47047-47056	cognitive	_	
215-396	47057-47064	control	_	
215-397	47065-47067	in	_	
215-398	47068-47073	early	_	
215-399	47074-47083	abstinent	_	
215-400	47084-47109	methamphetamine-dependent	_	
215-401	47110-47118	subjects	_	
215-402	47119-47125	Factor	_	
215-403	47126-47135	structure	_	
215-404	47136-47138	of	_	
215-405	47139-47142	the	_	
215-406	47143-47150	Barratt	_	
215-407	47151-47164	impulsiveness	_	
215-408	47165-47170	scale	_	
215-409	47171-47186	Decision-making	_	
215-410	47187-47199	dysfunctions	_	
215-411	47200-47202	in	_	
215-412	47203-47213	psychiatry	_	
215-413	47213-47214	-	_	
215-414	47214-47215	-	_	
215-415	47215-47222	altered	_	
215-416	47223-47234	homeostatic	_	
215-417	47235-47245	processing	_	
215-418	47245-47246	?	_	

#Text=An insular view of anxiety
#Text=Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects
#Text=A roadmap for the development of applied computational psychiatry
#Text=
#Text=Human insula activation reflects risk prediction errors as well as risk
#Text=A unifying Bayesian account of contextual effects in value-based choice
#Text=Evidence for surprise minimization over value maximization in choice behavior
#Text=Neural signals encoding shifts in beliefs
#Text=When habits are dangerous-alcohol expectancies and habitual decision-making predict relapse in alcohol dependence
#Text=The angular gyrus multiple functions and multiple subdivisions
#Text=Temporal filtering of reward signals in the dorsal anterior cingulate cortex during a mixed-strategy game
#Text=Rational decision-making in inhibitory control
#Text=A rational decision making framework for inhibitory control
#Text=A common role of insula in feelings, empathy and uncertainty
#Text=The neural correlates of negative prediction error signaling in human fear conditioning
#Text=Are the neural correlates of stopping and not going identical?
216-1	47247-47249	An	_	
216-2	47250-47257	insular	_	
216-3	47258-47262	view	_	
216-4	47263-47265	of	_	
216-5	47266-47273	anxiety	_	
216-6	47274-47284	Behavioral	_	
216-7	47285-47288	and	_	
216-8	47289-47299	functional	_	
216-9	47300-47312	neuroimaging	_	
216-10	47313-47321	evidence	_	
216-11	47322-47325	for	_	
216-12	47326-47336	prefrontal	_	
216-13	47337-47348	dysfunction	_	
216-14	47349-47351	in	_	
216-15	47352-47377	methamphetamine-dependent	_	
216-16	47378-47386	subjects	_	
216-17	47387-47388	A	_	
216-18	47389-47396	roadmap	_	
216-19	47397-47400	for	_	
216-20	47401-47404	the	_	
216-21	47405-47416	development	_	
216-22	47417-47419	of	_	
216-23	47420-47427	applied	_	
216-24	47428-47441	computational	_	
216-25	47442-47452	psychiatry	_	
216-26	47454-47459	Human	_	
216-27	47460-47466	insula	_	
216-28	47467-47477	activation	_	
216-29	47478-47486	reflects	_	
216-30	47487-47491	risk	_	
216-31	47492-47502	prediction	_	
216-32	47503-47509	errors	_	
216-33	47510-47512	as	_	
216-34	47513-47517	well	_	
216-35	47518-47520	as	_	
216-36	47521-47525	risk	_	
216-37	47526-47527	A	_	
216-38	47528-47536	unifying	_	
216-39	47537-47545	Bayesian	_	
216-40	47546-47553	account	_	
216-41	47554-47556	of	_	
216-42	47557-47567	contextual	_	
216-43	47568-47575	effects	_	
216-44	47576-47578	in	_	
216-45	47579-47590	value-based	_	
216-46	47591-47597	choice	_	
216-47	47598-47606	Evidence	_	
216-48	47607-47610	for	_	
216-49	47611-47619	surprise	_	
216-50	47620-47632	minimization	_	
216-51	47633-47637	over	_	
216-52	47638-47643	value	_	
216-53	47644-47656	maximization	_	
216-54	47657-47659	in	_	
216-55	47660-47666	choice	_	
216-56	47667-47675	behavior	_	
216-57	47676-47682	Neural	_	
216-58	47683-47690	signals	_	
216-59	47691-47699	encoding	_	
216-60	47700-47706	shifts	_	
216-61	47707-47709	in	_	
216-62	47710-47717	beliefs	_	
216-63	47718-47722	When	_	
216-64	47723-47729	habits	_	
216-65	47730-47733	are	_	
216-66	47734-47751	dangerous-alcohol	_	
216-67	47752-47764	expectancies	_	
216-68	47765-47768	and	_	
216-69	47769-47777	habitual	_	
216-70	47778-47793	decision-making	_	
216-71	47794-47801	predict	_	
216-72	47802-47809	relapse	_	
216-73	47810-47812	in	_	
216-74	47813-47820	alcohol	_	
216-75	47821-47831	dependence	_	
216-76	47832-47835	The	_	
216-77	47836-47843	angular	_	
216-78	47844-47849	gyrus	_	
216-79	47850-47858	multiple	_	
216-80	47859-47868	functions	_	
216-81	47869-47872	and	_	
216-82	47873-47881	multiple	_	
216-83	47882-47894	subdivisions	_	
216-84	47895-47903	Temporal	_	
216-85	47904-47913	filtering	_	
216-86	47914-47916	of	_	
216-87	47917-47923	reward	_	
216-88	47924-47931	signals	_	
216-89	47932-47934	in	_	
216-90	47935-47938	the	_	
216-91	47939-47945	dorsal	_	
216-92	47946-47954	anterior	_	
216-93	47955-47964	cingulate	_	
216-94	47965-47971	cortex	_	
216-95	47972-47978	during	_	
216-96	47979-47980	a	_	
216-97	47981-47995	mixed-strategy	_	
216-98	47996-48000	game	_	
216-99	48001-48009	Rational	_	
216-100	48010-48025	decision-making	_	
216-101	48026-48028	in	_	
216-102	48029-48039	inhibitory	_	
216-103	48040-48047	control	_	
216-104	48048-48049	A	_	
216-105	48050-48058	rational	_	
216-106	48059-48067	decision	_	
216-107	48068-48074	making	_	
216-108	48075-48084	framework	_	
216-109	48085-48088	for	_	
216-110	48089-48099	inhibitory	_	
216-111	48100-48107	control	_	
216-112	48108-48109	A	_	
216-113	48110-48116	common	_	
216-114	48117-48121	role	_	
216-115	48122-48124	of	_	
216-116	48125-48131	insula	_	
216-117	48132-48134	in	_	
216-118	48135-48143	feelings	_	
216-119	48143-48144	,	_	
216-120	48145-48152	empathy	_	
216-121	48153-48156	and	_	
216-122	48157-48168	uncertainty	_	
216-123	48169-48172	The	_	
216-124	48173-48179	neural	_	
216-125	48180-48190	correlates	_	
216-126	48191-48193	of	_	
216-127	48194-48202	negative	_	
216-128	48203-48213	prediction	_	
216-129	48214-48219	error	_	
216-130	48220-48229	signaling	_	
216-131	48230-48232	in	_	
216-132	48233-48238	human	_	
216-133	48239-48243	fear	_	
216-134	48244-48256	conditioning	_	
216-135	48257-48260	Are	_	
216-136	48261-48264	the	_	
216-137	48265-48271	neural	_	
216-138	48272-48282	correlates	_	
216-139	48283-48285	of	_	
216-140	48286-48294	stopping	_	
216-141	48295-48298	and	_	
216-142	48299-48302	not	_	
216-143	48303-48308	going	_	
216-144	48309-48318	identical	_	
216-145	48318-48319	?	_	

#Text=Quantitative meta-analysis of two response inhibition tasks
#Text=North American adult Reading test: age norms, reliability, and validity
#Text=Between-task competition and cognitive control in task switching
#Text=Sequential effects: superstition or rational behavior
#Text=Uncertainty, neuromodulation, and attention
#Text=Expectations and violations: delineating the neural network of proactive inhibitory control
#Text=Construct validity for the sensation-seeking scale
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2019.101794.
217-1	48320-48332	Quantitative	_	
217-2	48333-48346	meta-analysis	_	
217-3	48347-48349	of	_	
217-4	48350-48353	two	_	
217-5	48354-48362	response	_	
217-6	48363-48373	inhibition	_	
217-7	48374-48379	tasks	_	
217-8	48380-48385	North	_	
217-9	48386-48394	American	_	
217-10	48395-48400	adult	_	
217-11	48401-48408	Reading	_	
217-12	48409-48413	test	_	
217-13	48413-48414	:	_	
217-14	48415-48418	age	_	
217-15	48419-48424	norms	_	
217-16	48424-48425	,	_	
217-17	48426-48437	reliability	_	
217-18	48437-48438	,	_	
217-19	48439-48442	and	_	
217-20	48443-48451	validity	_	
217-21	48452-48464	Between-task	_	
217-22	48465-48476	competition	_	
217-23	48477-48480	and	_	
217-24	48481-48490	cognitive	_	
217-25	48491-48498	control	_	
217-26	48499-48501	in	_	
217-27	48502-48506	task	_	
217-28	48507-48516	switching	_	
217-29	48517-48527	Sequential	_	
217-30	48528-48535	effects	_	
217-31	48535-48536	:	_	
217-32	48537-48549	superstition	_	
217-33	48550-48552	or	_	
217-34	48553-48561	rational	_	
217-35	48562-48570	behavior	_	
217-36	48571-48582	Uncertainty	_	
217-37	48582-48583	,	_	
217-38	48584-48599	neuromodulation	_	
217-39	48599-48600	,	_	
217-40	48601-48604	and	_	
217-41	48605-48614	attention	_	
217-42	48615-48627	Expectations	_	
217-43	48628-48631	and	_	
217-44	48632-48642	violations	_	
217-45	48642-48643	:	_	
217-46	48644-48655	delineating	_	
217-47	48656-48659	the	_	
217-48	48660-48666	neural	_	
217-49	48667-48674	network	_	
217-50	48675-48677	of	_	
217-51	48678-48687	proactive	_	
217-52	48688-48698	inhibitory	_	
217-53	48699-48706	control	_	
217-54	48707-48716	Construct	_	
217-55	48717-48725	validity	_	
217-56	48726-48729	for	_	
217-57	48730-48733	the	_	
217-58	48734-48751	sensation-seeking	_	
217-59	48752-48757	scale	_	
217-60	48758-48771	Supplementary	_	
217-61	48772-48776	data	_	
217-62	48777-48790	Supplementary	_	
217-63	48791-48795	data	_	
217-64	48796-48798	to	_	
217-65	48799-48803	this	_	
217-66	48804-48811	article	_	
217-67	48812-48815	can	_	
217-68	48816-48818	be	_	
217-69	48819-48824	found	_	
217-70	48825-48831	online	_	
217-71	48832-48834	at	_	
217-72	48835-48840	https	_	
217-73	48840-48841	:	_	
217-74	48841-48842	/	_	
217-75	48842-48843	/	_	
217-76	48843-48850	doi.org	_	
217-77	48850-48851	/	_	
217-78	48851-48858	10.1016	_	
217-79	48858-48859	/	_	
217-80	48859-48865	j.nicl	_	
217-81	48865-48877	.2019.101794	_	
217-82	48877-48878	.	_	
